

04/14/98

JCS86 U.S. PT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

MEYERS ET AL.

Attorney Docket No. I/6412-554/D1

Serial Number: To be assigned

Group Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: HOG CHOLERA VIRUS VACCINE AND DIAGNOSTIC

Corresponding to:

USSN 08/873,759, filed June 12, 1997, which is a continuation of USSN 08/462,495, filed June 5, 1995, which is a divisional of USSN 08/123,596, filed September 20, 1993, which is a continuation of USSN 07/797,554, now abandoned, which is a continuation-in-part of USSN 07/494,991, filed March 16, 1990.

37 C.F.R. 1.53(b) DIVISIONAL
PATENT APPLICATION TRANSMITTAL LETTER

Assistant Commissioner of Patents
Washington, D.C. 20231

April 14, 1998

Sir:

This is a request for filing a ☐ continuation ☒ divisional application under 37 CFR 1.53(b) of pending prior application Serial Number 08/873,759 filed June 12, 1997 by Gregor Meyers, Tillman Rumenapf, and Heinz-Jurgen Thiel originally entitled HOG CHOLERA VIRUS VACCINE AND DIAGNOSTIC.

☒ Enclosed is a copy of the prior application, including the oath or declaration as originally filed and an affidavit or declaration verifying it is a true copy.

☐ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 ☐ is enclosed ☐ was filed in the prior application and such status is still proper and desired.

☒ The fee is calculated below:

Claims as Filed in the Prior Application, Less any claims Cancelled by Amendment Below:

FOR:	NO. FILED	NO. EXTRA	RATE	FEE
BASIC FEE				\$790.00
TOTAL CLAIMS	9-20	0	X\$22	\$ 0
INDEP CLAIMS	5- 3	2	X\$82	\$164.00
+ 1 MULTIPLE DEPENDENT CLAIMS PRESENTED			+\$270	\$ 0
				TOTAL \$954.00

☒ Please charge my Deposit Account No. 02-2334 in the amount of \$954.00.

☒ Please charge any additional filing fees required or credit any overpayment to Deposit Account No. 02-2334.

☒ Cancel in the application original claims 1 - 7 and 9 - 13 of the prior application before calculating the filing fee.

☒ Amend the specification by inserting before the first line the sentence: -- This is a ☐ continuation, ☒ division, of application USSN 08/873,759, filed June 12, 1997, which is a continuation of USSN 08/462,495, filed June 5, 1995, which is a divisional of USSN 08/123,596, filed September 20, 1993, which is a continuation of USSN 07/797,554, now abandoned, which is a continuation-in-part of USSN 07/494,991, filed March 16, 1990. --

☐ Transfer the drawings from the prior application to this application and abandon prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.

☒ New ☐ informal ☒ formal drawings are enclosed.

☒ The benefit of priority under 35 USC 119 is claimed of the filing date of March 19, 1989, (European) 89.104921.5. A certified copy of the priority document is of record in the parent application.

Express Mail No.
EL041880454US

Page 1 of 2

[X] This application is assigned to Akzo Nobel N.V. by virtue of an assignment in the parent application which was recorded June 12, 1997, at Reel 8605, Frame 0926 of the Patent and Trademark Office assignment records.

[X] Address all future communications to:
William M. Blackstone
AKZO NOBEL PATENT DEPARTMENT
1300 Piccard Drive, Suite 206
Rockville, MD 20850

[] Applicants hereby petition that the period for response to the Official Action dated _____, 198_, in patent application Serial No.06/_____, be extended, if necessary, to the filing date of the present continuation application. The fee for any such extension may be charged to our Deposit Account No. 02-2334.


[X] A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

[] Also enclosed:

[X] I hereby verify that the attached papers are a true copy of the prior application Serial No. 08/462,495 as originally filed on June 5, 1995.

The undersigned declares further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,


Mary E. Gormley
Attorney for Applicants
Registration No. 34,409

AKZO NOBEL PATENT DEPARTMENT
1300 Piccard Drive, Suite 206
Rockville, Maryland 20850-4373
Tel: (301) 948-7400
Fax: (301) 948-9751
MEG/ms

48meyers.div

Express Mail No.
EL041880454US

Page 2 of 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: **Atty Docket No. I/6412-554/D1**
MEYERS ET AL.
Serial Number: not assigned Group Art Unit: not assigned
Filed: concurrently herewith Examiner: not assigned
For: HOG CHOLERA VIRUS VACCINE AND DIAGNOSTIC

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231
Sir:

April 14, 1998

Prior to calculation of the fee in the present application,
and prior to examination on the merits, please enter the
following amendments.

IN THE CLAIMS:

Please cancel claims 1 - 7 and 9 - 13, and insert the
following new claims.

-- 14. An isolated hog cholera virus (HCV) protein, which is
the 44/48 kD protein. --

-- 15. The protein according to claim 14, which comprises the
amino acid sequence from about 263 - 487 of SEQ ID NO:2. --

-- 16. An isolated HCV protein which is expressed by a
recombinant nucleic acid molecule comprising a DNA sequence
encoding the 44/48 kD protein of HCV. --

-- 17. A method for the preparation of an HCV protein,
comprising growing a recombinant host cell or recombinant virus
comprising a nucleic acid sequence encoding the 44/48 kD protein
of HCV, in a culture under conditions whereby the protein is
expressed, followed by isolating the 44/48 kD protein from the
culture. --

-- 18. A vaccine for the protection of animals against HCV infection, comprising a protein according to claim 14. --

-- 19. The vaccine according to claim 18, wherein the protein comprises the amino acid sequence from about 263 - 487 of SEQ ID NO:2. --

-- 20. The vaccine according to claim 18, wherein the protein is recombinantly expressed. --

-- 21. A method for the detection of the presence of HCV antibodies in an animal, comprising reacting the 44/48 kD protein of HCV with the serum of the animal, and determining the presence of an antibody/antigen complex, whereby the presence of the complex indicates a positive result. --

REMARKS


Claims 1 - 7 and 9 - 13 are canceled and new claims 14 - 21 are added hereby. Claims 8 and 14 - 21 are now pending.

The new claims correspond to the claims allowed in the parent application, USSN 08/873,759 (which are based on the nucleic acid sequence that encodes the 44/48 kD protein), as well as on the non-elected claims in the parent application.

Favorable consideration on the merits is earnestly solicited.

If any other fees are due in this application, please charge our Deposit Account No. 02-2334.

Respectfully submitted,


Mary E. Gormley
Attorney for Applicants
Registration No. 34,409

AKZO NOBEL Patent Dept.
1300 Piccard Drive, Suite 206
Rockville, Maryland 20850-4373
Tel: (301) 948-7400
Fax: (301) 948-9751
MEG/mg 48meyers.pre

Exp. Mail No. ELO41880454US

-2-

Hog cholera virus vaccine and diagnostic

The present invention is concerned with a nucleic acid sequence, a recombinant nucleic acid molecule comprising such a nucleic acid sequence, a recombinant expression system comprising such a recombinant nucleic acid molecule, a polypeptide characteristic of the hog cholera virus, a vaccine comprising such a polypeptide or recombinant expression system as well as a method for the preparation of such vaccines.

Classical swine fever or hog cholera (HC) represents an economically important disease of swine in many countries worldwide. Under natural conditions, the pig is the only animal known to be susceptible to HC. Hog cholera is a highly contagious disease which causes degeneration in the walls of capillaries, resulting in hemorrhages and necrosis of the internal organs. In the first instance hog cholera is characterized by fever, anorexia, vomiting and diarrhea which can be followed by a chronic course of the disease characterized by infertility, abortion and weak offsprings of sows. However, nearly all pigs die within 2 weeks after the first symptoms appear.

The causative agent, the hog cholera virus (HCV) has been shown to be structurally and serologically related to bovine viral diarrhea virus (BVDV) of cattle and to border disease virus (BDV) of sheep.

These viruses are grouped together into the genus pestivirus within the family togaviridae. The nature of the genetic material of pestiviruses has long been known to be RNA, i.e. positive-strand RNA which lacks significant polyadenylation. The HCV probably comprises 3-5 structural proteins of which two are possibly glycosylated. The number of non-structural viral proteins is unknown.

Modified HCV vaccines (comprising attenuated or killed viruses) for combating HC infection have been developed and are presently used. However, infection of tissue culture cells to obtain HCV material to be used in said modified virus vaccines, leads to low virus yields and the virions are hard to purify. Modified live virus vaccines always involve the risk of inoculating animals with partially attenuated pathogenic HCV which is still pathogenic and can cause disease in the inoculated animal or offspring and of contamination by other viruses in the vaccine. In addition the attenuated virus may revert to a virulent state.

There are also several disadvantages using inactivated vaccines, e.g. the risk of only partial inactivation of viruses, the problem that only a low level of immunity is achieved requiring additional immunizations and the problem that antigenic determinants are altered by the inactivation treatment leaving the inactivated virus less immunogenic.

Furthermore, the usage of modified HCV vaccines is not suited for eradication programmes.

Until now, according to our knowledge diagnostic tests in swine which can distinguish between HCV or BVDV infection are not available. This is important as BVDV infection in pigs is of lower significance than HCV infection which means that BVDV infected pigs do not have to be eradicated.

Vaccines containing only the necessary and relevant HCV immunogenic material which is capable of eliciting an immune response against the pathogen do not display abovementioned disadvantages of modified vaccines.

According to the present invention a nucleic acid sequence encoding a polypeptide characteristic of hog cholera virus has been found. Fragments of said nucleic acid sequence or said polypeptide are also within the present invention. Both the nucleic acid sequence and the polypeptide or fragments thereof can be used for the preparation of a vaccine containing only the necessary and relevant immunogenic material for immunizing animals against HCV infection. "Nucleic acid sequence" refers both to a ribonucleic acid sequence and a deoxy-ribonucleic acid sequence.

A nucleic acid sequence according to the present invention is shown in figure 2 (SEQ ID NO: 1). As is well known in the art, the degeneracy of the genetic code permits substitution of bases in a codon resulting in an other codon but still coding for the same amino acid, e.g. the codon for the amino acid glutamic acid is both GAT and GAA. Consequently, it is clear that for the expression of a polypeptide with the amino acid sequence shown in figure 2 (SEQ ID NO: 1-2) use can be made of a nucleic acid sequence with such an alternative codon composition different from the nucleic acid sequence shown in figure 2 (SEQ ID NO: 1).

Also included within the scope of the invention are nucleic acid sequences which hybridize under stringent conditions to the nucleic acid sequence shown in figure 2 (SEQ ID NO: 1). These nucleic acid sequences are related to the nucleic acid sequence shown in figure 2 (SEQ ID NO: 1) but may comprise nucleotide substitutions, mutations, insertions, deletions etc. and encode polypeptides which are functionally equivalent to the polypeptide shown in figure 2 (SEQ ID NO: 1-2), i.e. the amino acid sequence of a related polypeptide is not identical with the amino acid sequence shown in figure 2 (SEQ ID NO: 1-2) but features corresponding immunological properties characteristic for HCV.

Within the scope of the invention are also polypeptides encoded by such related nucleic acid sequences.

The nucleic acid sequence shown in figure 2 (SEQ ID NO: 1) is a cDNA sequence derived from the genomic RNA of HCV. This continuous sequence is 12284 nucleotides in length, and contains one long open reading frame (ORF), starting with the ATG codon at position 364 to 366 and ending with a TGA codon as a translational stop codon at position 12058 to 12060. This ORF consists of 3898 codons capable of encoding 435 kDa of protein.

In vivo, during HCV replication in an infected cell, this protein is synthesized as a polyprotein precursor molecule which is subsequently processed to fragment polypeptides by (enzymatic) cleavage of the precursor molecule. These fragments form after possible post-translational modifications the structural and non-structural proteins of the virus. A preferred nucleic acid sequence contains the genetic information for such a fragment with immunizing properties against HCV or immunological properties characteristic for HCV or contains the genetic

information for a portion of such a fragment which still has the immunizing properties or the immunological properties characteristic for HCV.

The term "fragment or portion" as used herein means a DNA or amino acid sequence comprising a subsequence of one of the nucleic acid sequences or polypeptides of the invention. Said fragment or portion is or encodes a polypeptide having one or more immunoreactive and/or antigenic determinants of a HCV polypeptide, i.e. has one or more epitopes which are capable of eliciting an immune response in pigs and/or is capable of specifically binding to a complementary antibody. Such epitope containing sequences are at least 5-8 residues long (Geysen, H.M. et al., 1987). Methods for determining usable polypeptide fragments are outlined below. Fragments or portions can inter alia be produced by enzymatic cleavage of precursor molecules, using restriction endonucleases for the DNA and proteases for the polypeptides. Other methods include chemical synthesis of the fragments or the expression of polypeptide fragments by DNA fragments.

Fragment polypeptides of the polypeptide according to figure 2 (SEQ ID NO: 1-2) and the portions thereof, which can be used for the immunisation of animals against HC or for diagnosis of HC also form part of the present invention.

A fragment-coding region is located within the amino acid position about 1-249, 263-487, 488-688 or 689-1067. The 1-249 region essentially represents the core protein whereas the 263-487, 488-688 and 689-1067 regions essentially represent glycoproteins of 44/48 kD, 33 kD and 55 kD respectively. Within the scope of the invention are also nucleic acid sequences comprising the genetic information for one or more of the coding regions mentioned above or portions thereof.

A preferred region to be incorporated into a vaccine against HCV infection is the region corresponding to the 55 kD protein of HCV or a portion thereof still having immunizing activity.

Furthermore, a nucleic acid sequence at least comprising the coding sequences for said 55 kD protein or portion thereof can advantageously be applied according to the present invention.

In addition, a preferred portion of the HCV 55 kD protein, which can be used for immunization of pigs against HCV infection, is determined by analyses of HCV deletion mutants with anti-55 kD protein monoclonal antibodies having virus neutralizing activity. Such a portion comprising an epitope spans the amino acid sequence about 812-859 and is coded by the nucleotide sequence about 2799-2938. A polypeptide at least comprising said amino acid sequence or a nucleic acid sequence at least comprising said nucleotide sequence form part of the present invention too.

A nucleic acid sequence according to the invention which can be used for the diagnosis of HCV infection in pigs and which can be applied to discriminate HCV from BVDV can be derived from the gene encoding the 55 kD protein.

Preferably, such a nucleic acid sequence is derived from the nucleotide sequences 2587-2619 or 2842-2880, both sequences being part of the gene encoding the 55 kD protein. A preferred oligonucleotide for diagnostic purposes is (SEQ ID NO: 3 and 4, respectively):

5' - CCT ACT AAC CAC GTT AAG TGC TGT GAC TTT AAA - 3'

or

5' - TTC TGT TCT CAA GGT TGT GGG GCT CAC TGC TGT GCA CTC - 3'

Moreover, a nucleic acid sequence comprising at least a sub-sequence of said oligonucleotides and which still can be used to differentiate between HCV and BVDV forms part of the invention.

The invention also relates to a test kit to be used in an assay, this test kit containing a nucleic acid sequence according to the invention.

Preferably the test kit comprises an oligonucleotide mentioned above or a nucleic acid sequence comprising at least a sub-sequence thereof.

Variations or modifications in the polypeptide shown in figure 2 (SEQ ID NO: 1-2) or fragments thereof, such as natural variations between different strains or other derivatives, are possible while retaining the same immunologic properties. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said polypeptide.

Moreover, the potential exists, in the use of recombinant DNA technology, for the preparation of various derivatives of the polypeptide shown in figure 2 (SEQ ID NO: 1-2) or fragments thereof, variously modified by resultant single or multiple amino acid substitutions, deletions, additions or replacements, for example by means of site directed mutagenesis of the underlying DNA. All such modifications resulting in derivatives of the polypeptide shown in figure 2 (SEQ ID NO: 1-2) or fragments thereof are included within the scope of the present invention so long as the essential characteristic activity of said polypeptide or fragment thereof, remains unaffected in essence.

RNA isolated from pelleted virions was isolated and used for the synthesis of cDNA. This cDNA was cloned in phage λ gt11 and the respective library was amplified and screened with goat anti-HCV antiserum.

Two positive clones could be identified and shown to have inserts with sizes of 0,8 kb and 1,8 kb. The 0,8 kb λ gt11 insert was partially sequenced (see figure 3, SEQ ID NO: 12-13)) and determined to be located between about 1,2 and 2,0 kb on the HCV genome (see figure 2).

A nucleic acid sequence according to the invention which can be used for the diagnosis of HCV in infected animals and which surprisingly can be applied to discriminate HCV from BVDV is represented by the nucleotide sequence 5551-5793 shown in figure 2 (SEQ ID NO: 1).

Moreover, a nucleic acid sequence comprising at least a sub-sequence of said nucleotide sequence and which still can be used to differentiate between HCV and BVDV forms part of the invention.

The invention also relates to a test kit to be used in an assay, this test kit containing a nucleic acid sequence according to the invention.

Preferably the test kit comprises the nucleic acid sequence represented by the nucleotide sequence 5551-5793 shown in figure 2 (SEQ ID NO: 1) or a nucleic acid sequence comprising at least a sub-sequence thereof mentioned above.

RNA isolated from pelleted virions was isolated and used for the synthesis of cDNA. This cDNA was cloned in phage λ gt11 and the respective library was amplified and screened with goat anti-HCV antiserum. Two positive clones could be identified and shown to have inserts with sizes of 0,8 kb and 1,8 kb. The 0,8 kb λ gt11 insert was partially sequenced (see figure 3, SEQ ID NO: 12-13) and determined to be located between about 1,2 and 2,0 kb on the HCV genome (see figure 2).

A nucleic acid sequence according to the present invention can be ligated to various vector nucleic acid molecules such as plasmid DNA, bacteriophage DNA or viral DNA to form a recombinant nucleic acid molecule. The vector nucleic acid molecules preferably contain DNA sequences to initiate, control and terminate transcription and translation. A recombinant expression system comprising a host containing such a recombinant nucleic acid molecule can be used to allow for a nucleic acid sequence according to the present invention to express a polypeptide encoded by said nucleic acid sequence. The host of above-mentioned recombinant expression system can be of procaryotic origin, e.g. bacteria such as E.coli, B.subtilis and Pseudomonas, viruses such as vaccinia and fowl pox virus or eucaryotic origin such as yeasts or higher eucaryotic cells such as insect, plant or animal cells.

Immunization of animals against HC can, for example, be achieved by administering to the animal a polypeptide according to the invention as a so-called "sub-unit" vaccine. The subunit vaccine according to the invention comprises a polypeptide generally in a pure form, optionally in the presence of a pharmaceutically acceptable carrier.

Small fragments are preferably conjugated to carrier molecules in order to raise their immunogenicity. Suitable carriers for this purpose are macromolecules, such as natural polymers (proteins, like key hole limpet hemocyanin, albumin, toxins), synthetic polymers like polyamino acids (polylysine, polyalanine), or micelles of amphiphilic compounds like saponins. Alternatively these fragments may be provided as polymers thereof, preferably linear polymers. Polypeptides to be used in such subunit vaccines can be prepared by methods known in the art,

e.g. by isolation said polypeptides from hog cholera virus, by recombinant DNA techniques or by chemical synthesis.

If required the polypeptides according to the invention to be used in a vaccine can be modified in vitro or in vivo, for example by glycosylation, amidation, carboxylation or phosphorylation.

An alternative to subunit vaccines are "vector" vaccines. A nucleic acid sequence according to the invention is integrated by recombinant techniques into the genetic material of another micro-organism (e.g. virus or bacterium) thereby enabling the micro-organism to express a polypeptide according to the invention. This recombinant expression system is administered to the animal to be immunized whereafter it replicates in the inoculated animal and expresses the polypeptide resulting in the stimulation of the immune system of the animal. Suitable examples of vaccine vectors are pox viruses (such as vaccinia, cow pox, rabbit pox), avian pox viruses (such as fowl pox virus) pseudorabies virus, adeno viruses, influenza viruses, bacteriophages or bacteria (such as Escherichia coli and Salmonella).

The recombinant expression system having a nucleic acid sequence according to the invention inserted in its nucleic acid sequence can for example be grown in a cell culture and can if desired be harvested from the infected cells and formed to a vaccine optionally in a lyophilized form. Said genetically manipulated micro-organism can also be harvested from live animals infected with said micro-organism. Abovementioned recombinant expression system can also be propagated in a cell culture expressing a polypeptide according to the invention, whereafter the polypeptide is isolated from the culture.

A vaccine comprising a polypeptide or a recombinant expression system according to the present invention can be prepared by procedures well-known in the art for such vaccines. A vaccine according to the invention can consist inter alia of whole host, host extract, partially or completely purified polypeptide or a partially or completely purified recombinant expression system as above-mentioned.

The vaccine according to the invention can be administered in a conventional active immunization scheme: single or repeated administration in a manner compatible with the dosage formulation and in such amount as will be therapeutically effective and immunogenic. The administration of the vaccine can be done, e.g. intradermally, subcutaneously, intramuscularly, intra-venously or intranasally. For parenteral administration the vaccines may additionally contain a suitable carrier, e.g. water, saline or buffer solution with or without adjuvants, stabilizers, solubilizers, emulsifiers etc.

The vaccine may additionally contain immunogens related to other diseases or nucleic acid sequences encoding these immunogens like antigens of parvovirus, pseudorabies virus, swine influenza virus, TGE virus, rotavirus, Escherichia coli, Bordetella, Pasteurella, Erysipelas etc. to produce a multivalent vaccine.

Polypeptides according to the present invention can also be used in diagnostic methods to detect the presence of HCV antigen or antibody in an animal. Moreover, nucleic acid sequences according to the invention can be used to produce polypeptides to be used in above-mentioned diagnostic methods or as a hybridisation probe for the detection of the presence of HCV nucleic acid in a sample.

Example 1Immunological identification of cDNA clones

Infection of cells and harvesting of virus. PK15 and 38A₁D cells were grown in DMEM with 10% FCS and were infected in suspension by the virulent HCV strain Alfort in a volume of 20-30 ml at a cell concentration of 5×10^7 /ml at 37 °C for 90 min with an m.o.i. of 0.01 to 0.001 (as determined by immunofluorescence assay). Thereafter, the PK15 cells were seeded in tissue culture plates (150 mm diameter), while the suspension cells 38A₁D were incubated in bottles with gentle stirring (Tecnomara, Switzerland). For cDNA synthese, the tissue culture supernatant was harvested 48 hours after infection, clarified at 12,000 g, and afterwards the virus pelleted in a TFA 20 rotor (Contron, Italy) at 54,000 g for 12 hours.

Preparation of goat anti-HCV serum. A fibroblastic cell strain was established from the skin biopsy of a young goat by standard cell culture techniques. The cells were initially grown in F-10 medium with 10% FCS and later in DMEM with 10% FCS. Goat fibroblasts were infected with HCV. Over the first 26 hours p.i., the cells were washed every 8 hours 3 times with PBS and afterwards incubated in DMEM with 10% preimmune goat serum (PGS). 48 hours p.i., the tissue culture supernatant was harvested and used as stock virus. Before immunization, goat cells for 30 tissue culture dishes (150 mm diameter) were kept for 3 passages in medium with 10% PGS and then infected with the stock virus. 48 hours p.i., the goat was immunized with X-ray-inactivated pelleted virus and infected cells. Both were emulsified in Freund's adjuvant (complete for basis immunization, incomplete for booster injections) and injected subcutaneously.

To obtain antibodies recognizing denatured molecules, the antigen preparations were incubated in 0.2% SDS, 3 mM DTT at 95 °C for 5 min before injection.

RNA preparation, cDNA synthesis and cloning. RNA from virions was isolated by using the guanidine thiocyanate method described by Chirgwin et al. (1979). RNA from pelleted virions (5 µg total RNA, approximately 0.5 µg HCV RNA) and 0.1 µg of random hexanucleotide primer (Pharmacia, Sweden) in 20 µl of water were heated to 65 °C for 10 min, chilled on ice, and adjusted to first strand buffer (50 mM Tris-HCl pH 8.3; 30 mM KCl; 8 mM MgCl₂; 1 mM DTT, dATP, dCTP, dGTP, dTTP 1 mM each and 500 units RNAGuard [Pharmacia, Sweden] per ml) in a final volume of 32 µl. 35 units of AMV reverse transcriptase (Life Sciences Inc., USA) were added. After 1 hour at 43 °C the reaction mixture was added to one vial of second strand synthesis mixture (cDNA synthesis kit, Pharmacia, Sweden). Second strand synthesis, preparation of blunt ends, and Eco RI adaptor ligation and phosphorylation were done as recommended by the supplier.

The cDNA was size-fractionated by preparative agarose gel electrophoresis. The part of the gel containing DNA molecules smaller than 0.5 kb was discarded. The remaining DNA was concentrated by running the gel reversely for 15 min and extracted from the agarose after 3 cycles of freezing and thawing with phenol.

Ethanol co-precipitated cDNA and λgt11 DNA (1 µg EcoRI digested dephosphorylated arms, Promega, USA) was ligated by 3 units of T4 DNA ligase (Pharmacia, Sweden) in a total volume of 10 µl ligase buffer (30 mM Tris-HCl pH 7.4; 10 mM MgCl₂; 10 mM DTT; 1 mM ATP).

In vitro packaging with a commercially available extract (Packagene, Promega, USA) and infection of E.coli K12 cells, strain Y 1090, with resulting phages was performed as recommended by the supplier. The library was amplified once as described (Davis et al., 1986).

Screening of λ gt11 library. Screening was basically performed as described (Young and Davis, 1983) using the Protoblot system purchased from Promega, USA (Huynh et al., 1985) and a serum dilution of 10^{-3} . For background reduction the goat anti HCV serum was treated with E.coli lysate (strain Y1090) at 0.8 mg/ml (Huynh et al., 1985). Two positive clones having inserts of 0.8 kb and 1.8 kb, respectively could be identified.

Nick translation and Northern hybridization. 50 ng of the 0.8 kb HCV nucleic acid sequence labeled with [α^{32} P]dCTP (3000 Ci per mMole, Amersham Buchler, FRG) by nick translation (nick translation kit, Amersham Buchler, FRG) was hybridized to Northern filters at a concentration of 5 ng per ml of hybridization mixture (5 x SSC; 1 x Denhardt's; 20 mM sodium phosphate pH 6.8; 0.1% SDS and 100 μ g yeast tRNA [Boehringer-Mannheim, FRG] per ml) at 68 °C for 12 to 14 hours. Membranes were then washed as described (Keil et al., 1984) and exposed at -70 °C to Kodak X-Omat AR films for varying times using Agfa Curix MR 800 intensifying screens.

The 0.8 kb nucleic acid sequence hybridized not only to intact HCV RNA but also to degradation products thereof. The 0.8 kb nucleic acid sequence did not hybridize to the 1.8 kb nucleic acid sequence, indicating that these two nucleic acid sequences correspond with fragments of the HCV genome which are not located in the same region of the genomic RNA.

Nucleotide sequencing. Subcloning of HCV specific phage DNA inserts into plasmid pEMBL 18 plus was done according to standard procedures (Maniatis et al., 1982). Single-stranded DNA of recombinant pEMBL plasmids was prepared as described (Dente et al., 1985). Dideoxy sequencing reactions (Sanger et al., 1977) were carried out as recommended by the supplier (Pharmacia, Sweden).

Example 2

Molecular cloning and nucleotide sequence of the genome of HCV

RNA preparation, cDNA synthesis and cloning. RNA preparation, cDNA synthesis, size selection and ligation of co-precipitated cDNA and λ gt10 DNA (1 μ g EcoRI digested dephosphorylated arms, Promega, USA) were done as described above. In vitro packaging of phage DNA using Packagene (Promega, USA) and titration of phages on E.coli strain C 600 HFL were performed as suggested by the supplier. The library was amplified once (Davis et al., 1986), and replicas transferred to nicrocellulose membranes (Amersham Buchler, FRG) (Benton and Davis, 1977) were hybridized with oligonucleotides as described above for Northern hybridization. Screening with cDNA fragments labeled with [α^{32} P] dCTP by nick translation (nick translation kit, Amersham Buchler, FRG) was done as described by Benton and Davis (1977). Positive clones were plaque purified and inserts subcloned into pEMBL plasmids (Maniatis et al., 1982; Dente et al., 1985; Davis et al., 1986).

A ^{32}P 5'-end labeled oligonucleotide of 17 bases complementary to the RNA sequence encoding the amino acid sequence Cys Gly Asp Asp Gly Phe was used for screening a λ gt10 cDNA library. This oligonucleotide which hybridized to the about 12 kb genomic RNA of HCV, identified inter alia a clone with an insert of 0.75 kb, which hybridized also to HCV RNA. This 0.75 kb nucleic acid sequence which represents a fragment of the HCV genome together with the 0.8 kb λ gt11 nucleic acid sequence insert were used for further library screening resulting in a set of overlapping HCV nucleic acid sequences of which the relative positions and restriction site maps are shown in figure 1. These nucleic acid sequence fragments of the HCV genome are located between the following nucleic acid positions

4.0 kb fragment: 27-4027
4.5 kb fragment: 54-4494
0.8 kb fragment: 1140-2002
4.2 kb fragment: 3246-7252
5.5 kb fragment: 6656-11819

and within about the following nucleic acid positions

3.0 kb fragment: 8920-11920
1.9 kb fragment: 10384-12284
0.75 kb fragment: 10913-11663

Nucleotide sequencing. For complete nucleotide sequence determination exonuclease III and nuclease S1 (enzymes from Boehringer Mannheim, FRG) were used to establish deletion libraries of HCV derived cDNA inserts subcloned into pEMBL 18+ or 19+ plasmids (Hennikoff, 1987). Dideoxy sequencing (Sanger et al. 1977) of single stranded (Dente et al., 1985) or double stranded DNA templates was carried out using the T7 polymerase sequencing kit (Pharmacia, Sweden).

From the cDNA fragments a continuous sequence of 12284 nucleotides in length could be determined as shown in figure 2 (SEQ ID NO: 1). This sequence contains one long open reading frame (ORF), starting with the ATG codon at position 364 to 366 and ending with TGA as a translational stop codon at 12058 to 12060. This ORF consists of 3898 codons capable of encoding a 435 kDa protein with an amino acid sequence shown in figure 2 (SEQ ID NO: 1-2). Three nucleotide exchanges were detected as a result of differences in nucleotide sequence caused by possible heterogeneity of the virus population, two of which resulted in changes in the deduced amino acid sequence (figure 2, SEQ ID NO: 1-2).

It is concluded that almost the complete HCV genome has been cloned and sequenced by the procedures described above.

The 0.8 kb λ gt11 nucleic acid sequence encoding an immunogenic HCV polypeptide identified with anti HCV serum was partially sequenced (see figure 3, SEQ ID NO: 12-13) which revealed that this sequence is located within 1.2 and 2.0 kb on the HCV RNA.

Example 3

Molecular cloning and expression of fusion proteins of HCV

cDNA fragments derived from two regions of the HCV genome, i.e. the 0,8 kb λ gt11 insert of example 1 encoding amino acids 262-546 (see figure 2, SEQ ID NO: 1-2) and the nucleic acid sequence encoding amino acids 747-1071 (figure 2, SEQ ID NO: 1-2), are expressed as fusion proteins in the pEx system (Strebel, K. et al., 1986).

Bacterial extracts were separated by SDS-PAGE and stained according to standard procedures, and then tested for reactivity with the goat anti-HCV serum of example 1 in a Western blot.

The HCV specific fusion proteins were partially purified by SDS-PAGE and transferred to nitrocellulose and incubated with the goat anti-HCV serum. Specific antibodies against said fusion proteins were obtained after elution.

Antibodies specific for the above-mentioned fusion proteins were employed in a radio-immuno precipitation assay.

Results

Both fusion proteins expressed in the pEx system were clearly identified as HCV specific after reaction with the goat anti-HCV serum.

Monospecific antiserum prepared against both fusions proteins precipitated HCV glycoproteins.

Antibodies specific for the 262-546-fusion protein precipitated the 44/48 kD and 33 kD protein, antibodies specific for the 747-1071-fusion protein precipitated the 55 kD protein from virus infected cells.

Example 4Molecular cloning and expression of structural proteins via vaccinia virus

A fragment of the 4,0 kb clone shown in figure 1 (pHCK11) is prepared starting at the HinfI restriction site (nucleotide 372) and ending at an artificial EcoRI site (nucleotide 4000) (Maniatis et al. 1982). For the 5' end an oligonucleotide adaptor was synthesized which contained an overhang compatible to BamHI, the original ATG(364-366) as translational start codon and a protruding end compatible to HinfI at the 3' end (SEQ ID NO: 5 and 6).

	5' GATCCACCATGGAGTT	HinfI
BamHI	GTGGTACCTCAACTTA	5'

At the 3' end of the construct a translational stop codon was introduced by deletion of the EcoRI protruding end with Mung bean nuclease and ligation into a blunt-end StuI/EcoRI adaptor residue (SEQ ID NO: 7):

5' GCCTGAATTC	3'EcoRI
CGGACTTAAG	

(Maniatis et al. 1982).

Prior to inserting above-mentioned HCV sequences into vaccinia virus the heterologous gene is cloned into a recombination vector. For this purpose a pGS62 plasmid (Cranage, M.P. et al. 1986) was used which contains a cloning site downstream the P7.5K promoter within the 4.9kb thymidine kinase sequence. The cloning site comprises three unique restriction sites, BamHI, SmaI and EcoRI. The recombination vector pGS62-3.8 was established by ligation of the described HCV sequence (372-4000) together with the adaptors into the BamHI/EcoRI digested pGS62.

Based on the plasmid a set of 15 deletion mutants was established. By treatment with ExonucleaseIII (Hennikof et al., 1987) subsequent shortening of the HCV cDNA from the 3' end was performed. All deletions are located within the region coding for the HCV 55 kD protein by removal of about 100bp; most of the 55 kD protein is lost in mutant 15 ending at nucleotide 2589. ExoIII shortened cDNA clones were ligated into the pGS62 giving rise to pGS62-3.8Exo 1-15 (figure 4).

CVI cells were infected with vaccinia (strain Copenhagen, mutant TS7) at a MOI of 0.1. Three hours after infection pGS62-3.8 DNA as well as vaccinia WR DNA were transfected by the $\text{Ca}_3(\text{PO}_4)_2$ precipitation method and incubated for two days. Virus progeny was harvested and selected for tk-phenotype on 143 tk-cells in the presence of brom-deoxy-Uridine (100 $\mu\text{g/ml}$). This selection was performed at least twice followed by two further cycles of plaque purification.

Characterization of vaccinia-HCV recombinants

CVI cells were infected at a MOI between 2 and 10 with vaccinia-HCV recombinants and incubated for 8-16 hours. After fixation of the cells indirect immunofluorescence was performed using either monoclonal antibodies specific for HCV 55 kD protein or polyvalent anti-HCV sera. In all cases a cytoplasmatic fluorescence could be demonstrated.

After radioimmunoprecipitation and western blot analysis of cells infected with vaccinia recombinants four HCV-specific proteins were detected. By labeling with [^3H] glucosamine it was shown that three of these proteins are glycosylated. The apparent molecular weights of these proteins were identical to those found in HCV infected cells with HCV specific sera, namely 20 kD(core), 44/48 kD, 33 kD and 55 kD.

Proteolytic processing and modifications appear to be authentic since HCV proteins produced by expression via vaccinia virus have the same apparent molecular weights as in HCV infected cells.

Induction of neutralizing antibodies against HCV in mice.

Four groups of mice (3 mice/group) were infected once with

- | | | |
|--|-----------------------------------|--------------|
| a. Vaccinia WR wildtype | (5×10^6 pfu/individual) | WR |
| b. Vaccinia 3.8 recombinant | (5×10^7 pfu/individual) | VAC3.8 |
| c. Vaccinia 3.8Exo 4
(55 kD deleted) | (5×10^7 pfu/individual) | VAC3.8Exo 4 |
| d. Vaccinia 3.8Exo 5 | (5×10^7 pfu/individual) | VAC3.8Exo 5 |
| e. Vaccinia 3.8Exo 15
(55 kD deleted) | (5×10^7 pfu/individual) | VAC3.8Exo 15 |

by injection of purified virus intraperitoneally.

Mice were bled three weeks later. The reactivity of the sera was checked in a virus neutralization assay with HCV (Alfort) on PK[15] cells after serial dilution. (Rümenapf, T. et al. 1989).

Neutralization titers

- | | |
|-----------------|------|
| a. WR | <1:2 |
| b. VAC3.8 | 1:96 |
| c. VAC3.8Exo 4 | 1:96 |
| d. VAC3.8Exo 5 | <1:2 |
| e. VAC3.8Exo 15 | <1.2 |

From the above it can be concluded that vaccinia virus containing a nucleic acid sequence comprising the genetic information for all structural proteins (VAC3.8) is able to induce virus neutralizing antibodies in mice, while incomplete constructs VAC3.8Exo 5-15 and WR are not.

As all deletions are located within the region coding for HCV 55 kD protein (most of the 55 kD protein is lost in mutant 15 ending at nucleotide 2589) and the other structural proteins are still being expressed by the recombinant vaccinia virus, it is clear that the 55 kD protein is responsible for the induction of HCV neutralizing antibodies.

Example 5

Immunization of pigs with VAC3.8

Out of three piglets (about 20 kg in weight) one animal (no. 28) was infected with wild type vaccinia virus (WR strain) and the other two (no. 26, 27) with recombinant VAC3.8 (i.p., i.v. and i.d., respectively). For infection 1×10^8 pfu of vaccinia virus is applied to each animal.

Clinical signs in the course of vaccinia infection were apparent as erythema at the side of scarification and fever (41°C) at day six after infection.

Titers against vaccinia and hog cholera virus:

Three weeks after infection the reactivity of the respective sera against vaccinia (WR on CVI cells) and HCV (Alfort on PK15 cells) was checked.

Neutralization was assayed after serial dilution of the sera by checking for complete absence of cpe (vaccinia) or specific signals in immunofluorescence (HCV). (Rümenapf, T. et al. 1989).

Neutralization titers against vaccinia:

pig 28 (WR)	1:8
pig 26 (VAC3.8)	1:16
pig 27 (VAC3.8)	1:16

Neutralization titers against HCV:

pig 28 (WR)	<1:2
pig 26 (VAC3.8)	1:32
pig 27 (VAC3.8)	1:16

Challenge with HCV:

Four weeks after immunization with vaccinia each of the pigs was challenged by infection with 5×10^7 TCID₅₀ HCV Alfort. Virus was applicated oronasal according to the natural route of infection. This amount of virus has been experimentally determined to be compulsory lethal for pigs.

On day five after the challenge infection pig 28 revealed fever of 41.5 °C and kept this temperature until day 12. The moribund animal was killed that day expressing typical clinical signs of acute hog cholera.

Both pigs (26, 27) immunized with VAC3.8 did not show any sign of illness after the challenge with HCV for more than 14 days.

Example 6Construction of a 55 kD protein expression vectorA. PRV vector.

Clone pHCK11 is digested with restriction enzymes SacI and HpaI according to standard techniques.

The resulting 1.3 kb fragment, located between nucleotides 2672 (AGCTC) and 3971 (GTT) comprising most of HCV 55 kD protein, is isolated and cloned into the pseudorabies virus (PRV) gX gene (Maniatis et al. 1982).

Briefly, the cloned gX sequence was digested with SacI and ApaI. The ApaI 5' protruding ends were made blunt by filling up with Klenow fragment. After ligation the putative gX leader peptide coding sequence was located just upstream of the inserted HCV 55 kD sequence.

A translational stop codon downstream the HCV sequence was introduced by digestion with Bgl II (Bgl II site: 3936-3941) and religation after filling up the overhangs with Klenow fragment. This construct was placed downstream of the PRV gX promoter (clone 16/4-1.3). Clone 16/4-1.3 was transfected into MDBK cells by the DEAE dextran method (Maniatis et al. 1989). 16 h. later cells were infected with PRV (m.o.i.=1). 4 h. post infection cells were fixed with a mixture of cold (-20 °C) methanol/acetone. Indirect immunofluorescence with monoclonal antibodies (MABs) anti-HCV 55 kD protein revealed a specific signal in 5-10% of the cells. PRV infected cells without transfection and cells only transfected with clone 16/4-1.3 did not show any signal in this assay.

B. Vaccinia vector.

Clone pHCK11 is digested with restriction enzymes NheI and HpaI according to standard techniques. NheI 5' protruding end was made blunt by treatment with mung bean nuclease. The resulting 1.5 kb fragment, located between nucleotides 2438 (C) and 3971 (GTT) comprising HCV 55 kD protein, is isolated and cloned into the pseudorabies virus (PRV) gx gene (Maniatis et al., 1989).

The cloned gx sequence was digested with SacI and ApaI. SacI and ApaI 3' protruding ends were made blunt by exonuclease treatment with Klenow fragment. After ligation the putative gx leader peptide coding sequence was located upstream of the inserted HCV 55 kD sequence.

A translational stop codon downstream the HCV sequence was introduced by digestion with BglIII (BglIII site 3936-3941) and religation after filling up the overhangs with Klenow fragment. This construct was isolated by digestion with restriction enzymes AvIII and ScaI. Vaccinia recombination plasmid pGS62A (Cranage et al.; 1986) is digested with SmaI. The HCV coding sequence with gx leader sequence is ligated into the SmaI site of pGS62A. CVI-cells were infected with wild type Vaccinia strain WR and transfected with pGS62A containing gp 55 coding sequences. (Macket et al., 1984) Recombinant Vaccinia viruses expressing HCV gp55 were isolated.

Metabolic labeling of CVI cells infected with the Vaccinia recombinant virus containing the HCV gp55 gene was performed. HCV gp55 was detected after radio-immuno precipitation with HCV neutralizing monoclonal antibodies, SDS-PAGE and fluorography. Under nonreducing conditions for SDS-PAGE, the disulfide linked HCV gp55 homodimer (apparent molecular weight of about 100 kD) was observed. The migration characteristics were the same as for HCV gp55 precipitated from HCV infected cells.

Example 7Construction of a 44/48 kD protein expression vector

Clone pHCK11 is digested with restriction enzymes *Egl*I and *Ban*I according to standard techniques. The resulting 0.7 kb fragment, located between nucleotide 1115 (TGTTGGC) and 1838 (GTGC) comprising the HCV 44/48 kD protein, is isolated and ligated to synthetic adaptors connecting the 5' *Bgl*I restriction site with the *Bam*HI site of the vaccinia recombination vector pGS62A and the 3' *Ban*I site with the *Eco*RI site of the vaccinia recombination vector. The sequence of the 5' adaptor is (SEQ ID NO: 8 and 9).

5'-GATCCACCATGGGGGCCCTGT-3'
GTGGTACCCCCGGG

The sequence of the 3' adaptor is (SEQ ID NO: 10 and 11)

5'-GTGCCTATGCCTGAG-3'
GATACGGACTCTTAA

CVI-cells were infected with wild type Vaccinia strain WR and transfected with pGS62A containing the gp 44/48 coding sequences. Recombinant Vaccinia viruses expressing HCV gp 44/48 were isolated.

Metabolic labeling of CVI cells infected with the Vaccinia recombinant virus containing the HCV gp 44/48 gene was performed. HCV gp 44/48 was detected after radio-immuno precipitation with monoclonal antibodies, SDS-PAGE and fluorography. Under nonreducing conditions for SDS-PAGE, the disulfide linked HCV gp 44/48 homodimer (apparent molecular weight of about 100 kD) was observed. The migration characteristics were the same as for HCV gp 44/48 precipitated from HCV infected cells. It was demonstrated that the monoclonal antibodies which precipitated gp 44/48 from cells infected with the Vaccinia recombinant neutralize HCV.

Brief description of the drawings

Fig. 1 displays physical maps of different HCV derived cDNA clones and their position relative to the RNA genome (upper line). Two HCV derived cDNA clones isolated after screening with either the antibody probe (0.8 kb clone) or the degenerated oligonucleotide probe (0.75 kb clone) are shown in the second line. The cDNA fragments chosen for nucleotide sequencing are indicated below. All numbers represent sizes of DNA fragments in kb. Restriction sites: B = Bgl II; E = EcoRI; H = Hind III; K = Kpn I; S = Sal I; Sm = Sma I.

Fig. 2 depicts a nucleic acid sequence of HCV and deduced amino acid sequence of the long open reading frame. Nucleotide exchanges between different cDNA clones and resulting changes in amino acid sequence are indicated. The part of the sequence corresponding to the oligonucleotide used for screening is underlined.

Fig. 3 shows the cDNA sequence from part of the 0.8 kb HCV insert of a λ gt11 clone and the deduced amino acid sequence in one-letter code.

Fig. 4 shows the length of the HCV DNA cloned in the pGS62 vector. A set of 15 deletion mutants derived from cDNA clone pHCK11 was established by treatment with Exonuclease III and cloned in the pGS62 vector giving rise to pGS62-3.8Exo 1-15. 3' end nucleotides are indicated.

References

- BENTON, W., and DAVIS, R. (1977). Screening λ gt recombinant clones by hybridization to single plaques in situ. *Science* 196, 180-182.
- CHIRGWIN, J.M., PRZYBYLA, A.E., MACDONALD, R.J., and RUTTER, W.J. (1979). Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease, *Biochemistry* 18, 5294-5299.
- CRANAGE, M.P. et al. (1986). *EMBO, J.* 5, 3057-3063.
- DAVIS, L.G., DIBNER, M.D., and BATTEY, J.F. (1986). *Basic Methods in Molecular Biology*, 190-191. Elsevier, New York, Amsterdam, London.
- DENTE, L., SOLLAZZO, M., BALDARI, C., CESARENI, G., and CORTESE, R. (1985). The pEMBL family of single-stranded vectors. In: *DNA Cloning*, Vol. 1, (Glover, D.M., ed.), IRL Press Oxford/Washington DC, pp. 101-107.
- GEYSEN et al., H.M. (1987) *J. Immunol. Meth.* 102, 259-274.
- HENNIKOFF, S. (1987). Unidirectional digestion with exonuclease III in DNA sequence analysis. In: *Meth. Enzymol.* (Wu, R., ed.) 155, 156-165.
- HUYNH, T.V., YOUNG, R.A., and DAVIS, R.W. (1985). Constructing and screening cDNA libraries in λ gt10 and λ gt11. In: *DNA Cloning: A Practical Approach*, Vol. 2, (Glover, D.M., ed.), IRL Press Oxford, pp. 49-78.
- KEIL, G.M., EBELING-KEIL, A., and KOSZINOWSKI, U.H. (1984). Temporal regulation of murine cytomegalovirus transcription and mapping of viral RNA synthesized at immediate early times after infection, *J. Virol.* 50, 784-795.
- MACKETT, M. et al. (1984) *J. Virol.* 49, 857-864.
- MANIATIS, T., FRITSCH, E.F., and SAMBROOKS, S. (1982). *Molecular Cloning, a Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

- SANGER, F., NICKLEN, S., and COULSON, A.R. (1977). DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74, 5363-5467.
- MANIATIS, T. et al. (1989). Molecular Cloning, a Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- STREBEL, K. et al. (1986). J. Virology 57, 983-991.
- RÜMENOPF, T. et al. (1989). Virology 171, 18-27.
- YOUNG, R.A., and DAVIS, R.W. (1983). Efficient isolation of genes by using antibody probes. Proc. Natl. Acad. Sci. U.S.A. 80, 1194-1198.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Gregor Meyers, Tillmann Rümenapf,
Heinz-Jürgen Thiel
- (ii) TITLE OF INVENTION: Hog cholera virus vaccine and diagnostic
- (iii) NUMBER OF SEQUENCES: 13
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Organon Teknika Corporation
Biotechnology Research Institute
 - (B) STREET: 1330-A Piccard Drive
 - (C) CITY: Rockville
 - (D) STATE: Maryland
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 20850
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 494,991
 - (B) FILING DATE: 16 March 1990
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: William M. Blackstone
 - (B) REGISTRATION NUMBER: 29,772
 - (C) REFERENCE/DOCKET NUMBER:
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (301) 258-5200

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12284 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Hog cholera virus
 - (B) STRAIN: Alfort
 - (H) CELL LINE: PK 15 and 38A1D
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 364..12060
 - (D) OTHER INFORMATION: /label= 435_kDA_protein
- (ix) FEATURE:
 - (A) NAME/KEY: primer_bind
 - (B) LOCATION: complement (2587..2619)
 - (D) OTHER INFORMATION: /label= primer_1
- (ix) FEATURE:
 - (A) NAME/KEY: primer_bind
 - (B) LOCATION: complement (2842..2880)
 - (D) OTHER INFORMATION: /label= primer_2
- (ix) FEATURE:
 - (A) NAME/KEY: variation
 - (B) LOCATION: replace(127, "c")
- (ix) FEATURE:
 - (A) NAME/KEY: variation
 - (B) LOCATION: replace(1522, "g")
- (ix) FEATURE:
 - (A) NAME/KEY: variation
 - (B) LOCATION: replace(10989, "t")

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

GTTAGCTCTT TCTCGTATAC GATATTGGAT AACTAAATT TCGATTGGT CTAGGGCACC      60
CCTCCAGCGA CGGCCGAAAT GGGCTAGCCA TGCCCATAGT AGGACTAGCA AACGGAGGGA      120
CTAGCCGTAG TGGCGAGCTC CCTGGGTGGT CTAAGTCCTG AGTACAGGAC AGTCGTCAGT      180
AGTTCGACGT GAGCACTAGC CCACCTCGAG ATGCTACGTG GACGAGGGCA TGCCCAAGAC      240
ACACCTTAAC CCTGGCGGGG GTCGCTAGGG TGAAATCACA TTATGTGATG GGGGTACGAC      300

```

CTGATAGGGT GCTGCAGAGG CCCACTAGCA GGCTAGTATA AAAATCTCTG CTGTACATGG	360
CAC ATG GAG TTG AAT CAT TTT GAA TTA TTA TAC AAA ACA AGC AAA CAA Met Glu Leu Asn His Phe Glu Leu Leu Tyr Lys Thr Ser Lys Gln 1 5 10 15	408
AAA CCA GTG GGA GTG GAG GAA CCG GTG TAT GAC ACC GCG GGG AGA CCA Lys Pro Val Gly Val Glu Glu Pro Val Tyr Asp Thr Ala Gly Arg Pro 20 25 30	456
CTA TTT GGG AAC CCA AGT GAG GTA CAC CCA CAA TCA ACG CTG AAG CTG Leu Phe Gly Asn Pro Ser Glu Val His Pro Gln Ser Thr Leu Lys Leu 35 40 45	504
CCA CAC GAC AGG GGG AGA GGA GAT ATC AGA ACA ACA CTG AGG GAC CTA Pro His Asp Arg Gly Arg Gly Asp Ile Arg Thr Thr Leu Arg Asp Leu 50 55 60	552
CCC AGG AAA GGT GAC TGT AGG AGT GGC AAC CAT CTA GGC CCG GTT AGT Pro Arg Lys Gly Asp Cys Arg Ser Gly Asn His Leu Gly Pro Val Ser 65 70 75	600
GGG ATA TAC ATA AAG CCC GGC CCT GTC TAC TAT CAG GAC TAC ACG GGC Gly Ile Tyr Ile Lys Pro Gly Pro Val Tyr Tyr Gln Asp Tyr Thr Gly 80 85 90 95	648
CCA GTC TAT CAC AGA GCT CCT TTA GAG TTC TTT GAT GAG GCC CAG TTC Pro Val Tyr His Arg Ala Pro Leu Glu Phe Phe Asp Glu Ala Gln Phe 100 105 110	696
TGC GAG GTG ACT AAG AGA ATA GGC AGG GTC ACG GGT AGT GAT GGT AAG Cys Glu Val Thr Lys Arg Ile Gly Arg Val Thr Gly Ser Asp Gly Lys 115 120 125	744
CTT TAC CAC ATA TAT GTG TGC GTC GAT GGT TGC ATA CTG CTG AAA TTA Leu Tyr His Ile Tyr Val Cys Val Asp Gly Cys Ile Leu Leu Lys Leu 130 135 140	792
GCC AAA AGG GGC ACA CCC AGA ACC CTA AAG TGG ATT AGG AAC TTC ACC Ala Lys Arg Gly Thr Pro Arg Thr Leu Lys Trp Ile Arg Asn Phe Thr 145 150 155	840
AAC TGT CCA TTA TGG GTA ACC AGT TGC TCC GAT GAC GGC GCA AGT GGC Asn Cys Pro Leu Trp Val Thr Ser Cys Ser Asp Asp Gly Ala Ser Gly 160 165 170 175	888
AGC AAG GAT AAG AAG CCA GAC AGA ATG AAC AAA GGT AAG TTG AAG ATA Ser Lys Asp Lys Lys Pro Asp Arg Met Asn Lys Gly Lys Leu Lys Ile 180 185 190	936
GCC CCA AGA GAG CAT GAG AAG GAC AGC AAG ACC AAG CCT CCT GAT GCA Ala Pro Arg Glu His Glu Lys Asp Ser Lys Thr Lys Pro Pro Asp Ala 195 200 205	984

ACG	ATT	GTA	GTA	GAG	GGA	GTA	AAA	TAC	CAA	ATC	AAA	AAG	AAA	GGC	AAA	1032
Thr	Ile	Val	Val	Glu	Gly	Val	Lys	Tyr	Gln	Ile	Lys	Lys	Lys	Gly	Lys	
		210					215					220				
GTC	AAA	GGG	AAG	AAC	ACA	CAA	GAC	GGC	CTG	TAC	CAT	AAT	AAG	AAC	AAG	1080
Val	Lys	Gly	Lys	Asn	Thr	Gln	Asp	Gly	Leu	Tyr	His	Asn	Lys	Asn	Lys	
	225					230					235					
CCA	CCA	GAG	TCC	AGG	AAG	AAA	CTA	GAA	AAA	GCC	CTG	TTG	GCT	TGG	GCG	1128
Pro	Pro	Glu	Ser	Arg	Lys	Lys	Leu	Glu	Lys	Ala	Leu	Leu	Ala	Trp	Ala	
240					245					250					255	
GTG	ATA	ACA	ATC	TTG	CTG	TAC	CAG	CCT	GTA	GCA	GCC	GAG	AAC	ATA	ACT	1176
Val	Ile	Thr	Ile	Leu	Leu	Tyr	Gln	Pro	Val	Ala	Ala	Glu	Asn	Ile	Thr	
			260						265					270		
CAA	TGG	AAC	CTG	AGT	GAC	AAC	GGC	ACT	AAT	GGT	ATT	CAG	CGA	GCC	ATG	1224
Gln	Trp	Asn	Leu	Ser	Asp	Asn	Gly	Thr	Asn	Gly	Ile	Gln	Arg	Ala	Met	
		275						280					285			
TAT	CTT	AGA	GGG	GTT	AAC	AGG	AGC	TTA	CAT	GGG	ATC	TGG	CCC	GAG	AAA	1272
Tyr	Leu	Arg	Gly	Val	Asn	Arg	Ser	Leu	His	Gly	Ile	Trp	Pro	Glu	Lys	
		290					295					300				
ATA	TGC	AAG	GGG	GTC	CCC	ACT	CAT	CTG	GCC	ACT	GAC	ACG	GAA	CTG	AAA	1320
Ile	Cys	Lys	Gly	Val	Pro	Thr	His	Leu	Ala	Thr	Asp	Thr	Glu	Leu	Lys	
	305					310					315					
GAG	ATA	CGC	GGG	ATG	ATG	GAT	GCC	AGC	GAG	AGG	ACA	AAC	TAT	ACG	TGC	1368
Glu	Ile	Arg	Gly	Met	Met	Asp	Ala	Ser	Glu	Arg	Thr	Asn	Tyr	Thr	Cys	
320				325						330					335	
TGT	AGG	TTA	CAA	AGA	CAT	GAA	TGG	AAC	AAA	CAT	GGA	TGG	TGT	AAC	TGG	1416
Cys	Arg	Leu	Gln	Arg	His	Glu	Trp	Asn	Lys	His	Gly	Trp	Cys	Asn	Trp	
			340						345					350		
TAC	AAC	ATA	GAC	CCT	TGG	ATT	CAG	TTA	ATG	AAC	AGG	ACC	CAA	ACA	AAT	1464
Tyr	Asn	Ile	Asp	Pro	Trp	Ile	Gln	Leu	Met	Asn	Arg	Thr	Gln	Thr	Asn	
			355					360					365			
TTG	ACA	GAA	GGC	CCT	CCA	GAT	AAG	GAG	TGT	GCC	GTG	ACC	TGC	AGG	TAT	1512
Leu	Thr	Glu	Gly	Pro	Pro	Asp	Lys	Glu	Cys	Ala	Val	Thr	Cys	Arg	Tyr	
		370					375					380				
GAC	AAA	AAT	ACC	GAT	GTC	AAC	GTG	GTC	ACC	CAG	GCC	AGG	AAT	AGG	CCA	1560
Asp	Lys	Asn	Thr	Asp	Val	Asn	Val	Val	Thr	Gln	Ala	Arg	Asn	Arg	Pro	
	385					390					395					
ACT	ACT	CTG	ACT	GGC	TGC	AAG	AAA	GGG	AAA	AAC	TTT	TCA	TTC	GCA	GGC	1608
Thr	Thr	Leu	Thr	Gly	Cys	Lys	Lys	Gly	Lys	Asn	Phe	Ser	Phe	Ala	Gly	
400				405						410					415	
ACA	GTC	ATA	GAG	GGC	CCG	TGC	AAT	TTC	AAC	GTT	TCC	GTG	GAG	GAC	ATC	1656
Thr	Val	Ile	Glu	Gly	Pro	Cys	Asn	Phe	Asn	Val	Ser	Val	Glu	Asp	Ile	
				420					425					430		

TTA	TAC	GGA	GAC	CAT	GAG	TGT	GGC	AGT	CTG	CTC	CAG	GAC	ACG	GCT	CTG	1704
Leu	Tyr	Gly	Asp	His	Glu	Cys	Gly	Ser	Leu	Leu	Gln	Asp	Thr	Ala	Leu	
		435					440					445				
TAC	CTA	TTG	GAT	GGA	ATG	ACC	AAC	ACT	ATA	GAG	AAT	GCC	AGG	CAA	GGT	1752
Tyr	Leu	Leu	Asp	Gly	Met	Thr	Asn	Thr	Ile	Glu	Asn	Ala	Arg	Gln	Gly	
		450					455					460				
GCG	GCG	CGG	GTG	ACA	TCT	TGG	CTT	GGG	AGG	CAG	CTC	AGT	ACC	GCA	GGG	1800
Ala	Ala	Arg	Val	Thr	Ser	Trp	Leu	Gly	Arg	Gln	Leu	Ser	Thr	Ala	Gly	
		465				470					475					
AAG	AAG	CTA	GAG	AGG	AGA	AGC	AAA	ACC	TGG	TTT	GGT	GCC	TAT	GCC	CTG	1848
Lys	Lys	Leu	Glu	Arg	Arg	Ser	Lys	Thr	Trp	Phe	Gly	Ala	Tyr	Ala	Leu	
480					485					490					495	
TCA	CCT	TAC	TGC	AAT	GTG	ACT	AGA	AAA	ATA	GGG	TAC	ATA	TGG	TAT	ACA	1896
Ser	Pro	Tyr	Cys	Asn	Val	Thr	Arg	Lys	Ile	Gly	Tyr	Ile	Trp	Tyr	Thr	
				500					505						510	
AAC	AAC	TGC	ACC	CCG	GCA	TGC	CTC	CCT	AAG	AAC	ACA	AAA	ATA	ATA	GGC	1944
Asn	Asn	Cys	Thr	Pro	Ala	Cys	Leu	Pro	Lys	Asn	Thr	Lys	Ile	Ile	Gly	
			515					520					525			
CCT	GGA	AAG	TTT	GAC	ACC	AAT	GCG	GAA	GAC	GGG	AAG	ATC	CTT	CAT	GAA	1992
Pro	Gly	Lys	Phe	Asp	Thr	Asn	Ala	Glu	Asp	Gly	Lys	Ile	Leu	His	Glu	
		530					535					540				
ATG	GGG	GGC	CAC	CTA	TCA	GAA	TTT	TTG	TTG	CTT	TCT	CTA	GTT	ATC	CTG	2040
Met	Gly	Gly	His	Leu	Ser	Glu	Phe	Leu	Leu	Leu	Ser	Leu	Val	Ile	Leu	
	545					550					555					
TCT	GAC	TTT	GCC	CCC	GAG	ACA	GCT	AGC	ACG	CTA	TAC	CTA	ATT	TTA	CAC	2088
Ser	Asp	Phe	Ala	Pro	Glu	Thr	Ala	Ser	Thr	Leu	Tyr	Leu	Ile	Leu	His	
560					565					570					575	
TAT	GCA	ATC	CCC	CAG	TCC	CAC	GAA	GAA	CCT	GAA	GGT	TGT	GAT	ACG	AAC	2136
Tyr	Ala	Ile	Pro	Gln	Ser	His	Glu	Glu	Pro	Glu	Gly	Cys	Asp	Thr	Asn	
				580					585						590	
CAA	CTT	AAC	CTA	ACA	GTG	AAA	CTT	AGG	ACA	GAA	GAC	GTA	GTG	CCA	TCA	2184
Gln	Leu	Asn	Leu	Thr	Val	Lys	Leu	Arg	Thr	Glu	Asp	Val	Val	Pro	Ser	
			595					600					605			
TCA	GTT	TGG	AAT	ATT	GGC	AAA	TAT	GTT	TGT	GTT	AGA	CCA	GAC	TGG	TGG	2232
Ser	Val	Trp	Asn	Ile	Gly	Lys	Tyr	Val	Cys	Val	Arg	Pro	Asp	Trp	Trp	
		610					615						620			
CCG	TAT	GAA	ACT	AAA	GTG	GCT	CTG	CTG	TTT	GAA	GAG	GCA	GGA	CAG	GTT	2280
Pro	Tyr	Glu	Thr	Lys	Val	Ala	Leu	Leu	Phe	Glu	Glu	Ala	Gly	Gln	Val	
		625				630					635					
ATA	AAG	CTA	GTC	CTA	CGG	GCA	CTG	AGG	GAT	TTA	ACT	AGG	GTC	TGG	AAC	2328
Ile	Lys	Leu	Val	Leu	Arg	Ala	Leu	Arg	Asp	Leu	Thr	Arg	Val	Trp	Asn	
640					645					650					655	

AGC	GCA	TCA	ACT	ACT	GCG	TTT	CTC	ATT	TGC	TTG	ATA	AAA	GTA	TTG	AGA	2376
Ser	Ala	Ser	Thr	Thr	Ala	Phe	Leu	Ile	Cys	Leu	Ile	Lys	Val	Leu	Arg	
				660					665					670		
GGA	CAG	GTT	GTG	CAA	GGT	ATA	ATA	TGG	CTG	CTG	CTG	GTG	ACC	GGG	GCA	2424
Gly	Gln	Val	Val	Gln	Gly	Ile	Ile	Trp	Leu	Leu	Leu	Val	Thr	Gly	Ala	
			675					680					685			
CAA	GGG	CGG	CTA	GCC	TGT	AAG	GAA	GAC	TAC	AGG	TAT	GCG	ATC	TCG	TCA	2472
Gln	Gly	Arg	Leu	Ala	Cys	Lys	Glu	Asp	Tyr	Arg	Tyr	Ala	Ile	Ser	Ser	
		690					695					700				
ACC	AAT	GAG	ATA	GGG	CTG	CTG	GGC	GCT	GAA	GGT	CTC	ACC	ACT	ACC	TGG	2520
Thr	Asn	Glu	Ile	Gly	Leu	Leu	Gly	Ala	Glu	Gly	Leu	Thr	Thr	Thr	Trp	
	705					710					715					
AAA	GAA	TAC	AGC	CAC	GGT	TTG	CAG	CTG	GAC	GAC	GGA	ACC	GTT	AAG	GCC	2568
Lys	Glu	Tyr	Ser	His	Gly	Leu	Gln	Leu	Asp	Asp	Gly	Thr	Val	Lys	Ala	
720					725				730						735	
GTC	TGC	ACT	GCA	GGG	TCC	TTT	AAA	GTC	ACA	GCA	CTT	AAC	GTG	GTT	AGT	2616
Val	Cys	Thr	Ala	Gly	Ser	Phe	Lys	Val	Thr	Ala	Leu	Asn	Val	Val	Ser	
				740					745					750		
AGG	AGG	TAT	CTA	GCA	TCA	TTG	CAC	AAG	AGG	GCT	CTA	CCC	ACC	TCA	GTG	2664
Arg	Arg	Tyr	Leu	Ala	Ser	Leu	His	Lys	Arg	Ala	Leu	Pro	Thr	Ser	Val	
			755					760					765			
ACA	TTT	GAG	CTC	CTA	TTT	GAC	GGG	ACC	AAC	CCA	GCA	ATC	GAG	GAG	ATG	2712
Thr	Phe	Glu	Leu	Leu	Phe	Asp	Gly	Thr	Asn	Pro	Ala	Ile	Glu	Glu	Met	
		770				775						780				
GAT	GAT	GAC	TTC	GGA	TTT	GGG	CTG	TGC	CCA	TTT	GAC	ACG	AGT	CCT	GTG	2760
Asp	Asp	Asp	Phe	Gly	Phe	Gly	Leu	Cys	Pro	Phe	Asp	Thr	Ser	Pro	Val	
	785					790					795					
ATC	AAA	GGG	AAG	TAC	AAC	ACC	ACT	TTG	TTA	AAC	GGC	AGT	GCT	TTC	TAT	2808
Ile	Lys	Gly	Lys	Tyr	Asn	Thr	Thr	Leu	Leu	Asn	Gly	Ser	Ala	Phe	Tyr	
800					805					810					815	
CTA	GTC	TGC	CCA	ATA	GGA	TGG	ACT	GGT	GTC	GTA	GAG	TGC	ACA	GCA	GTG	2856
Leu	Val	Cys	Pro	Ile	Gly	Trp	Thr	Gly	Val	Val	Glu	Cys	Thr	Ala	Val	
				820					825					830		
AGC	CCC	ACA	ACC	TTG	AGA	ACA	GAA	GTG	GTG	AAA	ACC	TTC	AGG	AGA	GAT	2904
Ser	Pro	Thr	Thr	Leu	Arg	Thr	Glu	Val	Val	Lys	Thr	Phe	Arg	Arg	Asp	
			835					840					845			
AAG	CCT	TTT	CCA	CAT	AGA	GTA	GAC	TGT	GTG	ACC	ACC	ATA	GTA	GAA	AAA	2952
Lys	Pro	Phe	Pro	His	Arg	Val	Asp	Cys	Val	Thr	Thr	Ile	Val	Glu	Lys	
		850					855					860				
GAA	GAC	CTA	TTC	CAT	TGC	AAG	TTG	GGG	GGT	AAT	TGG	ACA	TGT	GTA	AAA	3000
Glu	Asp	Leu	Phe	His	Cys	Lys	Leu	Gly	Gly	Asn	Trp	Thr	Cys	Val	Lys	
	865					870					875					

GGC	GAC	CCA	GTG	ACT	TAT	AAG	GGG	GGG	CAA	GTA	AAG	CAG	TGC	AGG	TGG	3048
Gly	Asp	Pro	Val	Thr	Tyr	Lys	Gly	Gly	Gln	Val	Lys	Gln	Cys	Arg	Trp	
880					885					890					895	
TGT	GGT	TTC	GAG	TTT	AAA	GAG	CCC	TAC	GGG	CTC	CCA	CAC	TAC	CCT	ATA	3096
Cys	Gly	Phe	Glu	Phe	Lys	Glu	Pro	Tyr	Gly	Leu	Pro	His	Tyr	Pro	Ile	
			900						905					910		
GGC	AAG	TGC	ATC	CTA	ACA	AAT	GAG	ACA	GGT	TAC	AGG	GTA	GTA	GAT	TCC	3144
Gly	Lys	Cys	Ile	Leu	Thr	Asn	Glu	Thr	Gly	Tyr	Arg	Val	Val	Asp	Ser	
			915					920					925			
ACA	GAC	TGC	AAC	AGA	GAT	GGC	GTC	GTT	ATT	AGC	ACT	GAA	GGG	GAA	CAT	3192
Thr	Asp	Cys	Asn	Arg	Asp	Gly	Val	Val	Ile	Ser	Thr	Glu	Gly	Glu	His	
		930					935					940				
GAG	TGC	TTG	ATT	GGC	AAC	ACT	ACC	GTC	AAG	GTG	CAT	GCA	CTG	GAT	GAA	3240
Glu	Cys	Leu	Ile	Gly	Asn	Thr	Thr	Val	Lys	Val	His	Ala	Leu	Asp	Glu	
	945					950					955					
AGA	TTG	GGC	CCT	ATG	CCG	TGC	AGA	CCC	AAA	GAA	ATC	GTC	TCT	AGT	GAG	3288
Arg	Leu	Gly	Pro	Met	Pro	Cys	Arg	Pro	Lys	Glu	Ile	Val	Ser	Ser	Glu	
960					965					970					975	
GGA	CCT	GTG	AGG	AAA	ACT	TCT	TGT	ACA	TTC	AAC	TAC	ACA	AAG	ACT	CTA	3336
Gly	Pro	Val	Arg	Lys	Thr	Ser	Cys	Thr	Phe	Asn	Tyr	Thr	Lys	Thr	Leu	
				980					985					990		
AGA	AAC	AAA	TAC	TAT	GAG	CCC	AGA	GAC	AGT	TAC	TTC	CAG	CAA	TAT	ATG	3384
Arg	Asn	Lys	Tyr	Tyr	Glu	Pro	Arg	Asp	Ser	Tyr	Phe	Gln	Gln	Tyr	Met	
		995						1000					1005			
CTC	AAG	GGC	GAG	TAT	CAA	TAC	TGG	TTT	AAT	CTG	GAC	GTG	ACC	GAC	CAC	3432
Leu	Lys	Gly	Glu	Tyr	Gln	Tyr	Trp	Phe	Asn	Leu	Asp	Val	Thr	Asp	His	
	1010						1015					1020				
CAC	ACA	GAC	TAC	TTT	GCC	GAG	TTT	GTT	GTC	TTG	GTA	GTA	GTA	GCA	CTG	3480
His	Thr	Asp	Tyr	Phe	Ala	Glu	Phe	Val	Val	Leu	Val	Val	Val	Ala	Leu	
	1025					1030					1035					
TTA	GGA	GGA	AGG	TAC	GTT	CTG	TGG	CTA	ATA	GTG	ACC	TAC	ATA	ATT	CTA	3528
Leu	Gly	Gly	Arg	Tyr	Val	Leu	Trp	Leu	Ile	Val	Thr	Tyr	Ile	Ile	Leu	
1040					1045					1050					1055	
ACA	GAG	CAG	CTC	GCT	GCT	GGT	CTA	CAG	CTA	GGC	CAG	GGT	GAG	GTG	GTA	3576
Thr	Glu	Gln	Leu	Ala	Ala	Gly	Leu	Gln	Leu	Gly	Gln	Gly	Glu	Val	Val	
			1060					1065						1070		
TTG	ATA	GGG	AAC	CTA	ATT	ACC	CAC	ACG	GAC	AAT	GAG	GTG	GTG	GTG	TAC	3624
Leu	Ile	Gly	Asn	Leu	Ile	Thr	His	Thr	Asp	Asn	Glu	Val	Val	Val	Tyr	
		1075						1080					1085			
TTC	CTA	CTG	CTC	TAC	TTA	GTA	ATA	AGA	GAT	GAG	CCC	ATA	AAG	AAA	TGG	3672
Phe	Leu	Leu	Leu	Tyr	Leu	Val	Ile	Arg	Asp	Glu	Pro	Ile	Lys	Lys	Trp	
		1090					1095						1100			

ATA CTA CTG CTG TTT CAT GCA ATG ACT AAC AAT CCA GTC AAG ACC ATA	3720
Ile Leu Leu Leu Phe His Ala Met Thr Asn Asn Pro Val Lys Thr Ile	
1105 1110 1115	
ACA GTA GCA TTG CTA ATG ATC AGT GGG GTT GCC AAG GGT GGT AAG ATA	3768
Thr Val Ala Leu Leu Met Ile Ser Gly Val Ala Lys Gly Gly Lys Ile	
1120 1125 1130 1135	
GAT GGT GGC TGG CAG AGA CAA CCG GTG ACC AGT TTT GAC ATC CAA CTC	3816
Asp Gly Gly Trp Gln Arg Gln Pro Val Thr Ser Phe Asp Ile Gln Leu	
1140 1145 1150	
GCA CTG GCA GTC GTA GTA GTC GTT GTG ATG TTG CTG GCA AAG AGA GAC	3864
Ala Leu Ala Val Val Val Val Val Val Met Leu Leu Ala Lys Arg Asp	
1155 1160 1165	
CCG ACT ACT TTC CCT TTG GTA ATC ACA GTG GCA ACC CTG AGA ACG GCC	3912
Pro Thr Thr Phe Pro Leu Val Ile Thr Val Ala Thr Leu Arg Thr Ala	
1170 1175 1180	
AAG ATA ACC AAC GGT TTT AGC ACA GAT CTA GTC ATA GCC ACA GTG TCG	3960
Lys Ile Thr Asn Gly Phe Ser Thr Asp Leu Val Ile Ala Thr Val Ser	
1185 1190 1195	
GCA GCT TTG TTA ACT TGG ACC TAT ATC AGC GAC TAC TAC AAA TAC AAG	4008
Ala Ala Leu Leu Thr Trp Thr Tyr Ile Ser Asp Tyr Tyr Lys Tyr Lys	
1200 1205 1210 1215	
ACT TGG CTA CAG TAC CTC GTC AGC ACG GTG ACT GGA ATC TTC CTG ATA	4056
Thr Trp Leu Gln Tyr Leu Val Ser Thr Val Thr Gly Ile Phe Leu Ile	
1220 1225 1230	
AGG GTG CTG AAG GGA ATA GGC GAA TTG GAT CTG CAC GCC CCA ACC TTG	4104
Arg Val Leu Lys Gly Ile Gly Glu Leu Asp Leu His Ala Pro Thr Leu	
1235 1240 1245	
CCG TCT CAC AGA CCC CTC TTT TAC ATC CTT GTA TAC CTT ATT TCC ACT	4152
Pro Ser His Arg Pro Leu Phe Tyr Ile Leu Val Tyr Leu Ile Ser Thr	
1250 1255 1260	
GCC GTG GTA ACT AGA TGG AAT CTG GAC GTA GCC GGA TTG TTG CTG CAG	4200
Ala Val Val Thr Arg Trp Asn Leu Asp Val Ala Gly Leu Leu Leu Gln	
1265 1270 1275	
TGC GTC CCA ACT CTT TTA ATG GTT TTT ACG ATG TGG GCA GAC ATT CTC	4248
Cys Val Pro Thr Leu Leu Met Val Phe Thr Met Trp Ala Asp Ile Leu	
1280 1285 1290 1295	
ACC CTA ATT CTC ATA CTA CCT ACT TAT GAG TTA ACA AAG TTA TAC TAC	4296
Thr Leu Ile Leu Ile Leu Pro Thr Tyr Glu Leu Thr Lys Leu Tyr Tyr	
1300 1305 1310	
CTT AAG GAA GTG AAG ATT GGG GCA GAA AGA GGT TGG CTG TGG AAA ACT	4344
Leu Lys Glu Val Lys Ile Gly Ala Glu Arg Gly Trp Leu Trp Lys Thr	
1315 1320 1325	

AAC TAT AAG AGG GTA AAC GAC ATC TAC GAG GTC GAC CAA ACT AGC GAA Asn Tyr Lys Arg Val Asn Asp Ile Tyr Glu Val Asp Gln Thr Ser Glu 1330 1335 1340	4392
GGG GTT TAC CTT TTC CCT TCT AAA CAG AGG ACG AGC GCT ATA ACT AGT Gly Val Tyr Leu Phe Pro Ser Lys Gln Arg Thr Ser Ala Ile Thr Ser 1345 1350 1355	4440
ACC ATG TTG CCA TTA ATC AAA GCC ATA CTC ATT AGC TGC ATC AGC AAC Thr Met Leu Pro Leu Ile Lys Ala Ile Leu Ile Ser Cys Ile Ser Asn 1360 1365 1370 1375	4488
AAG TGG CAA CTC ATA TAC TTA CTG TAC TTG ATA TTT GAA GTG TCT TAC Lys Trp Gln Leu Ile Tyr Leu Leu Tyr Leu Ile Phe Glu Val Ser Tyr 1380 1385 1390	4536
TAC CTC CAC AAG AAA GTT ATA GAT GAA ATA GCT GGT GGG ACC AAC TTC Tyr Leu His Lys Lys Val Ile Asp Glu Ile Ala Gly Gly Thr Asn Phe 1395 1400 1405	4584
GTT TCA AGG CTC GTG GCG GCT TTG ATT GAA GTC AAT TGG GCC TTC GAC Val Ser Arg Leu Val Ala Ala Leu Ile Glu Val Asn Trp Ala Phe Asp 1410 1415 1420	4632
AAT GAA GAA GTC AAA GGC TTA AAG AAG TTC TTC TTG CTG TCT AGT AGG Asn Glu Glu Val Lys Gly Leu Lys Lys Phe Phe Leu Leu Ser Ser Arg 1425 1430 1435	4680
GTC AAA GAG TTG ATC ATC AAA CAC AAA GTG AGG AAT GAA GTA GTG GTC Val Lys Glu Leu Ile Ile Lys His Lys Val Arg Asn Glu Val Val Val 1440 1445 1450 1455	4728
CGC TGG TTT GGA GAT GAA GAG ATT TAT GGG ATG CCA AAG CTG ATC GGC Arg Trp Phe Gly Asp Glu Glu Ile Tyr Gly Met Pro Lys Leu Ile Gly 1460 1465 1470	4776
TTA GTT AAG GCA GCA ACA CTA AGT AGA AAC AAA CAC TGT ATG TTG TGT Leu Val Lys Ala Ala Thr Leu Ser Arg Asn Lys His Cys Met Leu Cys 1475 1480 1485	4824
ACC GTC TGT GAG GAC AGA GAT TGG AGA GGG GAA ACT TGC CCT AAA TGT Thr Val Cys Glu Asp Arg Asp Trp Arg Gly Glu Thr Cys Pro Lys Cys 1490 1495 1500	4872
GGG CGT TTT GGA CCA CCA GTG GTC TGC GGT ATG ACC CTA GCC GAT TTC Gly Arg Phe Gly Pro Pro Val Val Cys Gly Met Thr Leu Ala Asp Phe 1505 1510 1515	4920
GAA GAA AAA CAC TAT AAA AGG ATT TTC ATT AGA GAG GAC CAA TCA GGC Glu Glu Lys His Tyr Lys Arg Ile Phe Ile Arg Glu Asp Gln Ser Gly 1520 1525 1530 1535	4968
GGG CCA CTT AGG GAG GAG CAT GCA GGG TAC TTG CAG TAC AAA GCC AGG Gly Pro Leu Arg Glu Glu His Ala Gly Tyr Leu Gln Tyr Lys Ala Arg 1540 1545 1550	5016

GGT CAA CTG TTT TTG AGG AAC CTC CCA GTG TTA GCT ACA AAA GTC AAG Gly Gln Leu Phe Leu Arg Asn Leu Pro Val Leu Ala Thr Lys Val Lys 1555 1560 1565	5064
ATG CTC CTG GTT GGT AAC CTC GGG ACA GAG ATT GGG GAT CTG GAA CAC Met Leu Leu Val Gly Asn Leu Gly Thr Glu Ile Gly Asp Leu Glu His 1570 1575 1580	5112
CTT GGC TGG GTG CTT AGA GGG CCA GCT GTT TGC AAG AAG GTT ACT GAA Leu Gly Trp Val Leu Arg Gly Pro Ala Val Cys Lys Lys Val Thr Glu 1585 1590 1595	5160
CAC GAA AGA TGC ACC ACG TCT ATA ATG GAT AAG TTG ACT GCT TTC TTT His Glu Arg Cys Thr Thr Ser Ile Met Asp Lys Leu Thr Ala Phe Phe 1600 1605 1610 1615	5208
GGA GTA ATG CCA AGG GGC ACT ACT CCC AGA GCT CCC GTA AGA TTC CCT Gly Val Met Pro Arg Gly Thr Thr Pro Arg Ala Pro Val Arg Phe Pro 1620 1625 1630	5256
ACC TCC CTC CTA AAG ATA AGA AGA GGG CTG GAG ACT GGT TGG GCT TAC Thr Ser Leu Leu Lys Ile Arg Arg Gly Leu Glu Thr Gly Trp Ala Tyr 1635 1640 1645	5304
ACA CAC CAA GGT GGC ATC AGC TCA GTA GAC CAT GTC ACT TGT GGG AAA Thr His Gln Gly Gly Ile Ser Ser Val Asp His Val Thr Cys Gly Lys 1650 1655 1660	5352
GAC TTA CTG GTG TGT GAC ACC ATG GGT CGG ACA AGG GTT GTT TGC CAG Asp Leu Leu Val Cys Asp Thr Met Gly Arg Thr Arg Val Val Cys Gln 1665 1670 1675	5400
TCA AAT AAT AAG ATG ACC GAC GAG TCC GAA TAC GGA GTC AAA ACT GAC Ser Asn Asn Lys Met Thr Asp Glu Ser Glu Tyr Gly Val Lys Thr Asp 1680 1685 1690 1695	5448
TCC GGG TGC CCA GAG GGA GCC AGG TGT TAC GTG TTT AAC CCG GAA GCA Ser Gly Cys Pro Glu Gly Ala Arg Cys Tyr Val Phe Asn Pro Glu Ala 1700 1705 1710	5496
GTT AAC ATA TCA GGC ACT AAA GGA GCC ATG GTC CAC TTA CAG AAA ACG Val Asn Ile Ser Gly Thr Lys Gly Ala Met Val His Leu Gln Lys Thr 1715 1720 1725	5544
GGT GGA GAA TTC ACC TGT GTG ACA GCA TCA GGA ACC CCG GCC TTC TTT Gly Gly Glu Phe Thr Cys Val Thr Ala Ser Gly Thr Pro Ala Phe Phe 1730 1735 1740	5592
GAC CTC AAG AAC CTT AAG GGC TGG TCA GGG CTA CCG ATA TTT GAA GCA Asp Leu Lys Asn Leu Lys Gly Trp Ser Gly Leu Pro Ile Phe Glu Ala 1745 1750 1755	5640
TCA AGT GGA AGG GTA GTC GGA AGG GTC AAG GTC GGG AAG AAC GAG GAT Ser Ser Gly Arg Val Val Gly Arg Val Lys Val Gly Lys Asn Glu Asp 1760 1765 1770 1775	5688

TCC	AAA	CCA	ACC	AAG	CTC	ATG	AGT	GGG	ATA	CAA	ACG	GTT	TCT	AAA	AGC	5736
Ser	Lys	Pro	Thr	Lys	Leu	Met	Ser	Gly	Ile	Gln	Thr	Val	Ser	Lys	Ser	
				1780					1785						1790	
GCC	ACA	GAC	TTG	ACG	GAG	ATG	GTG	AAG	AAG	ATA	ACG	ACC	ATG	AAC	AGG	5784
Ala	Thr	Asp	Leu	Thr	Glu	Met	Val	Lys	Lys	Ile	Thr	Thr	Met	Asn	Arg	
			1795					1800					1805			
GGA	GAG	TTC	AGA	CAA	ATA	ACC	CTG	GCC	ACA	GGT	GCC	GGA	AAA	ACT	ACA	5832
Gly	Glu	Phe	Arg	Gln	Ile	Thr	Leu	Ala	Thr	Gly	Ala	Gly	Lys	Thr	Thr	
		1810					1815					1820				
GAG	CTC	CCT	AGA	TCA	GTT	ATA	GAA	GAG	ATA	GGG	AGG	CAT	AAG	AGG	GTG	5880
Glu	Leu	Pro	Arg	Ser	Val	Ile	Glu	Glu	Ile	Gly	Arg	His	Lys	Arg	Val	
	1825					1830					1835					
TTG	GTC	TTA	ATC	CCC	TTG	AGG	GCG	GCA	GCA	GAA	TCA	GTA	TAC	CAA	TAC	5928
Leu	Val	Leu	Ile	Pro	Leu	Arg	Ala	Ala	Ala	Glu	Ser	Val	Tyr	Gln	Tyr	
1840					1845					1850					1855	
ATG	AGA	CAG	AAA	CAT	CCG	AGT	ATA	GCA	TTC	AAT	CTA	AGG	ATA	GGT	GAG	5976
Met	Arg	Gln	Lys	His	Pro	Ser	Ile	Ala	Phe	Asn	Leu	Arg	Ile	Gly	Glu	
				1860					1865					1870		
ATG	AAG	GAA	GGT	GAT	ATG	GCC	ACG	GGA	ATA	ACC	TAT	GCC	TCT	TAC	GGT	6024
Met	Lys	Glu	Gly	Asp	Met	Ala	Thr	Gly	Ile	Thr	Tyr	Ala	Ser	Tyr	Gly	
			1875					1880					1885			
TAC	TTT	TGC	CAG	ATG	TCA	CAA	CCC	AAG	CTG	AGA	GCC	GCA	ATG	GTA	GAA	6072
Tyr	Phe	Cys	Gln	Met	Ser	Gln	Pro	Lys	Leu	Arg	Ala	Ala	Met	Val	Glu	
		1890					1895					1900				
TAT	TCC	TTT	ATA	TTC	CTA	GAT	GAG	TAT	CAT	TGT	GCT	ACC	CCA	GAA	CAA	6120
Tyr	Ser	Phe	Ile	Phe	Leu	Asp	Glu	Tyr	His	Cys	Ala	Thr	Pro	Glu	Gln	
	1905					1910					1915					
CTG	GCA	ATC	ATG	GGG	AAG	ATC	CAC	AGA	TTC	TCA	GAA	AAC	CTG	CGG	GTG	6168
Leu	Ala	Ile	Met	Gly	Lys	Ile	His	Arg	Phe	Ser	Glu	Asn	Leu	Arg	Val	
1920					1925					1930					1935	
GTA	GCT	ATG	ACA	GCG	ACA	CCG	GCA	GGC	ACA	GTA	ACA	ACC	ACT	GGG	CAG	6216
Val	Ala	Met	Thr	Ala	Thr	Pro	Ala	Gly	Thr	Val	Thr	Thr	Thr	Gly	Gln	
				1940					1945					1950		
AAA	CAC	CCT	ATA	GAG	GAA	TTT	ATA	GCC	CCG	GAA	GTG	ATG	AAA	GGA	GAA	6264
Lys	His	Pro	Ile	Glu	Glu	Phe	Ile	Ala	Pro	Glu	Val	Met	Lys	Gly	Glu	
			1955					1960					1965			
GAC	TTG	GGT	TCT	GAG	TAC	TTA	GAT	ATT	GCC	GGA	CTG	AAG	ATA	CCA	GTA	6312
Asp	Leu	Gly	Ser	Glu	Tyr	Leu	Asp	Ile	Ala	Gly	Leu	Lys	Ile	Pro	Val	
		1970					1975					1980				
GAG	GAG	ATG	AAG	AAT	AAC	ATG	CTA	GTT	TTT	GTG	CCC	ACC	AGG	AAC	ATG	6360
Glu	Glu	Met	Lys	Asn	Asn	Met	Leu	Val	Phe	Val	Pro	Thr	Arg	Asn	Met	
	1985					1990						1995				

GCG GTA GAG GCG GCA AAG AAA TTG AAG GCC AAA GGA TAC AAC TCG GGC Ala Val Glu Ala Ala Lys Lys Leu Lys Ala Lys Gly Tyr Asn Ser Gly 2000 2005 2010 2015	6408
TAC TAC TAC AGC GGA GAG GAC CCA TCT AAC CTG AGG GTG GTG ACG TCG Tyr Tyr Tyr Ser Gly Glu Asp Pro Ser Asn Leu Arg Val Val Thr Ser 2020 2025 2030	6456
CAG TCC CCA TAC GTG GTG GTA GCA ACC AAC GCA ATA GAA TCG GGC GTT Gln Ser Pro Tyr Val Val Val Ala Thr Asn Ala Ile Glu Ser Gly Val 2035 2040 2045	6504
ACC CTC CCG GAC CTG GAC GTG GTT GTC GAC ACG GGA CTC AAG TGT GAA Thr Leu Pro Asp Leu Asp Val Val Val Asp Thr Gly Leu Lys Cys Glu 2050 2055 2060	6552
AAA AGA ATC CGA CTG TCA CCC AAG ATG CCT TTC ATA GTG ACG GGC CTG Lys Arg Ile Arg Leu Ser Pro Lys Met Pro Phe Ile Val Thr Gly Leu 2065 2070 2075	6600
AAA AGA ATG GCC GTC ACT ATT GGG GAA CAA GCC CAG AGA AGA GGG AGG Lys Arg Met Ala Val Thr Ile Gly Glu Gln Ala Gln Arg Arg Gly Arg 2080 2085 2090 2095	6648
GTT GGA AGA GTG AAG CCC GGG AGA TAC TAC AGG AGT CAA GAA ACA CCT Val Gly Arg Val Lys Pro Gly Arg Tyr Tyr Arg Ser Gln Glu Thr Pro 2100 2105 2110	6696
GTC GGC TCT AAA GAC TAC CAT TAT GAC TTA TTG CAA GCC CAG AGG TAC Val Gly Ser Lys Asp Tyr His Tyr Asp Leu Leu Gln Ala Gln Arg Tyr 2115 2120 2125	6744
GGC ATA GAA GAT GGG ATA AAT ATC ACC AAA TCC TTC AGA GAG ATG AAC Gly Ile Glu Asp Gly Ile Asn Ile Thr Lys Ser Phe Arg Glu Met Asn 2130 2135 2140	6792
TAC GAC TGG AGC CTT TAT GAG GAA GAT AGC CTG ATG ATC ACA CAA CTG Tyr Asp Trp Ser Leu Tyr Glu Glu Asp Ser Leu Met Ile Thr Gln Leu 2145 2150 2155	6840
GAA ATC CTC AAC AAC CTG TTG ATA TCA GAA GAG CTG CCG ATG GCA GTA Glu Ile Leu Asn Asn Leu Leu Ile Ser Glu Glu Leu Pro Met Ala Val 2160 2165 2170 2175	6888
AAA AAT ATA ATG GCC AGG ACC GAC CAC CCA GAA CCA ATT CAA CTC GCG Lys Asn Ile Met Ala Arg Thr Asp His Pro Glu Pro Ile Gln Leu Ala 2180 2185 2190	6936
TAT AAC AGC TAC GAG ACA CAG GTG CCG GTA TTA TTC CCA AAA ATA AGA Tyr Asn Ser Tyr Glu Thr Gln Val Pro Val Leu Phe Pro Lys Ile Arg 2195 2200 2205	6984
AAT GGA GAG GTG ACT GAT ACT TAC GAT AAT TAC ACC TTC CTC AAT GCA Asn Gly Glu Val Thr Asp Thr Tyr Asp Asn Tyr Thr Phe Leu Asn Ala 2210 2215 2220	7032

AGA AAA TTG GGA GAT GAC GTA CCC CCC TAC GTG TAT GCT ACA GAG GAT	7080
Arg Lys Leu Gly Asp Asp Val Pro Pro Tyr Val Tyr Ala Thr Glu Asp	
2225 2230 2235	
GAG GAC TTG GCA GTG GAA CTG TTG GGC CTA GAT TGG CCG GAC CCA GGA	7128
Glu Asp Leu Ala Val Glu Leu Leu Gly Leu Asp Trp Pro Asp Pro Gly	
2240 2245 2250 2255	
AAC CAA GGC ACC GTG GAA GCT GGC AGA GCA CTA AAA CAG GTG GTT GGT	7176
Asn Gln Gly Thr Val Glu Ala Gly Arg Ala Leu Lys Gln Val Val Gly	
2260 2265 2270	
CTA TCA ACA GCA GAG AAC GCC CTG CTA GTC GCC CTG TTC GGC TAC GTG	7224
Leu Ser Thr Ala Glu Asn Ala Leu Leu Val Ala Leu Phe Gly Tyr Val	
2275 2280 2285	
GGG TAC CAG GCG CTT TCA AAG AGA CAT ATA CCA GTG GTC ACA GAT ATA	7272
Gly Tyr Gln Ala Leu Ser Lys Arg His Ile Pro Val Val Thr Asp Ile	
2290 2295 2300	
TAT TCA GTA GAA GAT CAC AGG CTA GAG GAC ACT ACG CAC CTA CAG TAT	7320
Tyr Ser Val Glu Asp His Arg Leu Glu Asp Thr Thr His Leu Gln Tyr	
2305 2310 2315	
GCT CCG AAT GCC ATC AAG ACG GAG GGG AAG GAA ACT GAA TTG AAG GAG	7368
Ala Pro Asn Ala Ile Lys Thr Glu Gly Lys Glu Thr Glu Leu Lys Glu	
2320 2325 2330 2335	
CTG GCT CAG GGG GAT GTG CAG AGA TGT GTG GAA GCA GTG ACC AAT TAT	7416
Leu Ala Gln Gly Asp Val Gln Arg Cys Val Glu Ala Val Thr Asn Tyr	
2340 2345 2350	
GCG AGA GAG GGC ATC CAA TTC ATG AAG TCG CAG GCA CTG AAA GTG AGA	7464
Ala Arg Glu Gly Ile Gln Phe Met Lys Ser Gln Ala Leu Lys Val Arg	
2355 2360 2365	
GAA ACC CCT ACC TAT AAA GAG ACA ATG AAC ACC GTG GCA GAT TAT GTG	7512
Glu Thr Pro Thr Tyr Lys Glu Thr Met Asn Thr Val Ala Asp Tyr Val	
2370 2375 2380	
AAA AAG TTT ATT GAG GCA CTG ACG GAT AGC AAG GAA GAC ATC ATT AAA	7560
Lys Lys Phe Ile Glu Ala Leu Thr Asp Ser Lys Glu Asp Ile Ile Lys	
2385 2390 2395	
TAT GGG CTG TGG GGG GCA CAT ACG GCA TTG TAT AAG AGC ATT GGT GCC	7608
Tyr Gly Leu Trp Gly Ala His Thr Ala Leu Tyr Lys Ser Ile Gly Ala	
2400 2405 2410 2415	
AGG CTT GGT CAC GAA ACC GCG TTC GCA ACT CTA GTT GTG AAG TGG TTG	7656
Arg Leu Gly His Glu Thr Ala Phe Ala Thr Leu Val Val Lys Trp Leu	
2420 2425 2430	
GCA TTT GGG GGG GAG TCA ATA TCA GAC CAC ATA AAG CAA GCG GCC ACA	7704
Ala Phe Gly Gly Glu Ser Ile Ser Asp His Ile Lys Gln Ala Ala Thr	
2435 2440 2445	

GAC	TTG	GTC	GTT	TAT	TAC	ATT	ATT	AAC	AGA	CCT	CAA	TTC	CCA	GGA	GAC	7752
Asp	Leu	Val	Val	Tyr	Tyr	Ile	Ile	Asn	Arg	Pro	Gln	Phe	Pro	Gly	Asp	
		2450						2455				2460				
ACA	GAA	ACA	CAA	CAA	GAA	GGG	AGA	AAA	TTT	GTT	GCC	AGC	CTG	CTA	GTC	7800
Thr	Glu	Thr	Gln	Gln	Glu	Gly	Arg	Lys	Phe	Val	Ala	Ser	Leu	Leu	Val	
		2465					2470					2475				
TCA	GCT	CTA	GCG	ACT	TAT	ACA	TAC	AAG	AGC	TGG	AAC	TAC	AAT	AAT	CTG	7848
Ser	Ala	Leu	Ala	Thr	Tyr	Thr	Tyr	Lys	Ser	Trp	Asn	Tyr	Asn	Asn	Leu	
		2480				2485					2490				2495	
TCC	AAA	ATA	GTT	GAA	CCG	GCT	TTG	GCT	ACC	CTG	CCC	TAT	GCC	GCT	AAA	7896
Ser	Lys	Ile	Val	Glu	Pro	Ala	Leu	Ala	Thr	Leu	Pro	Tyr	Ala	Ala	Lys	
				2500					2505					2510		
GCC	CTC	AAG	CTA	TTT	GCT	CCT	ACC	CGA	CTG	GAG	AGC	GTT	GTC	ATA	CTG	7944
Ala	Leu	Lys	Leu	Phe	Ala	Pro	Thr	Arg	Leu	Glu	Ser	Val	Val	Ile	Leu	
			2515					2520					2525			
AGC	ACT	GCA	ATC	TAC	AAA	ACA	TAC	CTA	TCA	ATA	AGG	CGA	GGC	AAA	AGT	7992
Ser	Thr	Ala	Ile	Tyr	Lys	Thr	Tyr	Leu	Ser	Ile	Arg	Arg	Gly	Lys	Ser	
		2530					2535					2540				
GAT	GGT	CTG	CTA	GGT	ACA	GGG	GTT	AGC	GCG	GCC	ATG	GAA	ATT	ATG	TCA	8040
Asp	Gly	Leu	Leu	Gly	Thr	Gly	Val	Ser	Ala	Ala	Met	Glu	Ile	Met	Ser	
		2545					2550				2555					
CAA	AAC	CCA	GTA	TCT	GTG	GGT	ATA	GCA	GTT	ATG	CTA	GGG	GTA	GGG	GCT	8088
Gln	Asn	Pro	Val	Ser	Val	Gly	Ile	Ala	Val	Met	Leu	Gly	Val	Gly	Ala	
		2560				2565				2570					2575	
GTA	GCA	GCC	CAC	AAT	GCA	ATT	GAA	GCC	AGT	GAG	CAA	AAA	AGA	ACA	CTA	8136
Val	Ala	Ala	His	Asn	Ala	Ile	Glu	Ala	Ser	Glu	Gln	Lys	Arg	Thr	Leu	
				2580					2585					2590		
CTT	ATG	AAA	GTC	TTT	GTG	AAA	AAC	TTC	TTA	GAC	CAG	GCC	GCC	ACC	GAC	8184
Leu	Met	Lys	Val	Phe	Val	Lys	Asn	Phe	Leu	Asp	Gln	Ala	Ala	Thr	Asp	
			2595					2600					2605			
GAA	CTA	GTC	AAA	GAG	AGC	CCT	GAG	AAA	ATA	ATA	ATG	GCT	TTG	TTC	GAA	8232
Glu	Leu	Val	Lys	Glu	Ser	Pro	Glu	Lys	Ile	Ile	Met	Ala	Leu	Phe	Glu	
		2610					2615					2620				
GCG	GTG	CAA	ACG	GTG	GGC	AAC	CCT	CTT	AGA	TTA	GTG	TAC	CAC	CTC	TAT	8280
Ala	Val	Gln	Thr	Val	Gly	Asn	Pro	Leu	Arg	Leu	Val	Tyr	His	Leu	Tyr	
		2625					2630					2635				
GGA	GTT	TTC	TAT	AAA	GGG	TGG	GAA	GCA	AAA	GAG	TTG	GCC	CAA	AGA	ACA	8328
Gly	Val	Phe	Tyr	Lys	Gly	Trp	Glu	Ala	Lys	Glu	Leu	Ala	Gln	Arg	Thr	
		2640				2645				2650					2655	
GCC	GGC	AGG	AAC	CTT	TTC	ACC	TTG	ATA	ATG	TTC	GAG	GCT	GTG	GAA	CTA	8376
Ala	Gly	Arg	Asn	Leu	Phe	Thr	Leu	Ile	Met	Phe	Glu	Ala	Val	Glu	Leu	
				2660					2665						2670	

CTG GGA GTA GAC AGT GAG GGA AAA ATT CGC CAG CTA TCG AGC AAT TAC	8424
Leu Gly Val Asp Ser Glu Gly Lys Ile Arg Gln Leu Ser Ser Asn Tyr	
2675 2680 2685	
ATA CTA GAG CTC TTG TAT AAG TTC CGC GAC AAT ATC AAG TCT AGT GTG	8472
Ile Leu Glu Leu Leu Tyr Lys Phe Arg Asp Asn Ile Lys Ser Ser Val	
2690 2695 2700	
AGG GAG ATA GCA ATC AGC TGG GCC CCC GCC CCC TTT AGT TGC GAT TGG	8520
Arg Glu Ile Ala Ile Ser Trp Ala Pro Ala Pro Phe Ser Cys Asp Trp	
2705 2710 2715	
ACA CCA ACA GAT GAC AGA ATA GGG CTT CCC CAT GAC AAT TAC CTC CGA	8568
Thr Pro Thr Asp Asp Arg Ile Gly Leu Pro His Asp Asn Tyr Leu Arg	
2720 2725 2730 2735	
GTG GAG ACA AAG TGC CCC TGT GGT TAC AGG ATG AAA GCG GTA AAA AAC	8616
Val Glu Thr Lys Cys Pro Cys Gly Tyr Arg Met Lys Ala Val Lys Asn	
2740 2745 2750	
TGC GCT GGG GAG TTG AGA CTT CTG GAG GAA GGG GGT TCA TTC CTC TGC	8664
Cys Ala Gly Glu Leu Arg Leu Leu Glu Glu Gly Gly Ser Phe Leu Cys	
2755 2760 2765	
AGA AAT AAA TTC GGT AGA GGC TCA CAA AAC TAC AGG GTG ACA AAA TAC	8712
Arg Asn Lys Phe Gly Arg Gly Ser Gln Asn Tyr Arg Val Thr Lys Tyr	
2770 2775 2780	
TAT GAT GAC AAT TTA TCA GAA ATA AAA CCA GTG ATA AGA ATG GAA GGA	8760
Tyr Asp Asp Asn Leu Ser Glu Ile Lys Pro Val Ile Arg Met Glu Gly	
2785 2790 2795	
CAC GTG GAA CTG TAT TAC AAG GGG GCC ACT ATC AAA CTG GAT TTT AAC	8808
His Val Glu Leu Tyr Tyr Lys Gly Ala Thr Ile Lys Leu Asp Phe Asn	
2800 2805 2810 2815	
AAC AGT AAA ACG GTA CTG GCA ACT GAC AAA TGG GAG GTT GAC CAC TCC	8856
Asn Ser Lys Thr Val Leu Ala Thr Asp Lys Trp Glu Val Asp His Ser	
2820 2825 2830	
ACC CTG GTT AGG GCA CTC AAG AGG TAC ACA GGG GCT GGA TAT CGA GGG	8904
Thr Leu Val Arg Ala Leu Lys Arg Tyr Thr Gly Ala Gly Tyr Arg Gly	
2835 2840 2845	
GCG TAT TTG GGT GAG AAA CCT AAC CAT AAA CAT CTG ATA CAG AGA GAC	8952
Ala Tyr Leu Gly Glu Lys Pro Asn His Lys His Leu Ile Gln Arg Asp	
2850 2855 2860	
TGT GCA ACG ATT ACC AAA GAC AAG GTC TGC TTC ATC AAA ATG AAG AGA	9000
Cys Ala Thr Ile Thr Lys Asp Lys Val Cys Phe Ile Lys Met Lys Arg	
2865 2870 2875	
GGG TGT GCG TTC ACT TAT GAC CTA TCC CTC CAC AAC CTT ACC CGG CTA	9048
Gly Cys Ala Phe Thr Tyr Asp Leu Ser Leu His Asn Leu Thr Arg Leu	
2880 2885 2890 2895	

ATC GAA TTG GTA CAC AAG AAT AAC CTG GAA GAT AGA GAA ATC CCT GCT Ile Glu Leu Val His Lys Asn Asn Leu Glu Asp Arg Glu Ile Pro Ala 2900 2905 2910	9096
GTG ACG GTT ACA ACC TGG CTG GCC TAC ACA TTT GTG AAT GAA GAC ATA Val Thr Val Thr Thr Trp Leu Ala Tyr Thr Phe Val Asn Glu Asp Ile 2915 2920 2925	9144
GGG ACC ATA AAA CCA ACT TTT GGG GAA AAG GTG ACA CCG GAG AAA CAG Gly Thr Ile Lys Pro Thr Phe Gly Glu Lys Val Thr Pro Glu Lys Gln 2930 2935 2940	9192
GAG GAG GTA GTC TTG CAG CCT GCT GTG GTG GTG GAC ACA ACA GAT GTA Glu Glu Val Val Leu Gln Pro Ala Val Val Val Asp Thr Thr Asp Val 2945 2950 2955	9240
GCC GTG ACC GTG GTA GGG GAA ACC TCT ACT ATG ACT ACA GGG GAG ACC Ala Val Thr Val Val Gly Glu Thr Ser Thr Met Thr Thr Gly Glu Thr 2960 2965 2970 2975	9288
CCG ACA ACA TTT ACC AGC TTA GGT TCG GAC TCG AAG GTC CGA CAA GTC Pro Thr Thr Phe Thr Ser Leu Gly Ser Asp Ser Lys Val Arg Gln Val 2980 2985 2990	9336
CTG AAG CTG GGC GTG GAC GAT GGT CAA TAC CCC GGG CCT AAT CAG CAG Leu Lys Leu Gly Val Asp Asp Gly Gln Tyr Pro Gly Pro Asn Gln Gln 2995 3000 3005	9384
AGA GCA AGC CTG CTC GAA GCT ATA CAA GGT GTG GAT GAA AGC CCC TCG Arg Ala Ser Leu Leu Glu Ala Ile Gln Gly Val Asp Glu Arg Pro Ser 3010 3015 3020	9432
GTA CTG ATA CTG GGG TCT GAT AAG GCC ACC TCC AAT AGG GTC AAG ACC Val Leu Ile Leu Gly Ser Asp Lys Ala Thr Ser Asn Arg Val Lys Thr 3025 3030 3035	9480
GCA AAG AAT GTG AAG ATA TAT AGG AGC AGG GAC CCC CTG GAA CTG AGA Ala Lys Asn Val Lys Ile Tyr Arg Ser Arg Asp Pro Leu Glu Leu Arg 3040 3045 3050 3055	9528
GAA ATG ATG AAA AGG GGA AAA ATC CTA GTC GTA GCC TTG TCT AGA GTC Glu Met Met Lys Arg Gly Lys Ile Leu Val Val Ala Leu Ser Arg Val 3060 3065 3070	9576
GAT ACC GCT CTG CTG AAA TTC GTT GAT TAC AAA GGC ACC TTC CTG ACC Asp Thr Ala Leu Leu Lys Phe Val Asp Tyr Lys Gly Thr Phe Leu Thr 3075 3080 3085	9624
AGA GAG ACC CTA GAG GCA TTA AGT CTG GGT AAG CCT AAG AAA AGA GAC Arg Glu Thr Leu Glu Ala Leu Ser Leu Gly Lys Pro Lys Lys Arg Asp 3090 3095 3100	9672
ATA ACT AAA GCA GAA GCA CAA TGG CTG CTG CGC CTC GAA GAC CAA ATA Ile Thr Lys Ala Glu Ala Gln Trp Leu Leu Arg Leu Glu Asp Gln Ile 3105 3110 3115	9720

GAA GAG CTG CCT GAC TGG TTC GCA GCC AAG GAA CCC ATA TTT CTA GAA Glu Glu Leu Pro Asp Trp Phe Ala Ala Lys Glu Pro Ile Phe Leu Glu 3120 3125 3130 3135	9768
GCC AAC ATT AAA CGT GAC AAG TAT CAC CTG GTA GGG GAC ATA GCC ACT Ala Asn Ile Lys Arg Asp Lys Tyr His Leu Val Gly Asp Ile Ala Thr 3140 3145 3150	9816
ATT AAA GAA AAA GCC AAA CAA CTG GGG GCA ACA GAC TCC ACA AAG ATA Ile Lys Glu Lys Ala Lys Gln Leu Gly Ala Thr Asp Ser Thr Lys Ile 3155 3160 3165	9864
TCA AAG GAG GTT GGC GCG AAA GTG TAT TCT ATG AAG CTG AGT AAC TGG Ser Lys Glu Val Gly Ala Lys Val Tyr Ser Met Lys Leu Ser Asn Trp 3170 3175 3180	9912
GTG ATA CAA GAA GAG AAT AAA CAA GGC AGC CTT GCC CCC CTG TTT GAA Val Ile Gln Glu Glu Asn Lys Gln Gly Ser Leu Ala Pro Leu Phe Glu 3185 3190 3195	9960
GAG CTC CTG CAA CAG TGC CCA CCC GGG GGC CAG AAC AAA ACC ACA CAT Glu Leu Leu Gln Gln Cys Pro Pro Gly Gly Gln Asn Lys Thr Thr His 3200 3205 3210 3215	10008
ATG GTC TCA GCC TAC CAA CTA GCT CAA GGG AAT TGG GTG CCA GTT AGT Met Val Ser Ala Tyr Gln Leu Ala Gln Gly Asn Trp Val Pro Val Ser 3220 3225 3230	10056
TGC CAC GTG TTC ATG GGG ACC ATA CCC GCC AGA AGA ACC AAG ACT CAT Cys His Val Phe Met Gly Thr Ile Pro Ala Arg Arg Thr Lys Thr His 3235 3240 3245	10104
CCT TAT GAG GCA TAC GTT AAG CTA AGG GAG TTG GTA GAT GAA CAT AAG Pro Tyr Glu Ala Tyr Val Lys Leu Arg Glu Leu Val Asp Glu His Lys 3250 3255 3260	10152
ATG AAG GCA TTA TGT GGC GGA TCA GGC CTA AGT AAG CAC AAC GAA TGG Met Lys Ala Leu Cys Gly Gly Ser Gly Leu Ser Lys His Asn Glu Trp 3265 3270 3275	10200
GTA ATT GGC AAG GTC AAG TAT CAA GGA AAC CTG AGG ACC AAA CAC ATG Val Ile Gly Lys Val Lys Tyr Gln Gly Asn Leu Arg Thr Lys His Met 3280 3285 3290 3295	10248
TTG AAC CCC GGA AAG GTG GCG GAG CAA CTG CAC AGA GAA GGG TAC AGG Leu Asn Pro Gly Lys Val Ala Glu Gln Leu His Arg Glu Gly Tyr Arg 3300 3305 3310	10296
CAC AAT GTG TAT AAT AAG ACA ATA GGT TCA GTG ATG ACA GCA ACT GGT His Asn Val Tyr Asn Lys Thr Ile Gly Ser Val Met Thr Ala Thr Gly 3315 3320 3325	10344
ATC AGG CTG GAG AAG TTA CCT GTG GTT AGG GCC CAA ACA GAC ACA ACC Ile Arg Leu Glu Lys Leu Pro Val Val Arg Ala Gln Thr Asp Thr Thr 3330 3335 3340	10392

AAC TTC CAC CAA GCA ATA AGG GAT AAA ATA GAC AAG GAG GAG AAC CTA Asn Phe His Gln Ala Ile Arg Asp Lys Ile Asp Lys Glu Glu Asn Leu 3345 3350 3355	10440
CAG ACC CCT GGC TTG CAT AAG AAG TTA ATG GAA GTC TTC AAT GCA TTA Gln Thr Pro Gly Leu His Lys Lys Leu Met Glu Val Phe Asn Ala Leu 3360 3365 3370 3375	10488
AAA AGA CCC GAG CTT GAG GCC TCT TAT GAC GCT GTG GAT TGG GAG GAA Lys Arg Pro Glu Leu Glu Ala Ser Tyr Asp Ala Val Asp Trp Glu Glu 3380 3385 3390	10536
TTG GAG AGA GGA ATA AAT AGG AAG GGT GCT GCT GGT TTC TTC GAA CGC Leu Glu Arg Gly Ile Asn Arg Lys Gly Ala Ala Gly Phe Phe Glu Arg 3395 3400 3405	10584
AAG AAC ATA GGA GAG GTT TTG GAT TCG GAA AAA AAT AAA GTC GAA GAG Lys Asn Ile Gly Glu Val Leu Asp Ser Glu Lys Asn Lys Val Glu Glu 3410 3415 3420	10632
GTT ATT GAC AGT TTG AAA AAA GGT AGG AAT ATC AGA TAC TAC GAA ACT Val Ile Asp Ser Leu Lys Lys Gly Arg Asn Ile Arg Tyr Tyr Glu Thr 3425 3430 3435	10680
GCA ATC CCG AAA AAC GAG AAG AGG GAT GTC AAT GAT GAC TGG ACC GCT Ala Ile Pro Lys Asn Glu Lys Arg Asp Val Asn Asp Asp Trp Thr Ala 3440 3445 3450 3455	10728
GGT GAC TTC GTA GAT GAG AAG AAG CCA AGA GTG ATA CAA TAC CCT GAG Gly Asp Phe Val Asp Glu Lys Lys Pro Arg Val Ile Gln Tyr Pro Glu 3460 3465 3470	10776
GCT AAA ACT AGG TTG GCT ATT ACT AAG GTA ATG TAC AAG TGG GTC AAA Ala Lys Thr Arg Leu Ala Ile Thr Lys Val Met Tyr Lys Trp Val Lys 3475 3480 3485	10824
CAG AAG CCA GTT GTC ATA CCG GGT TAT GAA GGT AAG ACA CCC CTG TTT Gln Lys Pro Val Val Ile Pro Gly Tyr Glu Gly Lys Thr Pro Leu Phe 3490 3495 3500	10872
CAA ATT TTT GAC AAA GTG AAG AAA GAA TGG GAT CAA TTC CAA AAC CCT Gln Ile Phe Asp Lys Val Lys Lys Glu Trp Asp Gln Phe Gln Asn Pro 3505 3510 3515	10920
GTG GCA GTT AGC TTT GAT ACC AAA GCG TGG GAT ACC CAG GTA ACC ACA Val Ala Val Ser Phe Asp Thr Lys Ala Trp Asp Thr Gln Val Thr Thr 3520 3525 3530 3535	10968
AGG GAT TTG GAG CTA ATA AGG GAT ATA CAG AAG TTC TAT TTT AAA AAG Arg Asp Leu Glu Leu Ile Arg Asp Ile Gln Lys Phe Tyr Phe Lys Lys 3540 3545 3550	11016
AAA TGG CAC AAA TTC ATT GAC ACC CTA ACC AAG CAC ATG TCA GAA GTA Lys Trp His Lys Phe Ile Asp Thr Leu Thr Lys His Met Ser Glu Val 3555 3560 3565	11064

CCC GTA ATC AGT GCC GAC GGG GAG GTA TAC ATA AGG AAA GGT CAG AGA Pro Val Ile Ser Ala Asp Gly Glu Val Tyr Ile Arg Lys Gly Gln Arg 3570 3575 3580	11112
GGC AGT GGG CAA CCT GAC ACG AGC GCA GGC AAC AGC ATG TTG AAT GTG Gly Ser Gly Gln Pro Asp Thr Ser Ala Gly Asn Ser Met Leu Asn Val 3585 3590 3595	11160
TTG ACA ATG GTG TAT GCC TTC TGC GAG GCC ACG GGG GTA CCC TAC AAG Leu Thr Met Val Tyr Ala Phe Cys Glu Ala Thr Gly Val Pro Tyr Lys 3600 3605 3610 3615	11208
AGT TTT GAC AGA GTG GCA AAG ATC CAT GTC TGC GGG GAT GAT GGT TTC Ser Phe Asp Arg Val Ala Lys Ile His Val Cys Gly Asp Asp Gly Phe 3620 3625 3630	11256
CTG ATT ACC GAA AGA GCT CTC GGT GAG AAA TTT GCG AGT AAA GGA GTC Leu Ile Thr Glu Arg Ala Leu Gly Glu Lys Phe Ala Ser Lys Gly Val 3635 3640 3645	11304
CAG ATC CTA TAC GAA GCT GGG AAG CCT CAA AAG ATC ACT GAA GGG GAC Gln Ile Leu Tyr Glu Ala Gly Lys Pro Gln Lys Ile Thr Glu Gly Asp 3650 3655 3660	11352
AAG ATG AAA GTA GCC TAT CAG TTT GAT GAT ATC GAG TTC TGC TCC CAT Lys Met Lys Val Ala Tyr Gln Phe Asp Asp Ile Glu Phe Cys Ser His 3665 3670 3675	11400
ACA CCA GTA CAA GTG AGG TGG TCA GAC AAT ACT TCC AGC TAC ATG CCG Thr Pro Val Gln Val Arg Trp Ser Asp Asn Thr Ser Ser Tyr Met Pro 3680 3685 3690 3695	11448
GGA AGG AAC ACG ACT ACA ATC CTG GCT AAA ATG GCT ACA AGG TTG GAT Gly Arg Asn Thr Thr Thr Ile Leu Ala Lys Met Ala Thr Arg Leu Asp 3700 3705 3710	11496
TCC AGT GGT GAG AGG GGT ACT ATA GCA TAT GAG AAG GCA GTG GCG TTC Ser Ser Gly Glu Arg Gly Thr Ile Ala Tyr Glu Lys Ala Val Ala Phe 3715 3720 3725	11544
AGC TTT TTG TTG ATG TAC TCC TGG AAC CCA CTG ATC AGA AGG ATA TGC Ser Phe Leu Leu Met Tyr Ser Trp Asn Pro Leu Ile Arg Arg Ile Cys 3730 3735 3740	11592
TTA CTG GTG TTG TCA ACT GAG TTG CAA GTG AGA CCA GGG AAG TCA ACC Leu Leu Val Leu Ser Thr Glu Leu Gln Val Arg Pro Gly Lys Ser Thr 3745 3750 3755	11640
ACC TAT TAC TAT GAA GGG GAC CCA ATA TCC GCT TAC AAG GAA GTC ATT Thr Tyr Tyr Tyr Glu Gly Asp Pro Ile Ser Ala Tyr Lys Glu Val Ile 3760 3765 3770 3775	11688
GGC CAC AAT CTC TTT GAC CTT AAA AGA ACA AGC TTC GAA AAG CTA GCA Gly His Asn Leu Phe Asp Leu Lys Arg Thr Ser Phe Glu Lys Leu Ala 3780 3785 3790	11736

AAG TTA AAT CTC AGC ATG TCC ACG CTC GGG GTG TGG ACT AGA CAC ACT	11784
Lys Leu Asn Leu Ser Met Ser Thr Leu Gly Val Trp Thr Arg His Thr	
3795 3800 3805	
AGC AAG AGA TTA CTA CAA GAT TGT GTC AAT GTT GGC ACC AAA GAG GGC	11832
Ser Lys Arg Leu Leu Gln Asp Cys Val Asn Val Gly Thr Lys Glu Gly	
3810 3815 3820	
AAC TGG CTG GTC AAT GCA GAC AGA CTA GTG AGT AGT AAG ACA GGA AAC	11880
Asn Trp Leu Val Asn Ala Asp Arg Leu Val Ser Ser Lys Thr Gly Asn	
3825 3830 3835	
AGG TAT ATA CCT GGA GAG GGC CAC ACC CTA CAA GGG AAA CAT TAT GAA	11928
Arg Tyr Ile Pro Gly Glu Gly His Thr Leu Gln Gly Lys His Tyr Glu	
3840 3845 3850 3855	
GAA CTG ATA CTG GCA AGG AAA CCG ATC GGT AAC TTT GAA GGG ACC GAT	11976
Glu Leu Ile Leu Ala Arg Lys Pro Ile Gly Asn Phe Glu Gly Thr Asp	
3860 3865 3870	
AGG TAT AAC TTG GGG CCA ATA GTC AAT GTA GTG TTG AGG AGA CTA AAA	12024
Arg Tyr Asn Leu Gly Pro Ile Val Asn Val Val Leu Arg Arg Leu Lys	
3875 3880 3885	
ATT ATG ATG ATG GCC CTG ATA GGA AGG GGG GTG TGAGCATGGT TGGCCCTTGA	12077
Ile Met Met Met Ala Leu Ile Gly Arg Gly Val	
3890 3895	
TCGGGCCCTA TCAGTAGAAC CCTATTGTAA ATAACATTAA CTTATTAATT ATTTAGATAC	12137
TATTATTTAT TTATTTATTT ATTTATTGAA TGAGCAAGTA CTGGTACAAA CTACCTCATG	12197
TTACCACACT ACACTCATTT TAACAGCACT TTAGCTGGAG GGAAAACCCCT GACGTCCACA	12257
GTTGGACTAA GGTAATTTCC TAACGGC	12284

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3898 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Glu	Leu	Asn	His	Phe	Glu	Leu	Leu	Tyr	Lys	Thr	Ser	Lys	Gln	Lys
1				5					10					15	
Pro	Val	Gly	Val	Glu	Glu	Pro	Val	Tyr	Asp	Thr	Ala	Gly	Arg	Pro	Leu
			20					25					30		

Phe Gly Asn Pro Ser Glu Val His Pro Gln Ser Thr Leu Lys Leu Pro
 35 40 45
 His Asp Arg Gly Arg Gly Asp Ile Arg Thr Thr Leu Arg Asp Leu Pro
 50 55 60
 Arg Lys Gly Asp Cys Arg Ser Gly Asn His Leu Gly Pro Val Ser Gly
 65 70 75 80
 Ile Tyr Ile Lys Pro Gly Pro Val Tyr Tyr Gln Asp Tyr Thr Gly Pro
 85 90 95
 Val Tyr His Arg Ala Pro Leu Glu Phe Phe Asp Glu Ala Gln Phe Cys
 100 105 110
 Glu Val Thr Lys Arg Ile Gly Arg Val Thr Gly Ser Asp Gly Lys Leu
 115 120 125
 Tyr His Ile Tyr Val Cys Val Asp Gly Cys Ile Leu Leu Lys Leu Ala
 130 135 140
 Lys Arg Gly Thr Pro Arg Thr Leu Lys Trp Ile Arg Asn Phe Thr Asn
 145 150 155 160
 Cys Pro Leu Trp Val Thr Ser Cys Ser Asp Asp Gly Ala Ser Gly Ser
 165 170 175
 Lys Asp Lys Lys Pro Asp Arg Met Asn Lys Gly Lys Leu Lys Ile Ala
 180 185 190
 Pro Arg Glu His Glu Lys Asp Ser Lys Thr Lys Pro Pro Asp Ala Thr
 195 200 205
 Ile Val Val Glu Gly Val Lys Tyr Gln Ile Lys Lys Lys Gly Lys Val
 210 215 220
 Lys Gly Lys Asn Thr Gln Asp Gly Leu Tyr His Asn Lys Asn Lys Pro
 225 230 235 240
 Pro Glu Ser Arg Lys Lys Leu Glu Lys Ala Leu Leu Ala Trp Ala Val
 245 250 255
 Ile Thr Ile Leu Leu Tyr Gln Pro Val Ala Ala Glu Asn Ile Thr Gln
 260 265 270
 Trp Asn Leu Ser Asp Asn Gly Thr Asn Gly Ile Gln Arg Ala Met Tyr
 275 280 285
 Leu Arg Gly Val Asn Arg Ser Leu His Gly Ile Trp Pro Glu Lys Ile
 290 295 300
 Cys Lys Gly Val Pro Thr His Leu Ala Thr Asp Thr Glu Leu Lys Glu
 305 310 315 320
 Ile Arg Gly Met Met Asp Ala Ser Glu Arg Thr Asn Tyr Thr Cys Cys
 325 330 335

Arg Leu Gln Arg His Glu Trp Asn Lys His Gly Trp Cys Asn Trp Tyr
 340 345 350
 Asn Ile Asp Pro Trp Ile Gln Leu Met Asn Arg Thr Gln Thr Asn Leu
 355 360 365
 Thr Glu Gly Pro Pro Asp Lys Glu Cys Ala Val Thr Cys Arg Tyr Asp
 370 375 380
 Lys Asn Thr Asp Val Asn Val Val Thr Gln Ala Arg Asn Arg Pro Thr
 385 390 395 400
 Thr Leu Thr Gly Cys Lys Lys Gly Lys Asn Phe Ser Phe Ala Gly Thr
 405 410 415
 Val Ile Glu Gly Pro Cys Asn Phe Asn Val Ser Val Glu Asp Ile Leu
 420 425 430
 Tyr Gly Asp His Glu Cys Gly Ser Leu Leu Gln Asp Thr Ala Leu Tyr
 435 440 445
 Leu Leu Asp Gly Met Thr Asn Thr Ile Glu Asn Ala Arg Gln Gly Ala
 450 455 460
 Ala Arg Val Thr Ser Trp Leu Gly Arg Gln Leu Ser Thr Ala Gly Lys
 465 470 475 480
 Lys Leu Glu Arg Arg Ser Lys Thr Trp Phe Gly Ala Tyr Ala Leu Ser
 485 490 495
 Pro Tyr Cys Asn Val Thr Arg Lys Ile Gly Tyr Ile Trp Tyr Thr Asn
 500 505 510
 Asn Cys Thr Pro Ala Cys Leu Pro Lys Asn Thr Lys Ile Ile Gly Pro
 515 520 525
 Gly Lys Phe Asp Thr Asn Ala Glu Asp Gly Lys Ile Leu His Glu Met
 530 535 540
 Gly Gly His Leu Ser Glu Phe Leu Leu Leu Ser Leu Val Ile Leu Ser
 545 550 555 560
 Asp Phe Ala Pro Glu Thr Ala Ser Thr Leu Tyr Leu Ile Leu His Tyr
 565 570 575
 Ala Ile Pro Gln Ser His Glu Glu Pro Glu Gly Cys Asp Thr Asn Gln
 580 585 590
 Leu Asn Leu Thr Val Lys Leu Arg Thr Glu Asp Val Val Pro Ser Ser
 595 600 605
 Val Trp Asn Ile Gly Lys Tyr Val Cys Val Arg Pro Asp Trp Trp Pro
 610 615 620

Tyr Glu Thr Lys Val Ala Leu Leu Phe Glu Glu Ala Gly Gln Val Ile
 625 630 635 640
 Lys Leu Val Leu Arg Ala Leu Arg Asp Leu Thr Arg Val Trp Asn Ser
 645 650 655
 Ala Ser Thr Thr Ala Phe Leu Ile Cys Leu Ile Lys Val Leu Arg Gly
 660 665 670
 Gln Val Val Gln Gly Ile Ile Trp Leu Leu Leu Val Thr Gly Ala Gln
 675 680 685
 Gly Arg Leu Ala Cys Lys Glu Asp Tyr Arg Tyr Ala Ile Ser Ser Thr
 690 695 700
 Asn Glu Ile Gly Leu Leu Gly Ala Glu Gly Leu Thr Thr Thr Trp Lys
 705 710 715 720
 Glu Tyr Ser His Gly Leu Gln Leu Asp Asp Gly Thr Val Lys Ala Val
 725 730 735
 Cys Thr Ala Gly Ser Phe Lys Val Thr Ala Leu Asn Val Val Ser Arg
 740 745 750
 Arg Tyr Leu Ala Ser Leu His Lys Arg Ala Leu Pro Thr Ser Val Thr
 755 760 765
 Phe Glu Leu Leu Phe Asp Gly Thr Asn Pro Ala Ile Glu Glu Met Asp
 770 775 780
 Asp Asp Phe Gly Phe Gly Leu Cys Pro Phe Asp Thr Ser Pro Val Ile
 785 790 795 800
 Lys Gly Lys Tyr Asn Thr Thr Leu Leu Asn Gly Ser Ala Phe Tyr Leu
 805 810 815
 Val Cys Pro Ile Gly Trp Thr Gly Val Val Glu Cys Thr Ala Val Ser
 820 825 830
 Pro Thr Thr Leu Arg Thr Glu Val Val Lys Thr Phe Arg Arg Asp Lys
 835 840 845
 Pro Phe Pro His Arg Val Asp Cys Val Thr Thr Ile Val Glu Lys Glu
 850 855 860
 Asp Leu Phe His Cys Lys Leu Gly Gly Asn Trp Thr Cys Val Lys Gly
 865 870 875 880
 Asp Pro Val Thr Tyr Lys Gly Gly Gln Val Lys Gln Cys Arg Trp Cys
 885 890 895
 Gly Phe Glu Phe Lys Glu Pro Tyr Gly Leu Pro His Tyr Pro Ile Gly
 900 905 910
 Lys Cys Ile Leu Thr Asn Glu Thr Gly Tyr Arg Val Val Asp Ser Thr
 915 920 925

Asp Cys Asn Arg Asp Gly Val Val Ile Ser Thr Glu Gly Glu His Glu
 930 935 940
 Cys Leu Ile Gly Asn Thr Thr Val Lys Val His Ala Leu Asp Glu Arg
 945 950 955 960
 Leu Gly Pro Met Pro Cys Arg Pro Lys Glu Ile Val Ser Ser Glu Gly
 965 970 975
 Pro Val Arg Lys Thr Ser Cys Thr Phe Asn Tyr Thr Lys Thr Leu Arg
 980 985 990
 Asn Lys Tyr Tyr Glu Pro Arg Asp Ser Tyr Phe Gln Gln Tyr Met Leu
 995 1000 1005
 Lys Gly Glu Tyr Gln Tyr Trp Phe Asn Leu Asp Val Thr Asp His His
 1010 1015 1020
 Thr Asp Tyr Phe Ala Glu Phe Val Val Leu Val Val Val Ala Leu Leu
 1025 1030 1035 1040
 Gly Gly Arg Tyr Val Leu Trp Leu Ile Val Thr Tyr Ile Ile Leu Thr
 1045 1050 1055
 Glu Gln Leu Ala Ala Gly Leu Gln Leu Gly Gln Gly Glu Val Val Leu
 1060 1065 1070
 Ile Gly Asn Leu Ile Thr His Thr Asp Asn Glu Val Val Val Tyr Phe
 1075 1080 1085
 Leu Leu Leu Tyr Leu Val Ile Arg Asp Glu Pro Ile Lys Lys Trp Ile
 1090 1095 1100
 Leu Leu Leu Phe His Ala Met Thr Asn Asn Pro Val Lys Thr Ile Thr
 1105 1110 1115 1120
 Val Ala Leu Leu Met Ile Ser Gly Val Ala Lys Gly Gly Lys Ile Asp
 1125 1130 1135
 Gly Gly Trp Gln Arg Gln Pro Val Thr Ser Phe Asp Ile Gln Leu Ala
 1140 1145 1150
 Leu Ala Val Val Val Val Val Val Met Leu Leu Ala Lys Arg Asp Pro
 1155 1160 1165
 Thr Thr Phe Pro Leu Val Ile Thr Val Ala Thr Leu Arg Thr Ala Lys
 1170 1175 1180
 Ile Thr Asn Gly Phe Ser Thr Asp Leu Val Ile Ala Thr Val Ser Ala
 1185 1190 1195 1200
 Ala Leu Leu Thr Trp Thr Tyr Ile Ser Asp Tyr Tyr Lys Tyr Lys Thr
 1205 1210 1215

Trp Leu Gln Tyr Leu Val Ser Thr Val Thr Gly Ile Phe Leu Ile Arg
 1220 1225 1230
 Val Leu Lys Gly Ile Gly Glu Leu Asp Leu His Ala Pro Thr Leu Pro
 1235 1240 1245
 Ser His Arg Pro Leu Phe Tyr Ile Leu Val Tyr Leu Ile Ser Thr Ala
 1250 1255 1260
 Val Val Thr Arg Trp Asn Leu Asp Val Ala Gly Leu Leu Leu Gln Cys
 1265 1270 1275 1280
 Val Pro Thr Leu Leu Met Val Phe Thr Met Trp Ala Asp Ile Leu Thr
 1285 1290 1295
 Leu Ile Leu Ile Leu Pro Thr Tyr Glu Leu Thr Lys Leu Tyr Tyr Leu
 1300 1305 1310
 Lys Glu Val Lys Ile Gly Ala Glu Arg Gly Trp Leu Trp Lys Thr Asn
 1315 1320 1325
 Tyr Lys Arg Val Asn Asp Ile Tyr Glu Val Asp Gln Thr Ser Glu Gly
 1330 1335 1340
 Val Tyr Leu Phe Pro Ser Lys Gln Arg Thr Ser Ala Ile Thr Ser Thr
 1345 1350 1355 1360
 Met Leu Pro Leu Ile Lys Ala Ile Leu Ile Ser Cys Ile Ser Asn Lys
 1365 1370 1375
 Trp Gln Leu Ile Tyr Leu Leu Tyr Leu Ile Phe Glu Val Ser Tyr Tyr
 1380 1385 1390
 Leu His Lys Lys Val Ile Asp Glu Ile Ala Gly Gly Thr Asn Phe Val
 1395 1400 1405
 Ser Arg Leu Val Ala Ala Leu Ile Glu Val Asn Trp Ala Phe Asp Asn
 1410 1415 1420
 Glu Glu Val Lys Gly Leu Lys Lys Phe Phe Leu Leu Ser Ser Arg Val
 1425 1430 1435 1440
 Lys Glu Leu Ile Ile Lys His Lys Val Arg Asn Glu Val Val Val Arg
 1445 1450 1455
 Trp Phe Gly Asp Glu Glu Ile Tyr Gly Met Pro Lys Leu Ile Gly Leu
 1460 1465 1470
 Val Lys Ala Ala Thr Leu Ser Arg Asn Lys His Cys Met Leu Cys Thr
 1475 1480 1485
 Val Cys Glu Asp Arg Asp Trp Arg Gly Glu Thr Cys Pro Lys Cys Gly
 1490 1495 1500
 Arg Phe Gly Pro Pro Val Val Cys Gly Met Thr Leu Ala Asp Phe Glu
 1505 1510 1515 1520

Glu Lys His Tyr Lys Arg Ile Phe Ile Arg Glu Asp Gln Ser Gly Gly
 1525 1530 1535
 Pro Leu Arg Glu Glu His Ala Gly Tyr Leu Gln Tyr Lys Ala Arg Gly
 1540 1545 1550
 Gln Leu Phe Leu Arg Asn Leu Pro Val Leu Ala Thr Lys Val Lys Met
 1555 1560 1565
 Leu Leu Val Gly Asn Leu Gly Thr Glu Ile Gly Asp Leu Glu His Leu
 1570 1575 1580
 Gly Trp Val Leu Arg Gly Pro Ala Val Cys Lys Lys Val Thr Glu His
 1585 1590 1595 1600
 Glu Arg Cys Thr Thr Ser Ile Met Asp Lys Leu Thr Ala Phe Phe Gly
 1605 1610 1615
 Val Met Pro Arg Gly Thr Thr Pro Arg Ala Pro Val Arg Phe Pro Thr
 1620 1625 1630
 Ser Leu Leu Lys Ile Arg Arg Gly Leu Glu Thr Gly Trp Ala Tyr Thr
 1635 1640 1645
 His Gln Gly Gly Ile Ser Ser Val Asp His Val Thr Cys Gly Lys Asp
 1650 1655 1660
 Leu Leu Val Cys Asp Thr Met Gly Arg Thr Arg Val Val Cys Gln Ser
 1665 1670 1675 1680
 Asn Asn Lys Met Thr Asp Glu Ser Glu Tyr Gly Val Lys Thr Asp Ser
 1685 1690 1695
 Gly Cys Pro Glu Gly Ala Arg Cys Tyr Val Phe Asn Pro Glu Ala Val
 1700 1705 1710
 Asn Ile Ser Gly Thr Lys Gly Ala Met Val His Leu Gln Lys Thr Gly
 1715 1720 1725
 Gly Glu Phe Thr Cys Val Thr Ala Ser Gly Thr Pro Ala Phe Phe Asp
 1730 1735 1740
 Leu Lys Asn Leu Lys Gly Trp Ser Gly Leu Pro Ile Phe Glu Ala Ser
 1745 1750 1755 1760
 Ser Gly Arg Val Val Gly Arg Val Lys Val Gly Lys Asn Glu Asp Ser
 1765 1770 1775
 Lys Pro Thr Lys Leu Met Ser Gly Ile Gln Thr Val Ser Lys Ser Ala
 1780 1785 1790
 Thr Asp Leu Thr Glu Met Val Lys Lys Ile Thr Thr Met Asn Arg Gly
 1795 1800 1805

Glu Phe Arg Gln Ile Thr Leu Ala Thr Gly Ala Gly Lys Thr Thr Glu
 1810 1815 1820
 Leu Pro Arg Ser Val Ile Glu Glu Ile Gly Arg His Lys Arg Val Leu
 1825 1830 1835 1840
 Val Leu Ile Pro Leu Arg Ala Ala Ala Glu Ser Val Tyr Gln Tyr Met
 1845 1850 1855
 Arg Gln Lys His Pro Ser Ile Ala Phe Asn Leu Arg Ile Gly Glu Met
 1860 1865 1870
 Lys Glu Gly Asp Met Ala Thr Gly Ile Thr Tyr Ala Ser Tyr Gly Tyr
 1875 1880 1885
 Phe Cys Gln Met Ser Gln Pro Lys Leu Arg Ala Ala Met Val Glu Tyr
 1890 1895 1900
 Ser Phe Ile Phe Leu Asp Glu Tyr His Cys Ala Thr Pro Glu Gln Leu
 1905 1910 1915 1920
 Ala Ile Met Gly Lys Ile His Arg Phe Ser Glu Asn Leu Arg Val Val
 1925 1930 1935
 Ala Met Thr Ala Thr Pro Ala Gly Thr Val Thr Thr Thr Gly Gln Lys
 1940 1945 1950
 His Pro Ile Glu Glu Phe Ile Ala Pro Glu Val Met Lys Gly Glu Asp
 1955 1960 1965
 Leu Gly Ser Glu Tyr Leu Asp Ile Ala Gly Leu Lys Ile Pro Val Glu
 1970 1975 1980
 Glu Met Lys Asn Asn Met Leu Val Phe Val Pro Thr Arg Asn Met Ala
 1985 1990 1995 2000
 Val Glu Ala Ala Lys Lys Leu Lys Ala Lys Gly Tyr Asn Ser Gly Tyr
 2005 2010 2015
 Tyr Tyr Ser Gly Glu Asp Pro Ser Asn Leu Arg Val Val Thr Ser Gln
 2020 2025 2030
 Ser Pro Tyr Val Val Val Ala Thr Asn Ala Ile Glu Ser Gly Val Thr
 2035 2040 2045
 Leu Pro Asp Leu Asp Val Val Val Asp Thr Gly Leu Lys Cys Glu Lys
 2050 2055 2060
 Arg Ile Arg Leu Ser Pro Lys Met Pro Phe Ile Val Thr Gly Leu Lys
 2065 2070 2075 2080
 Arg Met Ala Val Thr Ile Gly Glu Gln Ala Gln Arg Arg Gly Arg Val
 2085 2090 2095
 Gly Arg Val Lys Pro Gly Arg Tyr Tyr Arg Ser Gln Glu Thr Pro Val
 2100 2105 2110

Gly Ser Lys Asp Tyr His Tyr Asp Leu Leu Gln Ala Gln Arg Tyr Gly
 2115 2120 2125
 Ile Glu Asp Gly Ile Asn Ile Thr Lys Ser Phe Arg Glu Met Asn Tyr
 2130 2135 2140
 Asp Trp Ser Leu Tyr Glu Glu Asp Ser Leu Met Ile Thr Gln Leu Glu
 2145 2150 2155 2160
 Ile Leu Asn Asn Leu Leu Ile Ser Glu Glu Leu Pro Met Ala Val Lys
 2165 2170 2175
 Asn Ile Met Ala Arg Thr Asp His Pro Glu Pro Ile Gln Leu Ala Tyr
 2180 2185 2190
 Asn Ser Tyr Glu Thr Gln Val Pro Val Leu Phe Pro Lys Ile Arg Asn
 2195 2200 2205
 Gly Glu Val Thr Asp Thr Tyr Asp Asn Tyr Thr Phe Leu Asn Ala Arg
 2210 2215 2220
 Lys Leu Gly Asp Asp Val Pro Pro Tyr Val Tyr Ala Thr Glu Asp Glu
 2225 2230 2235 2240
 Asp Leu Ala Val Glu Leu Leu Gly Leu Asp Trp Pro Asp Pro Gly Asn
 2245 2250 2255
 Gln Gly Thr Val Glu Ala Gly Arg Ala Leu Lys Gln Val Val Gly Leu
 2260 2265 2270
 Ser Thr Ala Glu Asn Ala Leu Leu Val Ala Leu Phe Gly Tyr Val Gly
 2275 2280 2285
 Tyr Gln Ala Leu Ser Lys Arg His Ile Pro Val Val Thr Asp Ile Tyr
 2290 2295 2300
 Ser Val Glu Asp His Arg Leu Glu Asp Thr Thr His Leu Gln Tyr Ala
 2305 2310 2315 2320
 Pro Asn Ala Ile Lys Thr Glu Gly Lys Glu Thr Glu Leu Lys Glu Leu
 2325 2330 2335
 Ala Gln Gly Asp Val Gln Arg Cys Val Glu Ala Val Thr Asn Tyr Ala
 2340 2345 2350
 Arg Glu Gly Ile Gln Phe Met Lys Ser Gln Ala Leu Lys Val Arg Glu
 2355 2360 2365
 Thr Pro Thr Tyr Lys Glu Thr Met Asn Thr Val Ala Asp Tyr Val Lys
 2370 2375 2380
 Lys Phe Ile Glu Ala Leu Thr Asp Ser Lys Glu Asp Ile Ile Lys Tyr
 2385 2390 2395 2400

Gly Leu Trp Gly Ala His Thr Ala Leu Tyr Lys Ser Ile Gly Ala Arg
 2405 2410 2415
 Leu Gly His Glu Thr Ala Phe Ala Thr Leu Val Val Lys Trp Leu Ala
 2420 2425 2430
 Phe Gly Gly Glu Ser Ile Ser Asp His Ile Lys Gln Ala Ala Thr Asp
 2435 2440 2445
 Leu Val Val Tyr Tyr Ile Ile Asn Arg Pro Gln Phe Pro Gly Asp Thr
 2450 2455 2460
 Glu Thr Gln Gln Glu Gly Arg Lys Phe Val Ala Ser Leu Leu Val Ser
 2465 2470 2475 2480
 Ala Leu Ala Thr Tyr Thr Tyr Lys Ser Trp Asn Tyr Asn Asn Leu Ser
 2485 2490 2495
 Lys Ile Val Glu Pro Ala Leu Ala Thr Leu Pro Tyr Ala Ala Lys Ala
 2500 2505 2510
 Leu Lys Leu Phe Ala Pro Thr Arg Leu Glu Ser Val Val Ile Leu Ser
 2515 2520 2525
 Thr Ala Ile Tyr Lys Thr Tyr Leu Ser Ile Arg Arg Gly Lys Ser Asp
 2530 2535 2540
 Gly Leu Leu Gly Thr Gly Val Ser Ala Ala Met Glu Ile Met Ser Gln
 2545 2550 2555 2560
 Asn Pro Val Ser Val Gly Ile Ala Val Met Leu Gly Val Gly Ala Val
 2565 2570 2575
 Ala Ala His Asn Ala Ile Glu Ala Ser Glu Gln Lys Arg Thr Leu Leu
 2580 2585 2590
 Met Lys Val Phe Val Lys Asn Phe Leu Asp Gln Ala Ala Thr Asp Glu
 2595 2600 2605
 Leu Val Lys Glu Ser Pro Glu Lys Ile Ile Met Ala Leu Phe Glu Ala
 2610 2615 2620
 Val Gln Thr Val Gly Asn Pro Leu Arg Leu Val Tyr His Leu Tyr Gly
 2625 2630 2635 2640
 Val Phe Tyr Lys Gly Trp Glu Ala Lys Glu Leu Ala Gln Arg Thr Ala
 2645 2650 2655
 Gly Arg Asn Leu Phe Thr Leu Ile Met Phe Glu Ala Val Glu Leu Leu
 2660 2665 2670
 Gly Val Asp Ser Glu Gly Lys Ile Arg Gln Leu Ser Ser Asn Tyr Ile
 2675 2680 2685
 Leu Glu Leu Leu Tyr Lys Phe Arg Asp Asn Ile Lys Ser Ser Val Arg
 2690 2695 2700

Glu Ile Ala Ile Ser Trp Ala Pro Ala Pro Phe Ser Cys Asp Trp Thr
 2705 2710 2715 2720
 Pro Thr Asp Asp Arg Ile Gly Leu Pro His Asp Asn Tyr Leu Arg Val
 2725 2730 2735
 Glu Thr Lys Cys Pro Cys Gly Tyr Arg Met Lys Ala Val Lys Asn Cys
 2740 2745 2750
 Ala Gly Glu Leu Arg Leu Leu Glu Glu Gly Gly Ser Phe Leu Cys Arg
 2755 2760 2765
 Asn Lys Phe Gly Arg Gly Ser Gln Asn Tyr Arg Val Thr Lys Tyr Tyr
 2770 2775 2780
 Asp Asp Asn Leu Ser Glu Ile Lys Pro Val Ile Arg Met Glu Gly His
 2785 2790 2795 2800
 Val Glu Leu Tyr Tyr Lys Gly Ala Thr Ile Lys Leu Asp Phe Asn Asn
 2805 2810 2815
 Ser Lys Thr Val Leu Ala Thr Asp Lys Trp Glu Val Asp His Ser Thr
 2820 2825 2830
 Leu Val Arg Ala Leu Lys Arg Tyr Thr Gly Ala Gly Tyr Arg Gly Ala
 2835 2840 2845
 Tyr Leu Gly Glu Lys Pro Asn His Lys His Leu Ile Gln Arg Asp Cys
 2850 2855 2860
 Ala Thr Ile Thr Lys Asp Lys Val Cys Phe Ile Lys Met Lys Arg Gly
 2865 2870 2875 2880
 Cys Ala Phe Thr Tyr Asp Leu Ser Leu His Asn Leu Thr Arg Leu Ile
 2885 2890 2895
 Glu Leu Val His Lys Asn Asn Leu Glu Asp Arg Glu Ile Pro Ala Val
 2900 2905 2910
 Thr Val Thr Thr Trp Leu Ala Tyr Thr Phe Val Asn Glu Asp Ile Gly
 2915 2920 2925
 Thr Ile Lys Pro Thr Phe Gly Glu Lys Val Thr Pro Glu Lys Gln Glu
 2930 2935 2940
 Glu Val Val Leu Gln Pro Ala Val Val Val Asp Thr Thr Asp Val Ala
 2945 2950 2955 2960
 Val Thr Val Val Gly Glu Thr Ser Thr Met Thr Thr Gly Glu Thr Pro
 2965 2970 2975
 Thr Thr Phe Thr Ser Leu Gly Ser Asp Ser Lys Val Arg Gln Val Leu
 2980 2985 2990

Lys Leu Gly Val Asp Asp Gly Gln Tyr Pro Gly Pro Asn Gln Gln Arg
 2995 3000 3005
 Ala Ser Leu Leu Glu Ala Ile Gln Gly Val Asp Glu Arg Pro Ser Val
 3010 3015 3020
 Leu Ile Leu Gly Ser Asp Lys Ala Thr Ser Asn Arg Val Lys Thr Ala
 3025 3030 3035 3040
 Lys Asn Val Lys Ile Tyr Arg Ser Arg Asp Pro Leu Glu Leu Arg Glu
 3045 3050 3055
 Met Met Lys Arg Gly Lys Ile Leu Val Val Ala Leu Ser Arg Val Asp
 3060 3065 3070
 Thr Ala Leu Leu Lys Phe Val Asp Tyr Lys Gly Thr Phe Leu Thr Arg
 3075 3080 3085
 Glu Thr Leu Glu Ala Leu Ser Leu Gly Lys Pro Lys Lys Arg Asp Ile
 3090 3095 3100
 Thr Lys Ala Glu Ala Gln Trp Leu Leu Arg Leu Glu Asp Gln Ile Glu
 3105 3110 3115 3120
 Glu Leu Pro Asp Trp Phe Ala Ala Lys Glu Pro Ile Phe Leu Glu Ala
 3125 3130 3135
 Asn Ile Lys Arg Asp Lys Tyr His Leu Val Gly Asp Ile Ala Thr Ile
 3140 3145 3150
 Lys Glu Lys Ala Lys Gln Leu Gly Ala Thr Asp Ser Thr Lys Ile Ser
 3155 3160 3165
 Lys Glu Val Gly Ala Lys Val Tyr Ser Met Lys Leu Ser Asn Trp Val
 3170 3175 3180
 Ile Gln Glu Glu Asn Lys Gln Gly Ser Leu Ala Pro Leu Phe Glu Glu
 3185 3190 3195 3200
 Leu Leu Gln Gln Cys Pro Pro Gly Gly Gln Asn Lys Thr Thr His Met
 3205 3210 3215
 Val Ser Ala Tyr Gln Leu Ala Gln Gly Asn Trp Val Pro Val Ser Cys
 3220 3225 3230
 His Val Phe Met Gly Thr Ile Pro Ala Arg Arg Thr Lys Thr His Pro
 3235 3240 3245
 Tyr Glu Ala Tyr Val Lys Leu Arg Glu Leu Val Asp Glu His Lys Met
 3250 3255 3260
 Lys Ala Leu Cys Gly Gly Ser Gly Leu Ser Lys His Asn Glu Trp Val
 3265 3270 3275 3280
 Ile Gly Lys Val Lys Tyr Gln Gly Asn Leu Arg Thr Lys His Met Leu
 3285 3290 3295

Asn Pro Gly Lys Val Ala Glu Gln Leu His Arg Glu Gly Tyr Arg His
 3300 3305 3310
 Asn Val Tyr Asn Lys Thr Ile Gly Ser Val Met Thr Ala Thr Gly Ile
 3315 3320 3325
 Arg Leu Glu Lys Leu Pro Val Val Arg Ala Gln Thr Asp Thr Thr Asn
 3330 3335 3340
 Phe His Gln Ala Ile Arg Asp Lys Ile Asp Lys Glu Glu Asn Leu Gln
 3345 3350 3355 3360
 Thr Pro Gly Leu His Lys Lys Leu Met Glu Val Phe Asn Ala Leu Lys
 3365 3370 3375
 Arg Pro Glu Leu Glu Ala Ser Tyr Asp Ala Val Asp Trp Glu Glu Leu
 3380 3385 3390
 Glu Arg Gly Ile Asn Arg Lys Gly Ala Ala Gly Phe Phe Glu Arg Lys
 3395 3400 3405
 Asn Ile Gly Glu Val Leu Asp Ser Glu Lys Asn Lys Val Glu Glu Val
 3410 3415 3420
 Ile Asp Ser Leu Lys Lys Gly Arg Asn Ile Arg Tyr Tyr Glu Thr Ala
 3425 3430 3435 3440
 Ile Pro Lys Asn Glu Lys Arg Asp Val Asn Asp Asp Trp Thr Ala Gly
 3445 3450 3455
 Asp Phe Val Asp Glu Lys Lys Pro Arg Val Ile Gln Tyr Pro Glu Ala
 3460 3465 3470
 Lys Thr Arg Leu Ala Ile Thr Lys Val Met Tyr Lys Trp Val Lys Gln
 3475 3480 3485
 Lys Pro Val Val Ile Pro Gly Tyr Glu Gly Lys Thr Pro Leu Phe Gln
 3490 3495 3500
 Ile Phe Asp Lys Val Lys Lys Glu Trp Asp Gln Phe Gln Asn Pro Val
 3505 3510 3515 3520
 Ala Val Ser Phe Asp Thr Lys Ala Trp Asp Thr Gln Val Thr Thr Arg
 3525 3530 3535
 Asp Leu Glu Leu Ile Arg Asp Ile Gln Lys Phe Tyr Phe Lys Lys Lys
 3540 3545 3550
 Trp His Lys Phe Ile Asp Thr Leu Thr Lys His Met Ser Glu Val Pro
 3555 3560 3565
 Val Ile Ser Ala Asp Gly Glu Val Tyr Ile Arg Lys Gly Gln Arg Gly
 3570 3575 3580

Ser Gly Gln Pro Asp Thr Ser Ala Gly Asn Ser Met Leu Asn Val Leu
 3585 3590 3595 3600
 Thr Met Val Tyr Ala Phe Cys Glu Ala Thr Gly Val Pro Tyr Lys Ser
 3605 3610 3615
 Phe Asp Arg Val Ala Lys Ile His Val Cys Gly Asp Asp Gly Phe Leu
 3620 3625 3630
 Ile Thr Glu Arg Ala Leu Gly Glu Lys Phe Ala Ser Lys Gly Val Gln
 3635 3640 3645
 Ile Leu Tyr Glu Ala Gly Lys Pro Gln Lys Ile Thr Glu Gly Asp Lys
 3650 3655 3660
 Met Lys Val Ala Tyr Gln Phe Asp Asp Ile Glu Phe Cys Ser His Thr
 3665 3670 3675 3680
 Pro Val Gln Val Arg Trp Ser Asp Asn Thr Ser Ser Tyr Met Pro Gly
 3685 3690 3695
 Arg Asn Thr Thr Thr Ile Leu Ala Lys Met Ala Thr Arg Leu Asp Ser
 3700 3705 3710
 Ser Gly Glu Arg Gly Thr Ile Ala Tyr Glu Lys Ala Val Ala Phe Ser
 3715 3720 3725
 Phe Leu Leu Met Tyr Ser Trp Asn Pro Leu Ile Arg Arg Ile Cys Leu
 3730 3735 3740
 Leu Val Leu Ser Thr Glu Leu Gln Val Arg Pro Gly Lys Ser Thr Thr
 3745 3750 3755 3760
 Tyr Tyr Tyr Glu Gly Asp Pro Ile Ser Ala Tyr Lys Glu Val Ile Gly
 3765 3770 3775
 His Asn Leu Phe Asp Leu Lys Arg Thr Ser Phe Glu Lys Leu Ala Lys
 3780 3785 3790
 Leu Asn Leu Ser Met Ser Thr Leu Gly Val Trp Thr Arg His Thr Ser
 3795 3800 3805
 Lys Arg Leu Leu Gln Asp Cys Val Asn Val Gly Thr Lys Glu Gly Asn
 3810 3815 3820
 Trp Leu Val Asn Ala Asp Arg Leu Val Ser Ser Lys Thr Gly Asn Arg
 3825 3830 3835 3840
 Tyr Ile Pro Gly Glu Gly His Thr Leu Gln Gly Lys His Tyr Glu Glu
 3845 3850 3855
 Leu Ile Leu Ala Arg Lys Pro Ile Gly Asn Phe Glu Gly Thr Asp Arg
 3860 3865 3870
 Tyr Asn Leu Gly Pro Ile Val Asn Val Val Leu Arg Arg Leu Lys Ile
 3875 3880 3885

Met Met Met Ala Leu Ile Gly Arg Gly Val
 3890 3895

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..33
- (D) OTHER INFORMATION: /label= primer_1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CCTACTAACC ACGTTAAGTG CTGTGACTTT AAA

33

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..39
- (D) OTHER INFORMATION: /label= primer_2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTCTGTTCTC AAGGTTGTGG GGCTCACTGC TGTGCACTC

39

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..16
- (D) OTHER INFORMATION: /label= Adaptor_1
/note= "Upper strand of Bam HI - Hinf I adaptor,
containing ATG at 364-366"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GATCCACCAT GGAGTT

16

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..16
- (D) OTHER INFORMATION: /label= Adaptor_2
/note= "Lower strand of Bam HI - Hinf I adaptor,
containing ATG at 364-366"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GTGGTACCTC AACTTA

16

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..10
- (D) OTHER INFORMATION: /label= Adaptor_3
/note= "Double stranded Stu I - Eco RI blunt adaptor"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GCCTGAATTC

10

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..21
- (D) OTHER INFORMATION: /label= Adaptor_4
/note= "Upper strand of Bgl II - BamH I adaptor"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GATCCACCAT GGGGGCCCTG T

21

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..14
- (D) OTHER INFORMATION: /label= Adaptor_5
/note= "Lower strand of Bgl II - BamH I adaptor"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GTGGTACCCC CGGG

14

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..15
- (D) OTHER INFORMATION: /label= Adaptor_6
/note= "Upper strand of Ban I - Eco R I adaptor"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GTGCCTATGC CTGAG

15

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..15
- (D) OTHER INFORMATION: /label= Adaptor_7
/note= "Lower strand of Ban I - Eco R I adaptor"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GATACGGACT CTAA

15

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 300 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (B) CLONE: lambda gt11 clone

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..300
- (D) OTHER INFORMATION: /note= "Part of 0.8 kb insert of
Lambda gt11"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AGT	GAC	AAC	GGC	ACT	AAT	GGT	ATT	CAG	CGA	GCC	ATG	TAT	CTT	AGA	GGG	48
Ser	Asp	Asn	Gly	Thr	Asn	Gly	Ile	Gln	Arg	Ala	Met	Tyr	Leu	Arg	Gly	
1				5				10						15		
GTT	AAC	AGG	AGC	TTA	CAT	GGG	ATC	TGG	CCC	GAG	AAA	ATA	TGC	AAG	GGG	96
Val	Asn	Arg	Ser	Leu	His	Gly	Ile	Trp	Pro	Glu	Lys	Ile	Cys	Lys	Gly	
			20					25					30			
GTC	CCC	ACT	CAT	CTG	GCC	ACT	GAC	ACG	GAA	CTG	AAA	GAG	ATA	CGC	GGG	144
Val	Pro	Thr	His	Leu	Ala	Thr	Asp	Thr	Glu	Leu	Lys	Glu	Ile	Arg	Gly	
			35				40					45				

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

[illegible]

Claims

1. An isolated nucleic acid sequence encoding a polypeptide characteristic of hog cholera virus comprising the amino acid sequence about 689-1067 shown in SEQ ID NO: 2 or an antigenic fragment thereof.
2. A nucleic acid sequence according to claim 1 comprising at least part of the DNA sequence about 2428-3564 shown in SEQ ID NO: 1.
3. A recombinant nucleic acid molecule comprising a vector nucleic acid molecule and a nucleic acid sequence according to claim 1 or 2.
4. A recombinant nucleic acid molecule according to claim 3, wherein the nucleic acid sequence is operably linked to expression control sequences.
5. A host cell comprising the recombinant nucleic acid molecule according to claim 3 or 4.
6. A host cell according to claim 5, wherein the host cell is a virus or bacterium.
7. A host cell according to claim 6, wherein the virus is pseudorabies virus or vaccinia.
8. A polypeptide characteristic of hog cholera virus comprising the amino acid sequence about 689-1067 shown in SEQ ID NO: 2 or an antigenic fragment thereof.
9. A polypeptide characteristic of hog cholera virus expressed by the host cell according to claim 5.

- 10.A vaccine for the protection of animals against hog cholera virus infection comprising a polypeptide according to claims 8 or 9.
- 11.A vaccine for the protection of animals against hog cholera virus infection comprising a host cell according to claims 5-7.
- 12.A method for the preparation of a hog cholera virus vaccine comprising mixing an immunogenically effective amount of a polypeptide according to claims 8 or 9 with a pharmaceutically acceptable carrier.
- 13.A method for the preparation of a hog cholera virus vaccine comprising growing a host cell according to claims 5-7 in a culture, harvesting the cells and mixing the cells with a pharmaceutically acceptable carrier.

Abstract

The present invention is concerned with a hog cholera virus vaccine comprising a polypeptide characteristic of hog cholera virus. Vector vaccines capable to express a nucleic acid sequence encoding such a polypeptide also form part of the present invention. Said polypeptide and nucleic acid sequence can also be used for the detection of hog cholera virus infection.

Figure 1.




Figure 2.

1	GTT	AGC	TCT	TTC	TCG	TAT	ACG	ATA	TTG	GAT	ACA	CTA	AAT	TTC	GAT	TTG	CTC	TAG	GGC	ACC	CCT	CCA	CGG	ACG	GCC	GAA	ATG	GGC	84		
85	TAG	CCA	TGC	CCA	TAG	TAG	GAC	TAG	CAA	ACG	GAG	GGA	CTA	GCC	GTA	GTG	CGG	AGC	TCC	CTG	GGT	CTA	ACT	CCT	GAG	TAC	AGG	168			
169	ACA	GTC	GTC	AGT	AGT	TCG	ACG	TGA	GCA	CTA	GCC	CAC	CTC	GAG	ATG	CTA	CGT	CGA	CGG	CAT	GCC	CAA	GAC	ACA	CCT	TAA	CCC	252			
253	TGG	CGG	GGG	TCG	CTA	GGG	TGA	AAT	CAC	ATT	ATG	TGA	TGG	GGG	TAC	GAC	CTG	ATA	GGG	TGC	TGC	AGA	GGC	CCA	CTA	GCA	GGC	TAG	336		
337	TAT	AAA	AAT	CTC	TGC	TGT	ACA	TGG	CAC	ATG	GAG	TTG	AAT	CAT	TTT	GAA	TTA	TAC	AAA	ACA	AGC	AAA	CAA	AAA	CCA	CCA	GTG	GGA	420		
1																												19			
421	GTG	GAG	GAA	CCG	GTG	TAT	GAC	ACC	CGG	GGG	AGA	CCA	CTA	TTT	GGG	AAC	CCA	AGT	GAG	GTA	CAC	CCA	CAA	TCA	ACG	CTG	AAG	CTG	504		
20	Val	Glu	Glu	Pro	Val	Tyr	Asp	Thr	Ala	Gly	Arg	Pro	Leu	Phe	Gly	Asn	Pro	Ser	Glu	Val	His	Pro	Gln	Ser	Thr	Leu	Lys	Leu	47		
505	CCA	CAC	GAC	AGG	GGG	AGA	GGA	GAT	ATC	AGA	ACA	ACA	CTG	AGG	GAC	CTA	CCC	AGG	AAA	GGT	GAC	TGT	AGG	AGT	GGC	AAC	CAT	CTA	588		
48	Pro	His	Asp	Arg	Gly	Arg	Gly	Asp	Ile	Arg	Thr	Thr	Leu	Arg	Asp	Leu	Pro	Arg	Lys	Gly	Asp	Cys	Arg	Ser	Gly	Asn	His	Leu	75		
589	GGC	CCG	GTT	AGT	GGG	ATA	TAC	ATA	AAG	CCC	GGC	CCG	CCT	GTC	TAC	TAT	CAG	GAC	TAC	ACG	GGC	CCA	GTC	TAT	CAC	AGA	GCT	CCT	TTA	672	
76	Gly	Pro	Val	Ser	Gly	Ile	Tyr	Ile	Tyr	Ile	Lys	Pro	Gly	Pro	Val	Tyr	Tyr	Gln	Asp	Tyr	Thr	Gly	Pro	Val	Tyr	His	Arg	Ala	Pro	Leu	103
673	GAG	TTC	TTT	GAT	GAG	GCC	CAG	TTC	TGC	GAG	GTG	ACT	AAG	AGA	ATA	GGC	AGG	GTG	ACG	GGT	AGT	GAT	GGT	AAG	CTT	TAC	CAC	ATA	756		
104	Glu	Phe	Phe	Asp	Glu	Ala	Gln	Phe	Cys	Glu	Val	Thr	Lys	Arg	Ile	Gly	Arg	Val	Thr	Gly	Ser	Asp	Gly	Lys	Leu	Tyr	His	Ile	131		
757	TAT	GTG	TGC	GTC	GAT	GAT	GAT	GAT	TGC	TCC	GAT	GAC	GGC	GCA	AGT	GGC	AGC	AAG	GAT	AAG	CCA	GAC	AGA	ATG	AAC	TTC	ACC	840			
132	Tyr	Val	Cys	Val	Asp	Gly	Cys	Ile	Leu	Leu	Lys	Leu	Ala	Lys	Arg	Gly	Thr	Pro	Arg	Thr	Leu	Lys	Trp	Ile	Arg	Asn	Phe	Thr	159		
841	AAC	TGT	CCA	TTA	TGG	GTA	ACC	AGT	TGC	TCC	GAT	GAC	GGC	GCA	AGT	GGC	AGC	AAG	GAT	AAG	CCA	GAC	AGA	ATG	AAC	AAA	GGT	924			
160	Asn	Cys	Pro	Leu	Trp	Val	Thr	Ser	Cys	Ser	Asp	Asp	Gly	Ala	Ser	Gly	Ser	Lys	Asp	Lys	Lys	Pro	Asp	Arg	Met	Asn	Lys	Gly	187		
925	AAG	TTG	AAG	ATA	GCC	CCA	AGA	GAG	CAT	GAG	AAG	GAC	AGC	AAG	ACC	AAG	CCG	CCT	GAT	GCA	ACG	ATT	GTA	GAG	GGA	GTA	AAA	1008			
188	Lys	Leu	Lys	Ile	Ala	Pro	Arg	Glu	His	Glu	Lys	Asp	Ser	Lys	Thr	Lys	Pro	Pro	Asp	Ala	Thr	Ile	Val	Val	Glu	Gly	Val	Lys	215		
1009	TAC	CAA	ATC	AAA	AAG	AAA	GGC	AAA	GTC	AAA	GGG	AAG	AAC	ACA	CAA	GAC	GGC	CTG	TAC	CAT	AAT	AAG	AAC	AAG	CCA	CCA	GAG	TCC	1092		
216	Tyr	Gln																													

1093 AGG AAG AAA CTA GAA GCC CTG TTG GCT TGG GCG GTG ATA ACA ATC TTG CTG TAC CAG CCT GTA GCA GCC CAG AAC ATA ACT 1176
244 Arg Lys Lys Leu Glu Lys Ala Leu Ala Trp Ala Val Ile Thr Ile Leu Leu Tyr Gln Pro Val Ala Ala Glu Asn Ile Thr 271
1177 CAA TGG AAC CTG AGT GAC AAC GGC ACT AAT GGT ATT CAG CGA GCC ATG TAT CTT AGA GGG GTT AAC AGG AGC TTA CAT GGG ATC 1260
272 Gln Trp Asn Leu Ser Asp Asn Gly Thr Asn Gly Ile Gln Arg Ala Met Tyr Leu Arg Gly Val Asn Arg Ser Leu His Gly Ile 299
1261 TGG CCC GAG AAA ATA TGC AAG GGG GTC CCC ACT CAT CTG GCC ACT GAC ACG GAA CTG AAA GAG ATA CGC GGG ATG ATG GAT GCC 1344
300 Trp Pro Glu Lys Ile Cys Lys Gly Val Pro Thr His Leu Ala Thr Asp Thr Glu Leu Lys Glu Ile Arg Gly Met Met Asp Ala 327
1345 AGC GAG AGG ACA AAC TAT ACG TGC TGT AGG TTA CAA AGA CAT GAA TGG AAC AAA CAT GGA TGG TGT AAC TGG TAC AAC ATA GAC 1428
328 Ser Glu Arg Thr Asn Tyr Thr Cys Cys Arg Leu Gln Arg His Glu Trp Asn Lys His Gly Trp Cys Asn Trp Tyr Asn Ile Asp 355
1429 CCT TGG ATT CAG TTA ATG AAC AGG ACC CAA ACA AAT TTG ACA GAA GGC CCT CCA GAT AAG GAG TGT GCC GTG ACC TGC AGG TAT 1512
356 Pro Trp Ile Gln Leu Met Asn Arg Thr Gln Thr Asn Leu Thr Glu Gly Pro Pro Asp Lys Glu Cys Ala Val Thr Cys Arg Tyr 383
1513 GAC AAA AAT ACC GAT GTC AAC GTG GTC ACC CAG GCC AGG AAT AGG CCA ACT ACT CTG ACT GGC TGC AAG AAA GGG AAA AAC TTT 1596
384 Asp Lys Asn Thr Asp Val Asn Val Val Thr Gln Ala Arg Asn Arg Pro Thr Thr Leu Thr Gly Cys Lys Lys Gly Lys Asn Phe 411
1597 TCA TTC GCA GGC ACA GTC ATA GAG GGC CCG TGC TGC AAT TTC AAC GTT TCC TCG GAG GAC ATC TTA TAC GGA GAC CAT GAG TGT GGC 1680
412 Ser Phe Ala Gly Thr Val Ile Glu Gly Pro Cys Asn Phe Asn Val Ser Val Glu Asp Ile Leu Tyr Gly Asp His Glu Cys Gly 439
1681 AGT CTG CTC CAG GAC ACG GCT CTG TAC CTA TTG GAT GGA ATG ACC AAC ACT ATA GAG AAT GCC AGG CAA GGT GCG GCG GTG 1764
440 Ser Leu Leu Gln Asp Thr Ala Leu Tyr Leu Leu Asp Gly Met Thr Asn Thr Ile Glu Asn Ala Arg Gln Gly Ala Ala Arg Val 467
1765 ACA TCT TGG CTT GGG AGG CAG CAG Gln Leu Ser Thr Ala Gly Lys Leu CTA GAG AGG AGA AGC AAA ACC TGG TTT GGT GCC TAT GCC CTG 1848
468 Thr Ser Trp Leu Gly Arg Gln Leu Ser Thr Ala Gly Lys Leu CTA GAG AGG AGA AGC AAA ACC TGG TTT GGT GCC TAT GCC CTG 495
1849 TCA CCT TAC TGC AAT GTG ACT AGA AAA ATA GGG TAC ATA TGG TAT ACA AAC TGC ACC CCG GCA TGC CTC CCT AAG AAC ACA 1932
496 Ser Pro Tyr Cys Asn Val Thr Arg Lys Ile Gly Tyr Ile Trp Tyr Thr Asn Asn Cys Thr Pro Ala Cys Leu Pro Lys Asn Thr 523
1933 AAA ATA ATA GGC CCT GGA AAG TTT GAC ACC AAT GCG GAA GAC GGG AAG ATC CTT CAT GAA ATG GGG GGC CAC CTA TCA GAA TTT 2016
524 Lys Ile Ile Gly Pro Gly Lys Phe Asp Thr Asn Ala Glu Asp Gly Lys Ile Leu His Glu Met Gly Gly His Leu Ser Glu Phe 551
2017 TTG TTG CTT TCT CTA GTT ATC CTG TCT TCT GAC TTT GCC CCC GAG ACA GCT AGC ACG CTA TAC CTA ATT TTA CAC TAT GCA ATC CCC 2100
552 Leu Leu Leu Ser Leu Val Ile Leu Ser Asp Phe Ala Pro Glu Thr Ala Ser Thr Leu Tyr Leu Ile Leu His Tyr Ala Ile Pro 579

2101	CAG TCC CAC GAA GAA CCT GAA GGT TGT GAT ACG AAC CAA CTT AAC CTA ACA GTG AAA CTT AGG ACA GAA GAC GTA GTG CCA TCA	2184
580	Gln Ser His Glu Glu Pro Glu Gly Cys Asp Thr Asn Gln Leu Asn Leu Thr Val Lys Leu Arg Thr Glu Asp Val Val Pro Ser	607
2185	TCA GTT TGG AAT ATT GGC AAA TAT GTT TGT GAT GGT AGA CCA GAC TGG TGG CCG TAT GAA ACT AAA GTG GCT CTG CTG TTT GAA GAG	2268
608	Ser Val Trp Asn Ile Gly Lys Tyr Val Cys Val Arg Pro Asp Trp Trp Pro Tyr Glu Thr Lys Val Ala Leu Leu Phe Glu Glu	635
2269	GCA GGA CAG GTT ATA AAG CTA GTC CTA CGG GCA CTG AGG GAT TTA ACT AGG GTC TGG AAC AGC GCA TCA ACT ACT GCG TTT CTC	2352
636	Ala Gly Gln Val Ile Lys Leu Val Val Lys Leu Val Val Lys Leu Arg Ala Leu Arg Asp Leu Thr Arg Val Trp Asn Ser Ala Ser Thr Thr Ala Phe Leu	663
2353	ATT TGC TTG ATA AAA GTA TTG AGA GGA CAG GTT GTG CAA GGT ATA ATA TGG CTG CTG CTG GGC GCT GAA GGT CTC ACC ACT ACC TGG	2436
664	Ile Cys Leu Ile Lys Val Leu Arg Gly Gln Val Val Gln Gly Ile Ile Trp Leu Leu Leu Val Thr Gly Ala Gln Gly Arg Leu	691
2437	GCC TGT AAG GAA GAC TAC AGG TAT GCG ATC TCG TCA ACC AAT GAG ATA GGG CTG GGC CTG GGC GCT GAA GGT CTC ACC ACT ACC TGG	2520
692	Ala Cys Lys Glu Asp Tyr Arg Tyr Ala Ile Ser Ser Thr Asn Glu Ile Gly Leu Leu Leu Gly Ala Glu Gly Leu Thr Thr Trp	719
2521	AAA GAA TAC AGC CAC GGT TTG CAG CTG GAC GAC GGA ACC GTT AAG GCC CTC TGC ACT GCA GGG TCC TTT AAA GTC ACA GCA CTT	2604
720	Lys Glu Tyr Ser His Gly Leu Gln Leu Asp Asp Gly Thr Val Lys Ala Val Cys Thr Ala Gly Ser Phe Lys Val Thr Ala Leu	747
2605	AAC GTG GTT AGT AGG AGG TAT CTA GCA TCA TTG CAC AAG AGG GCT CTA CCC ACC TCA GTG ACA TTT GAG CTC CTA TTT GAC GGG	2688
748	Asn Val Val Ser Arg Arg Tyr Leu Ala Ser Leu His Lys Arg Ala Leu Pro Thr Ser Val Thr Phe Glu Leu Leu Phe Asp Gly	775
2689	ACC AAC CCA GCA ATC GAG GAG ATG GA ^m GAT GAC TTC GGA TTT GGG CTG TGC CCA TTT GAC ACG AGT CCT GTG ATC AAA GGG AAG	2772
776	Thr Asn Pro Ala Ile Glu Glu Met Asp Asp Phe Gly Phe Gly Leu Cys Pro Phe Asp Thr Ser Pro Val Ile Lys Gly Lys	803
2773	TAC AAC ACC ACT TTG TTA AAC GGC AGT GCT TTC TAT CTA GTC TGC CCA ATA GGA TGG ACT GGT GTC GTA GAG TGC ACA GCA GTG	2856
804	Tyr Asn Thr Thr Leu Leu Asn Gly Ser Ala Phe Tyr Leu Val Cys Pro Ile Gly Trp Thr Gly Val Val Glu Cys Thr Ala Val	831
2857	AGC CCC ACA ACC TTG AGA ACA GAA GTG GTG AAA ACC TTC AGG AGA GAT AAG CCT TTT CCA CAT AGA GTA GAC TGT GTG ACC ACC	2940
832	Ser Pro Thr Thr Leu Arg Thr Glu Val Val Lys Thr Phe Arg Arg Asp Lys Pro Phe Pro His Arg Val Asp Cys Val Thr Thr	859
2941	ATA GTA GAA AAA GAA GAC CTA TTC CAT TGC AAG TTG GGG GGT AAT TGG ACA TGT GTA AAA GGC GAC CCA GTG ACT TAT AAG GGG	3024
860	Ile Val Glu Lys Glu Asp Leu Phe His Cys Lys Leu Gly Gly Asn Trp Thr Cys Val Lys Gly Asp Pro Val Thr Tyr Lys Gly	887
3025	GGG CAA GTA AAG CAG TGC AGG TGG TGT GGT TTC GAG TTT AAA GAG CCC TAC GGG CTC CCA CAC TAC CCT ATA GGC AAG TGC ATC	3108
888	Gly Gln Val Lys Gln Cys Arg Trp Cys Gly Phe Glu Phe Lys Glu Pro Tyr Gly Leu Pro His Tyr Pro Ile Gly Lys Cys Ile	915

3109	CTA ACA AAT GAG ACA GGT TAC AGG GTA GTA GAT TCC ACA GAC TGC AAC AGA GAT GGC CTC GTT ATT AGC ACT GAA GGG GAA CAT	3192
916	Leu Thr Asn Glu Thr Gly Tyr Arg Val Val Asp Ser Thr Asp Cys Asn Arg Asp Gly Val Val Ile Ser Thr Glu Gly Glu His	943
3193	GAG TGC TTG ATT GGC AAC ACT ACC GTC AAG GTG CAT GCA CTG GAT GAA AGA TTG GGC CCT ATG CCG TGC AGA CCC AAA GAA ATC	3276
944	Glu Cys Leu Ile Gly Asn Thr Thr Val Lys Val His Ala Leu Asp Glu Arg Leu Gly Pro Met Pro Cys Arg Pro Lys Glu Ile	971
3277	GTC TCT AGT GAG GGA CCT GTG AGG AAA ACT TCT TGT ACA TTC AAC TAC ACA AAG ACT CTA AGA AAC AAA TAC TAT GAG CCC AGA	3360
972	Val Ser Ser Glu Gly Pro Val Arg Lys Thr Ser Cys Thr Phe Asn Tyr Thr Lys Thr Leu Arg Asn Lys Tyr Tyr Glu Pro Arg	999
3361	GAC AGT TAC TTC CAG CAA TAT ATG CTC AAG GGC GAG TAT CAA TAC TGG TTT AAT CTG GAC GTG ACC GAC CAC CAC ACA GAC TAC	3444
1000	Asp Ser Tyr Phe Gln Gln Tyr Met Leu Lys Gly Glu Tyr Gln Tyr Trp Phe Asn Leu Asp Val Thr Asp His His Thr Asp Tyr	1027
3445	TTT GCC GAG TTT GTT GTC TTG GTA GTA GCA CTG TTA GGA GGA AGG TAC TGG GTT CTG TGG CTA ATA GTG ACC TAC ATA ATT CTA	3528
1028	Phe Ala Glu Phe Val Val Leu Val Val Val Ala Leu Leu Gly Gly Arg Tyr Val Leu Trp Leu Ile Val Thr Tyr Ile Ile Leu	1055
3529	ACA GAG CAG CTC GCT GCT CTA CAG CTA GGC CAG GGT GAG GTG GTA TTG ATA GGG AAC CTA ATT ACC CAC ACG GAC AAT GAG	3612
1056	Thr Glu Gln Leu Ala Ala Gly Leu Gln Leu Gly Gln Gly Val Leu Ile Gly Asn Leu Ile Thr His Thr Asp Asn Glu	1083
3613	GTG GTG GTG TAC TTC CTA CTG CTC TAC TTA GTA ATA AGA GAT GAG CCC ATA AAG AAA TGG ATA CTA CTG CTG TTT CAT GCA ATG	3696
1084	Val Val Val Tyr Phe Leu Leu Leu Tyr Leu Val Ile Arg Asp Glu Pro Ile Lys Lys Trp Ile Leu Leu Leu Phe His Ala Met	1111
3697	ACT AAC AAT CCA GTC AAG ACC ATA ACA GTA TTA GCA TTG CTA ATG ATC AGT GGG GTT GCC AAG GGT GGT AAG ATA GAT GGT GGC TGG	3780
1112	Thr Asn Asn Pro Val Lys Thr Ile Thr Val Val Ala Leu Leu Met Ile Ser Gly Val Ala Lys Gly Gly Ile Asp Gly Gly Trp	1139
3781	CAG AGA CAA CCG GTG ACC AGT TTT GAC ATC CAA CTC GCA CTG GCA GTC GTA GTC GTT GTG ATG TTG CTG CCA AAG AGA GAC	3864
1140	Gln Arg Gln Pro Val Thr Ser Phe Asp Ile Gln Leu Ala Leu Ala Val Val Val Val Met Leu Leu Ala Lys Arg Asp	1167
3865	CCG ACT ACT TTC CCT TTG GTA ATC ACA GTG GCA ACC CTG AGA ACG GGC AAG ATA ACC AAC GGT TTT AGC ACA GAT CTA GTC ATA	3948
1168	Pro Thr Thr Phe Pro Leu Val Ile Thr Val Val Ala Thr Leu Arg Thr Ala Lys Ile Thr Asn Gly Phe Ser Thr Asp Leu Val Ile	1195
3949	GCC ACA GTG TCG GCA GCT TTG TTA ACT TGG ACC TAT ATC AGC GAC TAC TAC AAA TAC AAG ACT TGG CTA CAG TAC CTC GTC AGC	4032
1196	Ala Thr Val Ser Ala Ala Leu Leu Thr Trp Thr Tyr Ile Ser Asp Tyr Tyr Lys Tyr Thr Trp Leu Gln Tyr Leu Val Ser	1223
4033	ACG GTG ACT GGA ATC TTC CTG ATA AGG GTG CTG AAG GGA ATA GGC GAA TTG GAT CTG CAC GCC CCA ACC TTG CCG TCT CAC AGA	4116
1224	Thr Val Thr Gly Ile Phe Leu Ile Arg Val Leu Lys Gly Ile Gly Glu Leu Asp Leu His Ala Pro Thr Leu Pro Ser His Arg	1251

4117	CCC	CTC	TTT	TAC	ATC	GTA	CTT	ATT	TCC	ACT	GCC	GTG	GTA	ACT	AGA	TGG	AAT	CTG	GAC	GTA	GCC	GGA	TTG	TTG	CTG	CAG	4200			
1252	Pro	Leu	Phe	Tyr	Ile	Leu	Val	Tyr	Ile	Ser	Thr	Ala	Val	Val	Thr	Arg	Trp	Asn	Leu	Asp	Val	Ala	Gly	Leu	Leu	Gln	1279			
4201	TGC	GTC	CCA	ACT	CTT	TTA	ATG	GTT	TTT	ACG	ATG	TGG	GCA	GAC	ATT	CTC	ACC	CTA	ATT	CTC	ATA	CTA	CCT	ACT	TAT	GAG	TTA	ACA	4284	
1280	Cys	Val	Pro	Thr	Leu	Leu	Met	Val	Phe	Thr	Met	Trp	Ala	Asp	Ile	Leu	Thr	Leu	Ile	Leu	Ile	Leu	Pro	Thr	Tyr	Glu	Leu	Thr	1307	
4285	AAG	TTA	TAC	TAC	CTT	AAG	GAA	GTG	AAG	ATT	GGG	GCA	GAA	AGA	GGT	TGG	CTG	TGG	AAA	ACT	AAC	TAT	AAG	AGG	GTA	AAC	GAC	ATC	4368	
1308	Lys	Leu	Tyr	Tyr	Leu	Lys	Glu	Val	Lys	Ile	Gly	Ala	Glu	Arg	Gly	Trp	Leu	Trp	Lys	Thr	Asn	Tyr	Lys	Arg	Val	Asn	Asp	Ile	1335	
4369	TAC	GAG	GTC	GAC	CAA	ACT	AGC	GAA	GGG	GTT	TAC	CTT	TTT	TTC	CCT	TCT	AAA	CAG	AGG	ACG	AGC	GCT	ATA	ACT	AGT	ACC	ATG	TTG	CCA	4452
1336	Tyr	Glu	Val	Val	Asp	Gln	Thr	Ser	Glu	Gly	Val	Tyr	Leu	Phe	Pro	Ser	Lys	Gln	Arg	Thr	Ser	Ala	Ile	Thr	Ser	Thr	Met	Leu	Pro	1363
4453	TTA	ATC	AAA	GCC	ATA	CTC	ATT	AGC	TGC	ATC	AGC	AAC	AAG	TGG	CAA	CTC	ATA	TAC	TTA	CTG	TAC	TTG	ATA	TTT	GAA	GTG	TCT	TAC	4536	
1364	Leu	Ile	Lys	Ala	Ile	Leu	Ile	Ser	Cys	Ile	Ser	Asn	Lys	Trp	Gln	Leu	Ile	Tyr	Leu	Leu	Tyr	Leu	Ile	Phe	Glu	Val	Ser	Tyr	1391	
4537	TAC	CTC	CAC	AAG	AAA	GTT	ATA	GAT	GAA	ATA	GCT	GGT	GGG	ACC	AAC	TTT	GTT	TCA	AGG	CTC	GTG	GCG	GCT	TTG	ATT	GAA	GTC	AAT	4620	
1392	Tyr	Leu	His	Lys	Lys	Val	Ile	Asp	Glu	Ile	Ala	Gly	Gly	Thr	Asn	Phe	Val	Ser	Arg	Leu	Val	Ala	Ala	Leu	Ile	Glu	Val	Asn	1419	
4621	TGG	GCC	TTT	GAC	AAT	GAA	GAA	GTC	AAA	GGC	TTA	AAG	AAG	TTT	CTT	TTG	CTG	TCT	AGT	AGG	GTC	AAA	GAG	TTG	ATC	ATC	AAA	CAC	4704	
1420	Trp	Ala	Phe	Asp	Asn	Glu	Glu	Val	Lys	Gly	Leu	Lys	Lys	Phe	Phe	Leu	Leu	Ser	Ser	Arg	Val	Lys	Glu	Leu	Ile	Ile	Lys	His	1447	
4705	AAA	GTG	AGG	AAT	GAA	GTA	GTG	GTC	CGC	TGG	TTT	GGA	GAT	GAA	GAG	ATT	TAT	GGG	ATG	CCA	AAG	CTG	ATC	GGC	TTA	GTT	AAG	GCA	4788	
1448	Lys	Val	Arg	Asn	Glu	Val	Val	Val	Arg	Trp	Phe	Gly	Asp	Glu	Glu	Ile	Tyr	Gly	Met	Pro	Lys	Leu	Ile	Gly	Leu	Val	Lys	Ala	1475	
4789	GCA	ACA	CTA	AGT	AGA	AAC	AAA	CAC	TGT	ATG	TTG	TGT	ACC	GTC	TGT	GAG	GAC	AGA	GAT	TGG	AGA	GCG	GAA	ACT	TGC	CCT	AAA	TGT	4872	
1476	Ala	Thr	Leu	Ser	Arg	Asn	Lys	His	Cys	Met	Leu	Cys	Thr	Val	Cys	Glu	Asp	Arg	Asp	Trp	Arg	Gly	Glu	Thr	Cys	Pro	Lys	Cys	1503	
4873	GGG	CGT	TTT	GGA	CCA	CCA	GTG	GTC	TGC	GGT	ATG	ACC	CTA	GCC	GAT	TTT	GAA	GAA	AAA	CAC	TAT	AAA	AGG	ATT	TTC	ATT	AGA	GAG	4956	
1504	Gly	Arg	Phe	Gly	Pro	Pro	Val	Val	Cys	Gly	Met	Thr	Leu	Ala	Asp	Phe	Glu	Glu	Lys	His	Tyr	Lys	Arg	Ile	Phe	Ile	Arg	Glu	1531	
4957	GAC	CAA	TCA	GGC	GGG	CCA	CTT	AGG	GAG	GAG	GAG	CAT	GCA</																	

5125 CTT AGA GGG CCA GCT GTT TGC AAG AAG GTT ACT GAA CAC GAA AGA TGC ACC ACG TCT ATA ATG GAT AAG TTG ACT GCT TTC TTT 5208
1588 Leu Arg Gly Pro Ala Val Cys Lys Lys Val Thr Glu His Glu Arg Cys Thr Thr Ser Ile Met Asp Lys Leu Thr Ala Phe Phe 1615
5209 GGA GTA ATG CCA AGG GGC ACT ACT CCC AGA GCT CCC GTA AGA TTC CCT ACC TCC CTC CTA AAG ATA AGA AGA GGG CTG GAG ACT 5292
1616 Gly Val Met Pro Arg Gly Thr Thr Pro Arg Ala Pro Val Arg Phe Pro Thr Ser Leu Leu Lys Ile Arg Arg Gly Leu Glu Thr 1643
5293 GGT TGG GCT TAC ACA CAC CAA GGT GGC ATC AGC TCA GTA GAC CAT GTC ACT TGT GGG AAA GAC TTA CTG GTG TGT GAC ACC ATG 5376
1644 Gly Trp Ala Tyr Thr His Glu Gly Gly Ile Ser Ser Val Asp His Val Thr Cys Gly Lys Asp Leu Leu Val Cys Asp Thr Met 1671
5377 GGT CGG ACA AGG GTT GTT TGC CAG TCA AAT AAT AAG ATG ACC GAC GAG TCC GAA TAC GGA GTC AAA ACT GAC TCC GGG TGC CCA 5460
1672 Gly Arg Thr Arg Val Val Cys Glu Ser Asn Asn Lys Met Thr Asp Glu Ser Glu Tyr Gly Val Lys Thr Asp Ser Gly Cys Pro 1699
5461 GAG GGA GCC AGG TGT TAC GTG TTT AAC CCG GAA GCA GTT AAC ATA TCA GGC ACT AAA GGA GCC ATG GTC CAC TTA CAG AAA ACG 5544
1700 Glu Gly Ala Arg Cys Tyr Val Phe Asn Pro Glu Ala Val Asn Ile Ser Gly Thr Lys Gly Ala Met Val His Leu Glu Lys Thr 1727
5545 GGT GGA GAA TTC ACC TGT GTG ACA GCA GCA ACC CCG GCC TTC TTT GAC CTC AAG AAC CTT AAG GGC TGG TCA GGG CTA CCG 5628
1728 Gly Gly Glu Phe Thr Cys Val Thr Ala Ser Gly Thr Pro Ala Phe Phe Asp Leu Lys Asn Leu Lys Gly Trp Ser Gly Leu Pro 1755
5629 ATA TTT GAA GCA TCA AGT GGA AGG GTA GTC GGA AGG GTC AAG GTC GGC AAG AAC GAG GAT TCC AAA CCA ACC AAG CTC ATG AGT 5712
1756 Ile Phe Glu Ala Ser Ser Gly Arg Val Val Gly Arg Val Lys Val Gly Lys Asn Glu Asp Ser Lys Pro Thr Lys Leu Met Ser 1783
5713 GGG ATA CAA ACG GTT TCT AAA AGC GCC ACA GAC TCG ACG GAG ATG GTG AAG AAG ATA ACG ACC ATG AAC AGG GGA GAG TTC AGA 5796
1784 Gly Ile Glu Thr Val Ser Lys Ser Ala Thr Asp Leu Thr Glu Met Val Lys Lys Ile Thr Thr Met Asn Arg Gly Glu Phe Arg 1811
5797 CAA ATA ACC CTG GCC ACA GGT OCC GGA AAA ACT ACA GAG CTC CCT AGA TCA GTT ATA GAA GAG ATA GGG AGG CAT AAG AGG GTG 5880
1812 Glu Ile Thr Leu Ala Thr Glu Ala Thr Gly Ala Gly Lys Thr Thr Glu Leu Pro Arg Ser Val Ile Glu Glu Ile Gly Arg His Lys Arg Val 1839
5881 TTG GTC TTA ATC CCC TTG AGG GCG GCA GCA GAA TCA GTA TAC CAA TAC ATG AGA CAG AAA CAT CCG AGT ATA GCA TTC AAT CTA 5964
1840 Leu Val Leu Ile Pro Leu Arg Ala Ala Ala Glu Ser Val Tyr Glu Tyr Met Arg Glu Lys His Pro Ser Ile Ala Phe Asn Leu 1867
5965 AGG ATA GGT GAG ATG AAG GAA GGT GAT ATG GCC ACG GGA ATA ACC TAT GCC TCT TAC GGT TAC TTT TGC CAG ATG TCA CAA CCC 6048
1868 Arg Ile Gly Glu Met Lys Glu Gly Asp Met Ala Thr Gly Ile Thr Tyr Ala Ser Tyr Gly Tyr Phe Cys Glu Met Ser Glu Pro 1895
6049 AAG CTG AGA GCC GCA ATG GTA GAA TAT TCC TTT ATA TTC CTA GAT GAG TAT CAT TGT GCT ACC CCA GAA CAA CTG GCA ATC ATG 6132
1896 Lys Leu Arg Ala Ala Met Val Glu Tyr Ser Phe Ile Phe Leu Asp Glu Tyr His Cys Ala Thr Pro Glu Glu Leu Ala Ile Met 1923

6133	GGG	AAG	ATC	CAC	AGA	TTC	TCA	GAA	AAC	CTG	GTG	GTA	GCT	ATG	ACA	CGC	GCA	GGC	ACA	GTA	ACA	ACC	ACT	GGG	CAG	6216	
1924	Gly	Lys	Ile	His	Arg	Phe	Ser	Glu	Asn	Leu	Arg	Val	Val	Ala	Met	Thr	Ala	Gly	Thr	Val	Thr	Thr	Thr	Gly	Gln	1951	
6217	AAA	CAC	CCT	ATA	GAG	GAA	TTT	ATA	GCC	CCG	GAA	GTG	ATG	AAA	GGA	GAA	GAC	TTG	GGT	TCT	GAG	TAC	TTA	GAT	ATT	6300	
1952	Lys	His	Pro	Ile	Glu	Glu	Phe	Ile	Ala	Pro	Glu	Val	Met	Lys	Gly	Gly	Asp	Leu	Gly	Ser	Glu	Tyr	Leu	Asp	Ile	1979	
6301	AAG	ATA	CCA	GTA	GAG	GAG	ATG	AAG	AAT	AAC	ATG	CTA	GTT	TTT	GTG	CCC	ACC	AGG	AAC	ATG	CCG	GTA	GAG	GGC	GCA	6384	
1980	Lys	Ile	Pro	Val	Glu	Glu	Met	Lys	Asn	Asn	Met	Leu	Val	Phe	Val	Pro	Thr	Arg	Asn	Met	Ala	Val	Glu	Ala	Lys	2007	
6385	AAG	GCC	AAA	GGA	TAC	AAC	TCG	GGC	TAC	TAC	TAC	AGC	GGA	GAG	GAC	CCA	TCT	AAC	CTG	AGG	GTG	GTG	ACG	TCG	CAG	6468	
2008	Lys	Ala	Lys	Gly	Tyr	Asn	Ser	Gly	Tyr	Tyr	Tyr	Ser	Gly	Ser	Gly	Asp	Pro	Ser	Asn	Leu	Arg	Val	Val	Thr	Ser	2035	
6469	GTG	GTG	GTA	GCA	ACC	AAC	GCA	ATA	GAA	TCG	GGC	GTT	ACC	CTC	CCG	GAC	CTG	GAC	GTG	GTT	GTC	GAC	ACG	CGA	CTC	6552	
2036	Val	Val	Val	Ala	Ala	Thr	Asn	Ala	Ile	Glu	Ser	Gly	Val	Thr	Leu	Pro	Asp	Leu	Asp	Val	Val	Val	Asp	Thr	Gly	2063	
6553	AAA	AGA	ATC	CGA	CTG	TCA	CCC	AAG	ATG	CCC	AAG	ATG	CTT	TTC	ATA	GTG	ACG	GGC	CTG	AAA	AGA	ATG	GCC	ACT	ATT	GGG	6636
2064	Lys	Arg	Ile	Arg	Leu	Ser	Pro	Lys	Met	Pro	Lys	Met	Pro	Phe	Ile	Val	Thr	Gly	Leu	Lys	Arg	Met	Ala	Val	Thr	2091	
6637	AGA	AGA	GGG	AGG	GTT	GCA	AGA	GTG	AAG	CCC	GGG	AGA	TAC	TAC	AGG	AGA	ACA	ACA	CCT	GTC	GTC	TCT	AAA	GAC	TAC	6720	
2092	Arg	Arg	Gly	Arg	Val	Gly	Arg	Val	Lys	Pro	Gly	Arg	Tyr	Tyr	Arg	Ser	Gln	Gln	Thr	Pro	Val	Gly	Ser	Lys	Asp	2119	
6721	GAC	TTA	TTG	CAA	GCC	CAG	AGG	TAC	GGC	ATA	GGC	ATA	GAT	GGG	Gly	Ile	Asp	Gly	Ala	Arg	Tyr	Ala	GAG	ATG	AAC	6804	
2120	Asp	Leu	Leu	Gln	Ala	Gln	Ala	Gln	Arg	Tyr	Gly	Ile	Glu	Asp	Gly	Ile	Asn	Ile	Thr	Lys	Ser	Phe	Arg	Glu	Met	2147	
6805	CTT	TAT	GAG	GAA	GAT	AGC	CTG	ATG	ATC	ACA	CAA	CTG	GAA	ATC	CTC	AAC	AAC	CTG	TTG	ATA	TCA	GAA	GAG	CTG	CCG	6888	
2148	Leu	Tyr	Glu	Glu	Asp	Ser	Leu	Met	Ile	Thr	Gln	Leu	Glu	Ile	Leu	Asn	Asn	Leu	Leu	Ile	Ser	Glu	Glu	Leu	Pro	2175	
6889	AAA	AAT	ATA	ATG	GCC	AGG	ACC	GAC	CAC	CCA	GAA	CCA	ATT	CAA	CTC	CGC	TAT	AAC	AGC	TAC	GAG	ACA	CAG	GTG	CCG	GTA	6972
2176	Lys	Asn	Ile	Met	Ala	Arg	Thr	Asp	His	Pro	Glu	Pro	Ile	Gln	Leu	Ala	Tyr	Asn	Ser	Tyr	Glu	Thr	Gln	Val	Pro	2203	
6973	CCA	AAA	ATA	AGA	AAT	GGA	GAG	GTG	ACT	GAT	ACT	TAC	GAT	AAT	TAC	ACC	TTC	CTC	AAT	GCA	AGA	AAA	TTG	GGA	GAT	7056	
2204	Pro	Lys	Ile	Arg	Asn	Gly	Glu	Val	Thr	Asp	Thr	Tyr	Asp	Asn	Tyr	Thr	Phe	Leu	Asn	Ala	Arg	Lys	Leu	Gly	Asp	2231	
7057	CCC	TAC	GTG	TAT	GCT	ACA	GAG	GAT	GAG	GAC	TTG	GCA	GTG	GAA	CTG	TTG	GGC	CTA	GAT	TGG	CCG	GAC	CCA	GGA	AAC	CNA	7140
2232	Pro	Tyr	Val	Tyr	Ala	Thr	Glu	Asp	Glu	Asp	Glu	Ala	Val	Glu	Leu	Leu	Gly	Leu	Asp	Trp	Pro	Asp	Pro	Gly	Asn	Gln	2259

7141	GTG GAA GCT GGC AGA GCA CTA AAA CAG GTG GTT GGT CTA TCA ACA GCA GAG AAC GCC CTG CTA GTC GCC CTG TTC GGC TAC GTG	7224
2260	Val Glu Ala Gly Arg Ala Leu Lys Gln Val Val Gly Leu Ser Thr Ala Glu Asn Ala Leu Val Ala Leu Phe Gly Tyr Val	2287
7225	GGG TAC CAG GCG CTT TCA AAG AGA CAT ATA CCA GTG GTC ACA GAT ATA TAT TCA GTA GAA GAT CAC AGG CTA GAG GAC ACT ACG	7308
2288	Gly Tyr Gln Ala Leu Ser Lys Arg His Ile Pro Val Val Thr Asp Ile Tyr Ser Val Glu Asp His Arg Leu Glu Asp Thr Thr	2315
7309	CAC CTA CAG TAT GCT CCG AAT GCC ATC AAG ACC GAG GGG AAG GAA ACT GAA TTG AAG GAG CTG GCT CAG GCG GAT GTG CAG AGA	7392
2316	His Leu Gln Tyr Ala Pro Asn Ala Ile Lys Thr Glu Gly Lys Glu Thr Glu Leu Lys Glu Leu Ala Gln Gly Asp Val Gln Arg	2343
7393	TGT GTG GAA GCA GTG ACC AAT TAT GCG AGA GAG GGC ATC CAA TTC ATG AAG TCG CAG GCA CTG AAA GTG AGA GAA ACC CCT ACC	7476
2344	Cys Val Glu Ala Val Thr Asn Tyr Ala Arg Glu Gly Ile Gln Phe Met Lys Ser Gln Ala Leu Lys Val Arg Glu Thr Pro Thr	2371
7477	TAT AAA GAG ACA ATG AAC ACC GTG GCA GAT TAT GTG AAA AAG TTT ATT GAG GCA CTG ACG GAT AGC AAG GAA GAC ATC ATT AAA	7560
2372	Tyr Lys Glu Thr Met Asn Thr Val Val Ala Asp Tyr Val Lys Lys Phe Ile Glu Ala Leu Thr Asp Ser Lys Glu Asp Ile Ile Lys	2399
7561	TAT GGG CTG TGG GGG GCA CAT ACG GCA TTT TAT AAG AGC ATT GGT GCC AGG CTT GGT CAC GAA ACC GCG TTC GCA ACT CTA GTT	7644
2400	Tyr Gly Leu Trp Gly Ala His Thr Ala Leu Tyr Lys Ser Ile Gly Ala Arg Leu Gly His Glu Thr Ala Phe Ala Thr Leu Val	2427
7645	GTG AAG TGG TCG GCA TTT GGG GGG GAG TCA ATA TCA GAC CAC ATA AAG CAA JCG GCC ACA GAC TTT GTG GTC TCA GCT CTA GCG	7728
2428	Val Lys Trp Leu Ala Phe Gly Gly Phe Gly Gly Ser Ile Ser Asp His Ile Lys Gln Ala Ala Thr Asp Leu Val Val Tyr Tyr Ile Ile	2455
7729	AAC AGA CCT CAA TTC CCA GGA GAC ACA GAA ACA CAA GAG AGA AAA TTT GTT GCC AGC CTG CTA GTC TCA GCT CTA GCG	7812
2456	Asn Arg Pro Gln Phe Pro Gly Asp Thr Glu Thr Gln Gln Glu Gly Arg Lys Phe Val Ala Ser Leu Leu Val Ser Ala Leu Ala	2483
7813	ACT TAT ACA TAC AAG AGC TGG AAC TAC AAT AAT CTG TCC AAA ATA GTT GAA CCG GCT TTT GGT ACC CTG CCC TAT GCC GCT AAA	7896
2484	Thr Tyr Thr Tyr Lys Ser Trp Asn Tyr Asn Asn Leu Ser Lys Ile Val Glu Pro Ala Leu Ala Thr Leu Pro Tyr Ala Ala Lys	2511
7897	GCC CTC AAG CTA TTT GCT CCT ACC CCA CTG GAG AGC GTT GTC ATA CTG AGC ACT GCA ATC TAC AAA ACA TAC CTA TCA ATA AGG	7980
2512	Ala Leu Lys Leu Phe Ala Pro Thr Thr Arg Leu Glu Ser Val Val Ile Leu, Ser Thr Ala Ile Tyr Lys Thr Tyr Leu Ser Ile Arg	2539
7981	CGA GGC AAA AGT GAT GGT CTA GGT ACA GGG GTT AGC GCG GCC ATG GAA ATT ATG TCA CAA AAC CCA GTA TCT GTG GGT ATA	8064
2540	Arg Gly Lys Ser Asp Gly Leu Leu Gly Thr Gly Val Ser Ala Ala Met Glu Ile Met Ser Gln Asn Pro Val Ser Val Gly Ile	2567
8065	GCA GTT ATG CTA GGG GTA GGG GCT GTA GCA GCC CAC AAT GCA ATT GAA GCC AGT GAG CAA AAA AGA ACA CTA CTT ATG AAA GTC	8148
2568	Ala Val Met Leu Gly Val Gly Ala Val Ala Ala His Asn Ala Ile Glu Ala Ser Glu Gln Lys Arg Thr Leu Leu Met Lys Val	2595

8149 TTT GTG AAA AAC TTC TTA GAC CAG GCC GCC ACC GAC GAA CTA GTC AAA GAG AGC CCT GAG AAA ATA ATA ATG GCT TTG TTC GAA 8232
2596 Phe Val Lys Asn Phe Leu Asp Gln Ala Ala Thr Asp Glu Leu Val Lys Glu Ser Pro Glu Lys Ile Ile Met Ala Leu Phe Glu 2623
8233 GCG GTG CAA ACG GTG GGC AAC CCT AGA TTA GTG TAC CAC CTC TAT GGA GTT TTC TAT AAA GGG TGG G/A GCA AAA GAG TTG 8316
2624 Ala Val Gln Thr Val Gly Asn Pro Leu Arg Leu Val Tyr His Leu Tyr Gly Val Phe Tyr Lys Gly Trp Glu Ala Lys Glu Leu 2651
8317 GCC CAA AGA ACA GCC GGC AGG AAC CTT TTC ACC TTG ATA ATG TTC GAG GCT GTG GAA CTA CTG GGA GTA GAC AGT GAG GGA AAA 8400
2652 Ala Gln Arg Thr Ala Gly Arg Asn Leu Phe Thr Leu Ile Met Phe Glu Ala Val Glu Leu Leu Gly Val Asp Ser Glu Gly Lys 2679
8401 ATT CGC CAG CTA TCG AGC AAT TAC ATA CTA GAG CTC TTG TAT AAG TTC CGC GAC AAT ATC AAG TCT AGT GTG AGG GAG ATA GCA 8484
2680 Ile Arg Gln Leu Ser Ser Asn Tyr Ile Leu Glu Leu Leu Tyr Lys Phe Arg Asp Asn Ile Lys Ser Ser Val Arg Glu Ile Ala 2707
8485 ATC AGC TGG GCC CCC GCC CCC TTT AGT TGC GAT TGG ACA CCA ACA GAT GAC AGA ATA GGG CTT CCC CAT GAC AAT TAC CTC CGA 8568
2708 Ile Ser Trp Ala Pro Ala Pro Phe Ser Cys Asp Trp Thr Pro Thr Asp Arg Ile Gly Leu Pro His Asp Asn Tyr Leu Arg 2735
8569 GTG GAG ACA AAG TGC CCC TGT TAC AGG ATG AAA AAG GCG GTA AAA AAC TGC GCT GCG GAG TTG AGA CTT CTG GAG GAA GGG GGT 8652
2736 Val Glu Thr Lys Cys Pro Cys Gly Tyr Arg Met Lys Ala Val Lys Asn Cys Ala Gly Glu Leu Arg Leu Leu Glu Gly Gly 2763
8653 TCA TTC CTC TGC AGA AAT AAA TTC GGT AGA GGC TCA CAA AAC TAC AAG GTG ACA AAA TAC TAT GAT GAC AAT TTA TCA GAA ATA 8736
2764 Ser Phe Leu Cys Arg Asn Lys Phe Gly Arg Gly Ser Gln Asn Tyr Arg Val Thr Lys Tyr Tyr Asp Asn Leu Ser Glu Ile 2791
8737 AAA CCA GTG ATA AGA ATG GAA GGA CAC GTG GAA CAC GTG GAA CAC GTG GAA CAC GTG GAA CAC GTG GAA CAC GTG GAA CAC GTG GAA CAC 8820
2792 Lys Pro Val Ile Arg Met Glu Gly His Val Glu Leu Tyr Tyr Lys Gly Ala Thr Ile Lys Leu Asp Phe Asn Asn Ser Lys Thr 2819
8821 GTA CTG GCA ACT GAC AAA TGG GAG GTT GAC CAC TCC ACC CTG GTT AGG GCA CTC AAG AGG TAC ACA GGG GCT GGA TAT CGA GGG 8904
2820 Val Leu Ala Thr Asp Lys Trp Glu Val Val Asp His Ser Thr Leu Val Arg Ala Leu Lys Arg Tyr Thr Gly Ala Gly Tyr Arg Gly 2847
8905 GCG TAT TTG GGT GAG AAA CCT AAC CAT AAA CAT CTG ATA CAG AGA GAC TGT GCA ACG ATT ACC AAA GAC AAG GTC TGC TTC ATC 8988
2848 Ala Tyr Leu Gly Glu Lys Pro Asn His Lys His Leu Ile Gln Arg Asp Cys Ala Thr Ile Thr Lys Asp Lys Val Cys Phe Ile 2875
8989 AAA ATG AAG AGA GGG TGT GCG TTC ACT TAT GAC CTA TCC CTC CAC AAC CTT ACC CCG CTA ATC GAA TTG GTA CAC AAG AAT AAC 9072
2876 Lys Met Lys Arg Gly Cys Ala Phe Thr Tyr Asp Leu Ser Leu His Asn Leu Thr Arg Leu Ile Glu Leu Val His Lys Asn Asn 2903
9073 CTG GAA GAT AGA GAA ATC CCT GCT GTG ACG GTT ACA ACC TGG CTG GCC TAC ACA TTT GTG AAT GAA GAC ATA GGG ACC ATA AAA 9156
2904 Leu Glu Asp Arg Glu Ile Pro Ala Val Thr Val Thr Trp Leu Ala Tyr Thr Phe Val Asn Glu Asp Ile Gly Thr Ile Lys 2931
9157 CCA ACT TTT GGG GAA AAG GTG ACA CCG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG GAG 9240
2932 Pro Thr Phe Gly Glu Lys Val Thr Pro Glu Lys Gln Glu Glu Val Val Leu Gln Pro Ala Val Val Val Asp Thr Thr Asp Val 2959

9241 GCC GTG ACC GTG GTA GGG GAA ACC TCT ACT ATG AAT ACA GGG GAG ACC CCG ACA ACA TTT ACC AGC TTA GGT TCG GAC TCG AAG 9324
 2960 Ala Val Thr Val Val Gly Glu Thr Ser Thr Met Thr Thr Thr Pro Thr Thr Thr Phe Thr Ser Leu Gly Ser Asp Ser Lys 2987

 9325 GTC CGA CAA GTC CTG AAG CTG GGC GTG GAC GAT GGT CAA TAC CCC GGG CCT AAT CAG CAG AGA GCA AGC CTG CTC GAA GCT ATA 9408
 2988 Val Arg Gln Val Val Lys Leu Gly Val Asp Asp Gly Gln Tyr Pro Gly Pro Asn Gln Gln Arg Ala Ser Leu Leu Glu Ala Ile 3015

 9409 CAA GGT GTG GAT GAA AGG CCC TCG GTA CTG ATA CTG GGG TCT GAT AAG GCC ACC TCC AAT AGG GTC AAG ACC GCA AAG AAT GTG 9492
 3016 Gln Gly Val Asp Glu Arg Pro Ser Val Leu Ile Leu Gly Ser Asp Lys Ala Thr Ser Asn Arg Val Lys Thr Ala Lys Asn Val 3043

 9493 AAG ATA TAT AGG AGC AGG GAC CCC CTG GAA CTG AGA GAA ATG ATG AAA AGG GGA AAA ATC CTA GTC GTA GCC TTG TCT AGA GTC 9576
 3044 Lys Ile Tyr Arg Ser Arg Asp Pro Leu Glu Leu Arg Glu Met Met Lys Arg Gly Lys Ile Leu Val Val Ala Leu Ser Arg Val 3071

 9577 GAT ACC GCT CTG CTG AAA TTC GTT GAT TAC AAA GGC ACC TCC CTG ACC AGA GAG ACC CTA GAG GCA TTA AGT CTG GGT AAG CCT 9660
 3072 Asp Thr Ala Leu Leu Lys Phe Val Asp Tyr Lys Gly Thr Phe Leu Thr Arg Glu Thr Leu Glu Ala Leu Ser Leu Gly Lys Pro 3099

 9661 AAG AAA AGA GAC ATA ACT AAA GCA GAA GCA CAA TGG CTG CTG CCG CTC GAA GAC CAA ATA GAA GAG CTG CCT GAC TGG TTC GCA 9744
 3100 Lys Lys Arg Asp Ile Thr Lys Ala Glu Ala Gln Trp Leu Leu Arg Leu Glu Asp Gln Ile Glu Glu Leu Pro Asp Trp Phe Ala 3127

 9745 GCC AAG GAA CCC ATA TTT CTA GAA GCC AAC ATT AAA CGT GAC AAG TAT CAC CTG GTA GGG GAC ATA GCC ACT ATT AAA GAA AAA 9828
 3128 Ala Lys Glu Pro Ile Phe Leu Glu Ala Asn Ile Lys Arg Asp Lys Tyr His Leu Val Gly Asp Ile Ala Thr Ile Lys Glu Lys 3155

 9829 GCC AAA CAA CTG GGG GCA ACA GAC TCC ACA AAG ATA TCA AAG GAG GTT GGC GCG AAA GTG TAT TCT ATG AAG CTG AGT AAC TGG 9912
 3156 Ala Lys Gln Leu Gly Ala Thr Asp Ser Thr Lys Ile Ser Lys Glu Val Gly Ala Lys Val Tyr Ser Met Lys Leu Ser Asn Trp 3183

 9913 GTG ATA CAA GAA GAG AAT AAA CAA GGC AGC CTT GCC CTG TTT GAA GAG CTC CTG CAA CAG TGC CCA CCC GGG GGC CAG AAC 9996
 3184 Val Ile Gln Glu Glu Asn Lys Gln Gly Ser Leu Ala Pro Leu Phe Glu Glu Leu Leu Gln Gln Cys Pro Pro Gly Gly Gln Asn 3211

 9997 AAA ACC ACA CAT ATG GTC TCA GCC TAC CAA CTA GCT CAA GGG AAT TGG GTG CCA GTT AGT TGC CAC GTG TTC ATG GGG ACC ATA 10080
 3212 Lys Thr Thr His Met Val Ser Ala Tyr Gln Leu Ala Gln Gly Asn Trp Val Pro Val Ser Cys His Val Phe Met Gly Thr Ile 3239

 10081 CCC GCC AGA AGA ACC AAG ACT CAT CCT TAT GAG GCA TAC GTT AAG CTA AGG GAG TTG GTA GAT GAA CAT AAG ATG AAG GCA TTA 10164
 3240 Pro Ala Arg Arg Thr Lys Thr His Pro Tyr Glu Ala Tyr Val Lys Leu Arg Glu Leu Val Asp Glu His Lys Met Lys Ala Leu 3267

 10165 TGT GGC GGA TCA GGC CTA AGT AAG CAC AAC GAA TGG GTA ATT GGC AAG GTC AAG TAT CAA GGA AAC CTG AGG ACC AAA CAC ATG 10248
 3268 Cys Gly Gly Ser Gly Leu Ser Lys His Asn Glu Trp Val Ile Gly Lys Val Lys Tyr Gln Gly Asn Leu Arg Thr Lys His Met 3295

10249 TTG AAC CCC GGA AAG GTG GCG GAG CAA CTG CAC AGA GAA GGG TAC AGG CAC AAT GTG TAT JAT AAG ACA ATA GGT TCA GTG ATG 10332
3296 Leu Asn Pro Gly Lys Val Ala Glu Leu His Arg Glu Gly Tyr Arg His Asn Val Tyr Asn Lys Thr Ile Gly Ser Val Met 3323
10333 ACA GCA ACT GGT ATC AGG CTG GAG AAG TTA CCT GTG GTT AGG GCC CAA ACA GAC ACA ACC AAC TTC CAC CAA GCA ATA AGG GAT 10416
3324 Thr Ala Thr Gly Ile Arg Leu Glu Lys Leu Pro Val Val Arg Ala Gln Thr Asp Thr Asn Phe His Gln Ala Ile Arg Asp 3351
10417 AAA ATA GAC AAG GAG GAG AAC CTA CAG ACC CCT GGC TTG CAT AAG AAG TTA ATG GAA GTC TTC AAT GCA TTA AAA AGA CCC GAG 10500
3352 Lys Ile Asp Lys Glu Glu Asn Leu Thr Pro Gly Leu His Lys Lys Leu Met Glu Val Phe Asn Ala Leu Lys Arg Pro Glu 3379
10501 CTT GAG GCC TCT TAT GAC GCT GTG GAT TGG GAG GAA TTG GAG AGA GGA ATA AAT AGG AAG GGT GCT GCT GGT TTC TTC GAA CGC 10584
3380 Leu Glu Ala Ser Tyr Asp Ala Val Asp Trp Glu Glu Leu Glu Arg Gly Ile Asn Arg Lys Gly Ala Ala Gly Phe Glu Arg 3407
10585 AAG AAC ATA GGA GAG GTT TTG GAT TCG GAA AAA AAT AAA GTC GAA GAG GTT ATT GAC AGT TTG AAA AAA GGT AGG AAT ATC AGA 10668
3408 Lys Asn Ile Gly Glu Val Leu Asp Ser Glu Lys Asn Lys Val Glu Glu Val Ile Asp Ser Leu Lys Lys Gly Arg Asn Ile Arg 3435
10669 TAC TAC GAA ACT GCA ATC CCG AAA AAC GAG AAG AGG GAT GTC AAT GAT GAC TGG ACC GCT GGT GGT GAC TTC GTA GAT GAG AAG AAG 10752
3436 Tyr Tyr Glu Thr Ala Ile Pro Lys Asn Glu Lys Arg Asp Val Asn Asp Asp Trp Thr Ala Gly Asp Phe Val Asp Glu Lys Lys 3463
10753 CCA AGA GTG ATA CAA TAC CCT GAG GCT AAA ACT AGG TTG GCT ATT ACT AAG GTA ATG TAC AAG TGG GTC AAA CAG AAG CCA GTT 10836
3464 Pro Arg Val Ile Gln Tyr Pro Glu Ala Lys Thr Arg Leu Ala Ile Thr Lys Val Met Tyr Lys Trp Val Lys Gln Lys Pro Val 3491
10837 GTC ATA CCG GGT TAT GAA GGT AAG ACA CCC CTG TTT CAA ATT TTT GAC AAA GTG AAG AAA GAA TGG GAT CAA TTC CAA AAC CCT 10920
3492 Val Ile Pro Gly Tyr Glu Gly Lys Thr Pro Leu Phe Gln Ile Phe Asp Lys Val Lys Lys Glu Trp Asp Gln Phe Gln Asn Pro 3519
10921 GTG GCA GTT AGC TTT GAT ACC AAA GCG TGG GAT ACC CAG GTA ACC ACA AGG GAT TTG GAG CTA ATA AGG GAT ATA CAG AAG TTC 11004
3520 Val Ala Val Ser Phe Asp Thr Lys Ala Trp Asp Thr Gln Val Thr Thr Arg Asp Leu Glu Leu Ile Arg Asp Ile Gln Lys Phe 3547
11005 TAT TTT AAA AAG AAA TGG CAC AAA TTC ATT GAC ACC CTA ACC AAG CAC ATG TCA GAA GTA CCC GTA ATC AGT GCC GAC GGG GAG 11088
3548 Tyr Phe Lys Lys Lys Trp His Lys Phe Ile Asp Thr Leu Thr Lys His Met Ser Glu Val Pro Val Ile Ser Ala Asp Gly Glu 3575
11089 GTA TAC ATA AGG AAA GGT CAG AGA GGC ACT GGG CAA CCT GAC ACG AGC GCA GGC AAC AGC ATG TTG AAT GTG TTG ACA ATG GTG 11172
3576 Val Tyr Ile Arg Lys Gly Gln Arg Gly Ser Gly Gln Pro Asp Thr Ser Ala Gly Asn Ser Met Leu Asn Val Leu Thr Met Val 3603
11173 TAT GCC TTC TGC GAG GCC ACG GGG GTA CCC TAC AAG AGT TTT GAC AGA GTG GCA AAG ATC CAT GTC TGC GGG GAT GAT GGT TTC 11256
3604 Tyr Ala Phe Cys Glu Ala Thr Gly Val Pro Tyr Lys Ser Phe Asp Arg Val Ala Lys Ile His Val Cys Gly Asp Asp Gly Phe 3631

11257 CTG ATT ACC GAA AGA GCT CTC GGT GAG AAA TTT GCG AGT AAA GGA GTC CAG ATC CTA TAC GAA GCT GGG AAG CCT CAA AAG ATC 11340
3632 Leu Ile Thr Glu Arg Ala Leu Glu Gly Glu Lys Phe Ala Ser Lys Gly Val Gln Ile Leu Tyr Glu Ala Gly Lys Pro Gln Lys Ile 3659
11341 ACT GAA GGG GAC AAG ATG AAA GTA GCC TAT CAG TTT GAT GAT ATC GAG TTC TGC TCC CAT ACA CCA GTA CAA GTG AGG TGG TCA 11424
3660 Thr Glu Gly Asp Lys Met Lys Val Ala Tyr Gln Phe Asp Asp Ile Glu Phe Cys Ser His Thr Pro Val Gln Val Arg Trp Ser 3687
11425 GAC AAT ACT TCC AGC TAC ATG CCG GGA AGG AAC ACT ACA ATC CTG GCT AAA ATG GCT ACA AGG TTG GAT TCC AGT GGT GAG 11508
3688 Asp Asn Thr Ser Ser Tyr Met Pro Gly Arg Asn Thr Thr Ile Leu Ala Lys Met Ala Thr Arg Leu Asp Ser Ser Gly Glu 3715
11509 AGG GGT ACT ATA GCA TAT GAG AAG GCA GTG GCG TTC AGC TTT TTG TTG ATG TAC TCC TGG AAC CCA CTG ATC ACA AGG ATA TCC 11592
3716 Arg Gly Thr Ile Ala Tyr Glu Lys Ala Val Ala Phe Ser Phe Leu Leu Met Tyr Ser Trp Asn Pro Leu Ile Arg Arg Ile Cys 3743
11593 TTA CTG GTG TTG TCA ACT GAG TTG CAA GTG AGA CCA GGG AAG TCA ACC ACC TAT TAC TAT GAA GGG GAC CCA ATA TCC GCT TAC 11676
3744 Leu Leu Val Leu Ser Thr Glu Leu Gln Val Arg Pro Gly Lys Ser Thr Thr Tyr Tyr Tyr Glu Gly Asp Pro Ile Ser Ala Tyr 3771
11677 AAG GAA GTC ATT GGC CAC AAT CTC TTT GAC CTT AAA AGA ACA AGC TTC GAA AAG CTA GCA AAG TTA AAT CTC AGC ATG TCC ACG 11760
3772 Lys Glu Val Ile Gly His Asn Leu Phe Asp Leu Lys Arg Thr Ser Phe Glu Lys Leu Ala Lys Leu Asn Leu Ser Met Ser Thr 3799
11761 CTC GGG GTG TGG ACT AGA CAC ACT AGC AAG AGA TTA CTA CAA GAT TGT GTC AAT GTT GGC ACC AAA GAG GGC AAC TGG CTG GTC 11844
3800 Leu Gly Val Trp Thr Arg His Thr Ser Lys Arg Leu Leu Gln Asp Cys Val Asn Val Gly Thr Lys Glu Gly Asn Trp Leu Val 3827
11845 AAT GCA GAC AGA CTA GTG AGT AGT AAG ACA GGA AAC AGG TAT ATA CCT GGA GAG GGC CAC ACC CTA CAA GGG AAA CAT TAT GAA 11928
3828 Asn Ala Asp Arg Leu Val Ser Ser Lys Thr Gly Asn Arg Tyr Ile Pro Gly Glu Gly His Thr Leu Gln Gly Lys His Tyr Glu 3855
11929 GAA CTG ATA CTG GCA AGG AAA CCG ATC GGT AAC TTT GAA GGG ACC GAT AGG TAT AAC TTG GGG CCA ATA GTC AAT GTA GTG TTG 12012
3856 Glu Leu Ile Leu Ala Arg Lys Pro Ile Gly Asn Phe Glu Gly Thr Asp Arg Tyr Asn Leu Gly Pro Ile Val Asn Val Val Leu 3883
12013 AGG AGA CTA AAA ATT ATG ATG ATG GCC CTG ATA GGA AGG GGG GTG TGA GCA TGG TCG GCT GAT CCG GCC CTA TCA GTA GAA 12096
3884 Arg Arg Leu Lys Ile Met Met Met Ala Leu Ile Gly Arg Gly Val End 3899
12097 CCC TAT TGT AAA TAA CAT TAA CTT ATT AAT TAT TTA GAT ACT ATT TAT TTA TTT ATT TAT TTA TTG AAT GAG CAA GTA CTG 12180
12181 GTA CAA ACT ACC TCA TGT TAC CAC ACT ACA CTC ATT TTA ACA GCA CTT TAG CTG GAG GGA AAA CCC TGA COT CCA CAG TTG GAC 12264
12265 TAA GGT AAT TTC CTA ACG GC 12284

Figure 3. Nucleotide sequence.


HCV

AGTGACAACGGCACTAATGGTATTTCAGCGAGCCATGTATCTTAGAGGGGTAAACAGG
AGCTTACATGGGATCTGGCCCGAGAAAATATGCAAGGGGGTCCCCACTCATCTGGCC
ACTGACACGGAAGTAAAGAGATACGCGGGATGATGGATGCCAGCGAGAGGACAAAC
TATACGTGCTGTAGGTTACAAAGACATGAATGGAACAAACATGGATGGTGTAAGTGG
TACAACATAGACCCTTGGATTTCAGTTAATGAACAGGACCCAAACAAATTTGACAGAA
GGCCCTCCAGATAAG

Deduced amino acid sequence.

HCV	S	D	N	G	T	N	G	I	Q	R	A	M	Y	L	R	G	V	N	R	S
	L	H	G	I	W	P	E	K	I	C	K	G	V	P	T	H	L	A	T	D
	T	E	L	K	E	I	R	G	M	M	D	A	S	E	R	T	N	Y	T	C
	C	R	L	Q	R	H	E	W	N	K	H	G	W	C	N	W	Y	N	I	D
	P	W	I	Q	L	M	N	R	T	Q	T	N	L	T	E	G	P	P	D	K

Figure 4



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that: MEYERS, Gregor,

THIEL, Heinz-Jurgen
My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original first and joint inventor (if plural names are listed below) of the subject matter for which a patent is sought on the invention entitled "Hog cholera virus vaccine and diagnostic", the specification of which

[] is attached hereto.

[CHECK ONE]

[X] was filed on November 22, 1991 as Application Serial No. 07/797,554 and was amended on _____ [if applicable].

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to the examination of this application in accordance with Title 37, Code of Federal Regulations Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
_____	_____	_____	Yes	No
_____	_____	_____	Yes	No
_____	_____	_____	Yes	No

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

<u>07/494,991</u>	<u>16-03-1990</u>	<u>Pending</u>
(U.S. Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
_____	_____	_____
(U.S. Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

And I hereby appoint as principal attorney, William M. Blackstone, Registration No. 29,722; Donna Bobrowicz, Registration No. 32,196; Allen C. Turner, Registration No. 33,041; John W. Schneller, Registration No. 26,031 and Louis A. Morris, Registration No. 18,100.

Please address all communications to:

William M. Blackstone
AKZO PHARMA
1330-A Piccard Drive
Rockville, MD 20850-4373

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Gregor MEYERS
Inventor's signature *Gregor Meyers* Date 1-20-92

Residence 7000 Stuttgart 80
Citizenship Deutsch
Post Office Address Gammertingerstr. 79, 7000 Stuttgart 80, Germany

Full name of second joint inventor _____
Inventor's signature _____ Date _____

Residence _____
Citizenship _____
Post Office Address _____

Full name of third joint inventor Heinz-Jürgen THIEL
Inventor's signature *H.-J. Thiel* Date 1-20-92

Residence 7400 Tübingen
Citizenship Deutsch
Post Office Address Im Schönblick 67, 7400 Tübingen, Germany

Full name of fourth joint inventor _____
Inventor's signature _____ Date _____

Residence _____
Citizenship _____
Post Office Address _____

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that: Tillmann RUMENAPF

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original first and joint inventor (if plural names are listed below) of the subject matter for which a patent is sought on the invention entitled "Hog cholera virus vaccine and diagnostic", the specification of which

☐ is attached hereto.

[CHECK ONE]

☒ [X] was filed on November 22, 1991 as Application Serial No. 07/797,554 and was amended on _____ [if applicable].

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to the examination of this application in accordance with Title 37, Code of Federal Regulations Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
_____	_____	_____	Yes	No
_____	_____	_____	Yes	No
_____	_____	_____	Yes	No

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

<u>07/494,991</u>	<u>16-03-1990</u>	<u>Pending</u>
(U.S. Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
_____	_____	_____
(U.S. Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

And I hereby appoint as principal attorney, William M. Blackstone, Registration No. 29,722; Donna Bobrowicz, Registration No. 32,196; Allen C. Turner, Registration No. 33,041; John W. Schneller, Registration No. 26,031 and Louis A. Morris, Registration No. 18,100.

Please address all communications to:

William M. Blackstone
AKZO PHARMA
1330-A Piccard Drive
Rockville, MD 20850-4373

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor _____
Inventor's signature _____

Date

Residence _____
Citizenship _____
Post Office Address _____

Full name of second joint inventor Tillmann Rümenapf
Inventor's signature *T. Rümenapf*

Pasadena Ca. 91101

1/23/92 Date

Residence _____
Citizenship Deutsch
Post Office Address 425 S Hudson Av. 7, Pasadena Ca. 91101, U.S.A.

Full name of third joint inventor _____
Inventor's signature _____

Date

Residence _____
Citizenship _____
Post Office Address _____

Full name of fourth joint inventor _____
Inventor's signature _____

Date

Residence _____
Citizenship _____
Post Office Address _____